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The androgen receptor (AR) is a member of the superfamily of steroid hormone 
receptors. The AR binds to its ligands testosterone and 5α-dihydrotestosterone and 
mediates essential biological processes such as male sexual differentiation, 
spermatogenesis, development and maintenance of the prostate gland. The AR gene 
contains a polymorphic region comprising variable number of CAG trinucleotide 
repeats which encodes glutamine residues in its first exon. The average number of such 
repeats is 22.5+ 2 with a range of 11 to 30 in the population of Singapore. Expansions 
exceeding the value of 40 repeats cause a fatal neuromuscular disease named Spinal 
bulbar muscular atrophy  (SBMA) or Kennedy's disease. 
 
Recently, besides the pathological expansions of polyglutamine lengths found in 
SBMA, variations in this CAG microsatellite tract, while remaining within the normal 
polymorphic range, have been inversely correlated with receptor activity. Thus short 
tracts are associated with high intrinsic AR activity whereas longer CAG tracts are 
associated with low AR activity. 
 
In this thesis, the role of the polymorphic CAG repeats stretch in the activity of the AR 
was investigated in three diseases/conditions: male infertility, Polycystic Ovarian 
Syndrome (PCOS) in women, and prostate cancer. Subsequently, the mechanism by 
which the different CAG length confers different transactivation activity to the AR was 
investigated in cell culture studies by using human promoters. 
 
XX
 To elucidate the relationships between CAG repeats and male infertility, we examined 
the distribution of AR-CAG alleles in infertile population from an American center, 
compared it to a different ethnic group from Singapore, and explored clinical 
phenotypes associated with long AR-CAG alleles. The mean AR-CAG length of 
infertile American patients was significantly longer than fertile controls. Logistic 
regression showed that each unit increase in CAG length was associated with a 20% 
increase in the odds of being azoospermic. The odds ratio for azoospermia was 7-fold 
higher for patients with >26 CAG repeats than those with <26 CAGs. Although mean 
CAG length in Singapore subjects was longer than the corresponding American 
samples, long AR-CAG alleles were significantly related to male infertility in both 
populations. 
 
To investigate the role of the CAG repeat tract in PCOS, we measured its length in 91 
patients and compared them to 112 fertile subjects. There were no differences in the 
mean CAG length between patients and controls when both alleles were considered 
together or separately. Since there is a subset of PCOS patients whose serum 
androgens are normal, we compared differences in CAG length between patients 
whose serum T levels were below the normal laboratory mean, to those that were 
higher. There was a difference in CAG length between patients with low and high T 
levels (20.38±0.51 vs 21.98±0.29), (p=0.004) when only the shorter allele of each 
individual was considered. Ethnic differences were also evident in our data, Indian 
subjects had a significantly shorter AR-CAG length compared to Chinese, being 
22.08±0.50 and 23.16±0.17 respectively.  
 
XXI
 To understand the factors in the androgen economy that regulate Prostate Specific 
Antigen (PSA) levels (the most commonly used marker for prostate cancer), we 
measured levels of total and free T, Sex hormone binding globulin (SHBG), and the 
AR CAG repeat length. We then compared these to the total and free PSA levels in 91 
fertile subjects, and 112 subfertile men with defective spermatogenesis. Our data 
suggested that, firstly, PSA correlated with T only in an environment of relatively low 
androgenicity, such as in subfertile patients. Secondly, in a low androgenic 
environment, short CAG tracts were associated with high PSA levels.  
 
Lastly, to understand the molecular mechanism by which the size of the AR 
polyglutamine tract may modulate the activity of the AR, reporter systems containing 
androgen responsive human promoter were constructed and the activity of the AR 
tested in cell culture experiments. 
 
In summary, the results from the three different studies in humans indicated that short 
CAG tracts were associated with high levels of androgen action leading to PCOS in 
females and high levels of PSA in males.  Conversely, long CAG tracts were 






 MAIN INTRODUCTION 
 
1.   The nuclear receptors (NRs) 
1.1 Description 
The NRs are ligand-inducible transcription factors that specifically regulate the 
expression of many essential target genes involved in metabolism, development and 
reproduction. Their main function is to mediate the transcriptional response in target 
cells in response to ligands such as the sex steroids (progestins, estrogens and 
androgens), adrenal steroids (glucocorticoids and mineralocorticoids), vitamin D3, and 
thyroid and retinoid hormones. This superfamily encompasses the single largest class 
of eukaryotic transcription factors. 
 
1.2  Classification 
Phylogenetic analyses have identified three main subfamilies within this superfamily. 
Type I or steroid family includes the receptors for progestins, estrogens, androgens, 
glucocorticoids, and mineralocorticoids. In the absence of ligand they are bound to 
heat shock proteins and in this form they are inactive. In the presence of ligand they 
bind to palindromic repeats located in the promoter of targeted genes in a homodimeric 
head- to head arrangement. Type II receptors encompass those for thyroid hormone 
(TR), all-trans retinoic acid (RAR), 9-cisretinoic acid (RXR), and vitamin D3 (VDR). 
They are able to bind to their promoter DNA in the absence of ligand, and often exert a 
constitutive repressive effect upon the expression of the target genes. Ligand biding 
then relieves the repressive effect. The difference with the type I receptors is that they 
often form promiscuous dimers, mainly involving the presence of the RXR. Type III 
receptors contain the orphan receptors. 
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 1.3  NRs structure
In the majority of the NRs, the receptor structure is comprised of six domains, named 
from A to F. Domains A/B are highly variable in sequence and length and they 
comprise the amino terminal activation function 1 (AF-1) that activates target genes 
presumably by interacting with components of the core transcriptional machinery, 
coactivators, or other transactivators. The domain C named DNA-binding domain 
(DBD) contains two zinc fingers, which are responsible for DNA recognition and 
dimerization. The domain D allows the protein to bend or change conformation and 
often contains a nuclear localization signal sequence. Domain E or carboxy-terminal 
ligand binding domain (LBD) includes the activation function 2 (AF-2). This domain 
has been studied in great detail due to the availability of crystal structures with 
different ligands and coactivators. In addition to its ligand-binding properties this 
region is important for dimerization, nuclear localization, transactivation and 
intermolecular silencing. The domain F is present only in certain receptors and its 
function remains unknown. 
 
1.4  Mode of action of the NRs 
Steroid and thyroid/retinoid hormones regulate transcription via enhancer elements 
that may be several kilobases from their target promoters, at which transcription is 
mediated by RNA polymerase II (Mc Kenna et al., 1999). The nuclear receptors and 
some of its specific coactivators interact directly or indirectly with the components of 
the basal transcription machinery. Direct protein-protein interaction between NR and 
GTFs (general transcription factors) had been reported in a number of studies. For 
instance Schulman et al. (1995) described the association between a portion of the 
TBP (TATA–binding protein) and the AF-2 region of the RXR. This interaction is a 
direct, specific and ligand-dependant. 
2
  
Eukaryotic DNA is structured into nucleosomes, and this complex structure has to be 
dismantled in order to make the DNA accessible to the transcription machinery. One of 
the mechanisms to achieve the physical separation of the DNA from the histone 
proteins is through the acetylation of some core histone residues. The acquisition of 
negative charges as a result of acetylation makes the separation between histones and 
the negatively charged DNA possible, thereby creating an environment where the 
DNA is more accessible to transcription factors. In 1995 Brooks et al., identified the 
first histone acetyltransferase (HAT)-A, a Tetrahymena protein that contain 
acetyltransferase activity. Their discovery was the first indication that the recruitment 
of histone acetylation activity by sequence-specific transcription factors might be 
involved in transcriptional regulation in eukaryotes. After this first discovery, various 
proteins with acetylation activity have been identified including some nuclear 
coactivators. 
 
Numerous coactivators have been characterized in recent years and they have been 
classified into two major types. The Type I coactivators function primarily with the 
nuclear receptor at the target gene promoter to facilitate DNA occupancy, chromatin 
remodelling, or recruitment of general factors associated with the RNA polymerase II 
holocomplex. Examples of type I coactivators are those belonging to the steroid 
receptor coactivator (SCR) family such as the human SRC-1 (Li et al., 1997). The 
Type II coactivators modulate the appropriate folding of the AR and its ligand, and 
facilitate the AR NH2/COOH-terminal interaction. This category includes coactivators 
that stabilize the ligand-bound receptor, such as AR-associated protein 70 (ARA70) 




2. The androgen receptor (AR) 
2.1 Definition 
The AR is a member of the steroid family of NR. It is likely that all steroid receptors 
have evolved from a common ancestral gene. The human AR genomic DNA was first 
cloned by Lubahn et al. (1988) from a flow-sorted human X chromosome library by 
using a consensus nucleotide sequence from the DNA-binding domain of the family of 
nuclear receptors. It is located on the human X chromosome between the centromere 
and the q13. The gene comprises 75-90 Kb of genomic DNA. The cDNA has 8 exons. 
The protein has 910-919 amino acids (this variation in length is mainly due to a 
variable polyglutamine (poly-Gln) stretch in the transactivation domain (TAD), and a 
molecular weight of 110-114 kDa depending on the poly-Gln length. Like other steroid 
receptors, AR contains four major structural domains; the TAD, the DBD, a hinge 
region, and the LBD (Ligand Binding Domain). Sequence homology with other steroid 
receptors is present only in the last two domains. Fig.1 shows a schematic 




















Figure 1.  Schematic representation  of the Androgen Receptor  gene and protein 
The AR gene is located in the centromeric region of the long arm of the X-
chromosome. The AR gene spans 75-90 Kb of genomic DNA and it contains eight 
exons (numbered boxes) separated by 7 introns (lines in between the boxes). The 
cDNA molecule comprises a coding region of approximately 2760 bp. The number of 
bp for each exon is indicated above the exon boxes. The exon 1 codes for the TAD, the 
exons 2 and 3 for the DBD, part of the exon 4 for the hinge region, and the 3’-portion 
of exon 4 and exons 5-8 for the LBD. Fig.1 is a schematic representation of the AR 
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 2.2  The TAD domain  
This domain comprises more than half of the AR, which is a unique attribute of the AR 
when compared to other steroid receptors. Its structural and functional characteristics 
are also different from the rest of the members of the steroid receptor superfamily. For 
instance,  the TAD contains a number of homopolymeric amino acids stretches. The 
most amino-teminal of these is a polymorphic glutamine region with an average size of 
21+2 Gln residues in the Caucasian population (Edward et al., 1992). 
 
 
 There is a shorter stretch of nine proline residues, located at amino acids 372-379, 
which does not vary in size. The third stretch is a polymorphic tract of an average size 
of about 24 glycines residues located at amino acid 449. 
 
The main transactivation domain in the AR, named AF-1 is located in the TAD. The 
boundaries are not well defined but generally speaking the region between amino acids 
51-211 is essential for the transactivation function of the AR (Jenster et al., 1991).  
 
2.3  DNA-binding-domain (DBD)
The DBD of the AR is encoded by exon 2 and 3, and comprises the amino acids 559 to 
624. Similar to other steroid receptors it contains two zinc fingers motifs. There are 
three amino acids at the base of the first zinc finger (glycine 577, serine 578 and valine 
581) which are essential for the interaction of the AR protein with the hormone 





2.4  The hinge region 
This region is coded by the 5’portion of the exon 4 and contains the major part of the 
AR nuclear targeting signal formed by a cluster of basic amino acids (arginine, lysine, 
leucine, and lysine) at positions 629-633.  The function of the hinge region is to 
facilitate the transfer of the AR from the cytoplasm to the nucleus (Jenster et al., 
1991). 
 
2.5 Ligand binding domain (LBD)
The C-terminal domain is the LBD, encoded by the exons four to eight. It encompasses 
residues 670 to 919. During the last two years the three-dimensional structure of the 
AR LBD has been determined. Despite substantial differences in the primary amino 
acid sequence between the AR LBD and other steroid hormone receptor, the three-
dimensional structures of the LBDs of these molecules are quite similar. The LBDs of 
these receptors fold into 12 helices that form a ligand-binding pocket. When an agonist 
is bound, helix 12 folds over the pocket to enclose the ligand (Sack et al., 2001). 
 
The principal function of the LBD is the specific and high affinity binding of 
androgens. This site is also the binding site for heat shock proteins that have an 
inhibitory effect while they bind to the AR (Smith, 1993). 
 
The transcription activation function (AF-2) is located in the LBD. In comparison with 
others steroid receptors has a weak impact in the overall transactivation of the receptor. 
The AF-2  acts in a ligand dependent manner, and its activity is enhanced by numerous 
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 coactivators such as the transcription intermediary factor 2 (TIF 2)  (Jenster et al., 
1991). 
  
2.6  Mode of action of the AR  
After binding to the androgens, the receptor dissociates from the accessory proteins 
(heat shock proteins), translocates into the nucleus, dimerizes and, through its DNA-
binding domain, interacts with specific androgen-responsive elements (ARE) located 
in the promoter region of androgen responsive genes (Zhou et al., 1994). The AR 
requires the presence of coactivators, such as SRC-1, p300, p/CAF, CBP, which are 
stabilized in a heterocomplex by protein-protein interaction with the AR. These 
complexes recruit general transcription factors to the TATA box, and also exert HAT 
activity by modifying the structure of histones and chromatin. 
 
3.   The polymorphic region of CAG repeats in the androgen receptor gene  
3.1 Description 
The AR gene contains a polymorphic stretch of CAG triplets in the exon 1. The CAG 
repeats, which encodes glutamine residues, vary in number from 11 to 35 in the normal 
population. The average number of repeats is of 21+2 in the Caucasian population 
although this value is dependent on the population studied. For instance African-
Americans have shorter CAG repeats tracts, an average of 19 CAGs, while Chinese 
have an average of 23 CAGs (Edwards et al., 1992). Fig. 2 shows the location of the 
CAG stretch in the AR gene. 
Although poly-Gln stretches are present in other transcription-regulated proteins and 

















Figure 2. Schematic structure of the AR cDNA  
The eight numbered boxes represent the exons of the AR gene. The exon 1 
comprising more than half of the AR cDNA contains two polymorphic regions, 
the polymorphic region of CAG repeats at position 174 bp, and the GGC repeats 









































Conservation of segments of the AR gene throughout evolution implicates these 
regions as being critical for the activity of the molecule. Choong et al. (1998) 
compared the AR DNA coding sequence from five primate species, humans, 
chimpanzee, baboon, macaque and collared brown lemur. The DBD and LBD domains 
were totally conserved. Nevertheless, a linear increase in trinucleotide repeat 
expansion of homologous CAG and GGC sequences occurs in the NH2-terminal region 
and is proportional to the time of species divergence, suggesting that the CAG repeat 
expanded during divergence of the higher primate species. 
 
3.2 Polyglutamine regions in the expanded pathological range are found in various 
genes
Polyglutamine regions are frequently found as polyglutamine tracts, encoded by CAG 
repeats, and despite this wide distribution, the functions of CAG repeats are often 
unclear. However, expansion of CAG repeats in genes has been implicated in the 
pathogenesis in a number of progressive neurodegenerative diseases including 
Huntington’s disease, spinocerebellar ataxia, and dentatorubral-pallidoluysian atrophy, 
and in SBMA (Lieberman and Fischbeck, 2000). There are similarities shared among 
the diseases caused by poly-Gln stretches. With the exception of the X-linked SBMA, 
they all share the autosomal dominant mode of inheritance and anticipation on paternal 
transmission. The position of the poly-Gln in the coding region varies between the 
different proteins. For instance for AR and huntingtin, the poly-glutamine expansion 
are located within the amino terminal region, while for the atrophin is near in the C-
terminus (Choong et al, 1998). An interesting observation is that there are no common 
domains shared between these proteins, only the poly-Gln stretch, and that the mutated 
proteins seem to have similar expression levels that the no mutated ones. A common 
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 feature is the presence of insoluble intracellular aggregates in all of those disorders 
including SBMA. These aggregates are similar to those found in other neurodegenative 
disorders such as Alzheimer’s, Parkinson’s disease and prion diseases, suggesting that 
aggregates may be toxic for long living post-mitotic cells. It has been postulated that 
the expanded poly-Gln tracts exert a gain of toxic function (Brooks et al., 1997). 
Various hypotheses had been postulated regarding the mechanism by which expanded 
regions causes neuronal degeneration. Perutz et al. (1994) suggested that poly-Gln 
repeats might function as polar zippers, joining complementary proteins such as other 
transcription factors by hydrogen bonding. Longer stretches would result in stronger 
interactions. Choong et al. (1998) suggested that protein aggregation might occur after 
the proteolysis of the AR to smaller fragments encompassing an expanded CAG 
repeat. The AR with expanded CAG repeat would be preferentially digested by a 
protease, and with time, insoluble aggregates will form, triggering the apoptotic 
pathway. 
 
The exact molecular mechanism leading to expansion of trinucleotide repeats remains 
unknown. It is likely to be related to the ability of repeat tracts to form unusual DNA 
secondary structures such as hairpins and slipped-strand DNA duplexes, which can 
interfere with aspects of DNA metabolism (Usdin et al., 1998).  The amino acid 
repeats, particularly of uncharged polar amino acids can mediate or modulate protein-
protein interactions, raising the possibility that changes in their length during evolution 
could result in changes in the strength of protein-protein interactions. As a number of 
studies have associated glutamine repeats with transcription factors, this could have 
implications for the evolution of gene regulatory networks. Evolutionary studies of a 
number of genes involved in the human triplet expansion diseases have indicated that 
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 the repeats in these genes have arisen by gradual expansion of the tandem repeat, 
apparently resulting from replication slippage. Repeats are generally absent in rodent 
homologue genes and comparative studies indicate an increase in repeat length during 
primate evolution, with humans generally having the longest repeats (Rubinsztein et 
al., 1994) 
 
3.3 Kennedy’s syndrome, a pathological expansion of CAG repeats in the AR 
gene  beyond 40 
Males with expansions of the CAG tract in the AR gene beyond 40 repeats develop 
Kennedy's disease, also known as X-linked spinal and bulbar muscular atrophy 
(SBMA).  The X-linked SMBA was first reported by Kennedy in 1968. It is a rare 
inherited neurodegenerative disease characterized by progressive neuromuscular 
weakness due to the loss of motor neurons in the brain stem and spinal cord. Onset of 
this disorder is usually in the fourth or fifth decade, but may be as early as the mid-
teens or as late as 60 years. La Spada et al., (1991) first reported that the origin of the 
disease was associated with expansion of the poly-Gln tract of the AR to values higher 
than 40 Gln. Motoneunoral cell death does not appear to be linked to a loss of function 
of the mutated AR, since neurodegeneration does not occur in patients with testicular 
feminization who lack of AR function. 
 
The AR is expressed in many tissues including the central nervous and muscular 
system (Sar et al., 1990). The absence of any neuromuscular degeneration in patients 
with complete androgen insensitivity leads to the hypothesis that the AR with the 
expanded tracts is associated with a gain of neurotoxic function. The length of the 
CAG tract correlates inversely with the age of onset of the disease (La Spada et al., 
1991) but it still uncertain if the length correlates with the severity of the disease 
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 (Shimada et al., 1995). Endocrine abnormalities usually become manifest after 
neurological symptoms. More than half of patients with SBMA normally develop 
gynaecomastia, low sperm production, low testicular size, and one in three patients 
with SBMA has subnormal serum testosterone concentrations impairment (Harding et 
al., 1982; Arbizu et al., 1983) 
 
3.3  AR mutations and CAG polymorphisms within the normal range 
To date, the majority of the mutations in the AR gene have been found in the LBD 
and DBD domains. These mutations can cause a wide range of phenotypic 
manifestations, depending on the amino acid that is affected. The most severe case is 
complete androgen insensitivity syndrome (CAIS) due to a complete disruption of the 
AR, the affected individuals are healthy 46XY individuals with a female phenotype  
(Lim et al., 1997; Yong et al., 1994).  Other mutations can cause partial androgen 
insensitivity (PAIS), which impairs the activity of the receptor without totally 
disrupting its function. Accordingly, the phenotype of the individual depends on how 
severe the activity of the AR has been impaired (Yong et al., 1998).  
With the above reviewed on CAIS and PAIS, both related to point mutations on the 
AR, as well as the link of SBMA with the CAG polymorphism within the AR, the aim 
of this thesis was to investigate if the length of the CAG tracts within the non- 
pathological range or normal have an effect on the intrinsic activity of the AR.  To 
study this association different approaches were taken. The first one was to 
investigate whether expanded CAG tracts were implicated in reduced androgen action 
and therefore leading to a condition highly dependent on androgens such as defective 
spermatogenesis and male infertility. To investigate the relationship between AR-
CAG length and male infertility, two retrospective case-controls studies were 
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 performed. The first comprised of subjects from a predominantly Caucasian 
population recruited at Baylor College of Medicine; Houston, and the second included 
subjects of predominantly Chinese ethnic origin recruited at the National University 
Hospital in Singapore. The second question raised was whether having short CAG 
tracts would predispose to diseases characterized by high levels of androgen action. 
The disease investigated upon was the Polycystic Ovarian Syndrome (PCOS), in 
females. The third objective of this project was to determine whether the levels of 
Prostate Specific Antigen (PSA), a common oncogenic marker for prostate cancer, 
were related to the number of CAG repeats in the AR gene and consequently obtain a 
new molecular marker for prostate cancer. Lastly, the molecular mechanism by which 
the different CAG length modulate the activity of the AR was investigated in cell 
culture experiments using reporter systems containing the human promoters ALDH 
and PSA. In addition, the interaction between the LBD and TAD domain containing 
different CAG lengths was investigated in the mammalian cell of two-hybrid systems. 




CHAPTER 1: CAG REPEAT POLYMORPHISM IN THE ANDROGEN 




1.   Role of testosterone (T) in spermatogenesis 
Spermatogenesis is the process by which mature spermatozoa are produced and the 
number of chromosomes is reduced to the haploid state. One complete cycle takes 
approximately 60 days and it takes place within the coiled seminiferous tubules. Two 
types of cells facilitate the process of spermatogenesis: Sertoli and Leydig cells. Sertoli 
cells line the basal laminar of the seminiferous tubules and are attached to one other by 
specialized junctional complexes. They contribute to the formation of the blood-testis 
barrier, limiting the transport of certain molecules and fluid to the tubular lumen. Other 
functions are to provide an energy source for the developing spermatozoa and the 
phagocytosis of damaged cells. Outside the seminiferous tubules are the Leydig, which 
are the main source of the androgen T. 
 
Various hormones take part in the process of spermatogenesis. One of the most critical 
hormones is T. The production of T occurs in the Leydig cells under the stimulation of 
the hormone LH. This binds to the AR and ultimately activates some of the genes 
involved in the process of spermatogenesis. T not only has androgenic effects of its 
own but can be converted to a much more potent androgen called dihydrotestosterone 
(DHT) by the action of the enzyme 5 alpha-reductase. In addition, it can also be 
aromatised to 17 beta-oestradiol in the testicular Leydig cells.  
 
 17
T is required to maintain quantitatively normal spermatogenesis, and decreasing T 
levels in the seminiferous tubules results in defective sperm production (Zirkin et al, 
1989) 
 
FSH plays an important role too. It binds to specific receptors on the Sertoli cells and 
stimulates cAMP production resulting in the activation of a number of proteins 
responsible for the trafficking of nutrients from the Sertoli cells to the germ cells.  
 
2.   Genetic causes of male infertility 
In 40-60% of cases, the aetiology of male infertility remains unknown and has to be 
classified as idiopathic (De Kretser, 1997). Known factors of male infertility include 
varicocele, infections, irradiation chemotherapy, testicular torsion, cryptorchidism, 
sexual disorders, hyperprolactinaemia and hypogonadotrophic hypogonadism. With 
the advancement of molecular biology techniques it seems that more and more of the 
so-called idiopathic male infertility cases with impaired spermatogenesis appear to be 
of genetic origin. (Skakkebaek et al., 1994). Currently the main genetic defects that are 
known to lead to male infertility are: 
 
2.1. Structural chromosomal disorders 
Some genetic causes may be due to structural chromosomal disorders, the most 
frequent being Klinefelter’s syndrome (KS). KS accounts for 14% of the cases of 
azoospermia. It is present in 1 in 500 live male births and is the most common 
abnormality of sexual differentiation. Clinical symptoms of KS besides azoospermia 
are gynaecomastia and small firm testis. The chromosomal constitution of these 
patients is 47, XXY in 90% of the cases, and 46, XY/47, XXY in the other 10%.  
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Other types of chromosomal disorder are caused by autosomal translocations, and they 
are thought to be responsible for defective spermatogenesis in up to 7% of infertile 
males. They might interrupt important genes involved in spermatogenesis, gonadal 
differentiation, androgen biosynthesis, androgen action, and sperm quality. 
 
2.2. Y chromosome deletions 
In humans the Y chromosome is essential for normal testicular differentiation and 
spermatogenesis. Cytogenetic studies on azoospermic subjects two decades ago led to 
the postulation of the existence of a gene locus in the distal euchomatic part of Yq 
(Yq11), and it was defined as the azoospermia factor (AZF). With the advancement of 
molecular biology techniques numerous studies (Liow et al., 1998; Simoni et al., 
1997) have reported microdeletions in this gene region of infertile men. They represent 
the aetiological factor of 10-20% of idiopathic azoospermia and severe oligospermia, 
depending on the population studied.  
 
 Multiple non-overlaping spermatogenesis loci in this region have been identified, 
suggesting the involvement of more than one gene in Yq spermatogenesis. Some of the 
candidate genes identified are the RBM (RNA-binding motif) of which there are 
approximately 30 copies and are located on both arms of the Y chromosome; the DAZ 
(deleted in azoospermia), which like the RBM gene also has multiple copies in the Y 
chromosome; and the DFFRY (Drosophila fat-facets related Y). Out of these three 
genes, the DAZ gene represents the most frequently deleted region in infertile males. 
Such deletions appear to remove the entire DAZ gene cluster and have been associated 
with a wide range of spermatogenesis alterations, ranging from azoospermia, due to 
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Sertoli cell only, to oligospermia with different testicular phenotype (Reijo et al., 
1995; Liow et al., 1998). 
 
2.3. Androgen receptor mutations and polymorphisms
Androgens play an important function throughout the different stages of human 
development and reproduction. It is well known that sperm production is dependent on 
androgens (Zirkin et al., 1989) and suboptimal androgen action could lead to defective 
spermatogenesis (Aiman and Geiffin, 1982). Androgen action is mediated by the AR, 
so abnormalities of androgen action can be due to mutations on the AR gene that 
impairs its optimal transactivation capability. To date, the majority of the mutations 
have been found in the LBD and DBD domain of the AR. These mutations can cause a 
wide range of phenotypic manifestations, depending on the aa that is affected. The 
most severe case is complete androgen insensitivity syndrome (CAIS) that occurs 
when the mutation completely disrupts the function of the receptor. Patients with CAIS 
have a female phenotype: clitoris, labia minora and majora, but with an absence of 
pubic and axilar hair, a blind-ending vagina, and no uterus. Postpubertal individuals 
with CAIS have testis, increased levels of LH, and normal male levels of T. (Lim et 
al., 1997; Yong et al. 1994). Other mutations can cause partial androgen insensitivity 
(PAIS) when they impair the activity of the receptor without totally disrupting its 
function. Accordingly, the phenotype of the individual depends on how severe the 
activity of the AR has been impaired. (Yong et al., 1998).  
 
The majority of the AR mutations are found in the LBD perhaps because the screening 
of the TAD is quite difficult due to its high CG content and large size. However, Wang 
et al. (1998) described three G to A transitions in codons 210, 211 and 214 after 
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screening one hundred and fifty-three patients with various degrees of defective 
spermatogenesis. The transitions in codon 210 and 211 were polymorphisms and did 
not change the sense of the codon. They were associated with ethnic origin and were 
present in 15% of Indians and 10% of individuals from the Middle-East, but were 
absent in the Chinese population. The third mutation, in codon 214, resulted in a non-
conservative glycine to arginine substitution, and was associated with a 20% decrease 
in AR transactivation compared to the wild type. 
 
In the exon 1 of the AR gene is present a polymorphic trinucleotide repeat segment, 
(CAG)n; this segment encodes a poly-Gln tract which  normally ranges from 11 to 31. 
This tract has been the source of extraordinary interest in recent years because as 
mention in the main introduction, section 3.3 spinal (page 14), it was found that CAG 
expansion to beyond 40 repeats leads to SBMA, a fatal neuromuscular disease. 
Patients with SBMA have evidence of reduced androgen receptor function in the form 
of low virilization, oligospermia or azoospermia, testicular atrophy, and reduced 
fertility (Amato et al., 1993; Arbizu et al., 1983). Besides the pathological expansions 
of CAG lengths found in SBMA, short alleles were found to be associated with the 
androgen-dependent tumour prostate cancer. Accordingly, short CAG repeats increase 
AR androgenicity and are associated with earlier age of onset, increased tumour grade 
and increased risk of extra-prostatic extension in prostate cancer (Hardy et al., 1996; 
Giovannucci et al., 1997). If short CAG lengths lead to prostate cancer, we wanted to 
determine whether at the other end of the spectrum, long CAG repeats might cause 
reduced AR androgenicity, and a condition that is sensitive to reduction of AR activity 
such as impaired spermatogenesis. Preliminary data by Tut et al. (1997) indicated that 
long CAG repeats while still in the normal range could reduce the activity of the AR 
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leading to male infertility. In this first study, 153 patients with varying degrees of 
impaired spermatogenesis were analyzed and compared to 71 fertile individuals. The 
racial composition was mainly of Asian origin and made up of about 60% Chinese 
subjects. They concluded that patients with more than 28 Gln in their AR had more 
than a four fold increased risk of reduced spermatogenesis. There was also a trend 
whereby the more severe the spermatogenesis defect, the higher the number of 
glutamines in the AR protein. No data was available for a Caucasian population. In this 
project, to further understand the relationship between CAG repeats and male 
infertility a large U.S population of mainly Caucasian ethnic background was analyzed 
and compared to a population from Singapore of a Chinese ethnic background. In 
addition the phenotypes of the AR gene alleles with long CAG tracts were studied in 















MATERIALS AND METHODS 
 
1.   Subjects included in the study 
Patients were recruited from the Division of Male Reproductive Medicine and Surgery 
of the Scott Department of Urology, Baylor College of Medicine, Houston; and the 
Infertility Clinics, Department of Obstetrics and Gynecology, National University 
Hospital, Singapore. A complete history and physical examination were performed, 
and the use of any medications or previous surgery was recorded. The size of both 
testes was measured with a Prader orchidometer and presence of any associated 
varicoceles noted. Patients who had hypopituitarism, hyperprolactinemia, infective or 
obstructive syndromes of the genital tract were excluded from this study. All patients 
included in the study were 46XY males. Patients with mutations in the AR gene or Y- 
microdeletions were not included in the study. Sperm parameters were assessed 
according to standard criteria and were calculated by taking the mean of at least two 
analyses done 3 months apart. Azoospermia was defined as the absence of any 
spermatozoa despite centrifugation of the semen specimen, and oligospermia defined 
as the mean sperm density being <20 mil/ml. Control subjects of matched age were 
men of proven fertility with no previous infertility history or treatment, and without 
any genetic disease. The project was approved by the Ethical Review Committees of 
both Institutions. 
 
2.   DNA extraction 
DNA was extracted from the peripheral blood leucocytes of patients and control 
subjects. 10 mL of blood was collected in a EDTA tube and centrifuged for 15 minutes 
at 3000 rpm. The buffy coat was transferred to a clean tube and 8.5 mL of extraction 
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buffer was added (10mM Tris Cl, [pH 8.0], 0.1 M EDTA [pH 8.0], 0.5% SDS). This 
mixture was incubated for 1 hour at 37°C with occasional mixing. Afterwards 
proteinase K was added to a final concentration of 100µg/ml and the mixture 
transferred to a shaking waterbath at 55°C for 3 hours. Then the tubes were placed on 
ice to cool the solution and an equal volume of water saturated phenol added. The two 
aqueous and organic layers where vigorously mixed until a fine emulsion was formed. 
The two phases were afterwards separated by centrifugation at 3000 rpm for 15 min at 
4°C. The aqueous top phase were the DNA is present was transfered to a clean tube. 
To precipitate the DNA, 0.2 volumes of 10M ammonium acetate and 2 volumes of 
ethanol was added at room temperature. The tube was carefully inverted a few times 
until it was possible to see the swirled DNA. The DNA was taken out of the solution 
with the help of a pasteur pipette and dissolved in 1mL of sterile distilled water. The 
following day the DNA was quantified by measuring its absorvance at 260 nm 
 
3.   DNA amplification  
The CAG repeat segment was amplified using the sense (5’-
TCCAGAATCTGTTCCAGAGCGTGC) and antisense (5’-
GCTGTGAAGGTTGCTGTTCCTC) primers. The 30 μl reaction mix contained 500ng 
of genomic DNA, 50 μM of dNTPs (Epicentre Technologies), 0.25μM of each primer, 
the fluorescent-labeled dNTP (R6G) (Perking-Elmer) and 0.5 units of Taq polymerase 
(Pharmacia). A 2-step 30-cycle amplification protocol was used in which the 
denaturing temperature was 95°C for 45 sec, and the combined annealing and 
extension temperature was 68°C for 1.5 min. In the first cycle the sample was 
denatured for 5 min.  
 
 24
To verify the PCR amplified the expected fragment, the amplicons were resolved on a 
2% agarose gel with the 100pb marker (Promega). 
 
4.   Genescan analysis 
4.1 Preparation of the 4% Acrylamide-Urea gel. 
50 ml of the gel contained: 18 g of urea (Bio-Rad Laboratories), 5 ml of (19:1) 
acrylamide stock solution (Bio-Rad Laboratories), 1% of ion-exchange resin (ICN 
Biomedicals). The mixture was dissolved in 20 ml of water (some heat was necessary 
to dissolve the urea crystals). Afterwards the solution was filtered through a 0.22 µm 
filter and the de gas was removed by exposure to vacuum suction for 10 minutes. 
Afterwards 10 ml of 5X TBE buffer were added to the mixture and the volume made 
up to 50 ml with water. Before casting the gel, 250µl of freshly made 10% ammonium 
persulfate (Sigma-Aldrich) and 35µl of TEMED (Sigma-Aldrich) were added. The gel 
took about two hours to polymerize. 
 
4.2 Preparation of the PCR products for GeneScan analysis 
The amplified samples were mixed with formamide, loading buffer and the Rox(500) 
size standards (Perking-Elmer) in a ratio 1:10:2:2 respectively. This mixture was 
denatured for 5 min at 95°C and then loaded into the 4% denaturing polyacrylamide 
gel. The sizes of the samples were analyzed on a 377 DNA Sequencer running 
Genescan 672 software (Perking-Elmer). 
 
5.   Statistical Analysis 
Although the variable number of CAG repeats is a discrete variable the wide range of 
values, from 8 to 33 repeats allowed us to consider it as a continuous one. The Q-Q 
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plot is a graph used to determine if a sample is approximately normally distributed. It 
plots a set of quantiles or percentiles from the sample versus the corresponding set of 
quantiles from a normal distribution. If the graph appears close to a straight line then 
the assumption that the sample is approximately normally distributed can be made. In 
modern goodness of fit analysis this quantile graphs are preferred to formal goodness 
of fit tests because the test tend to be always significant for large samples. Results 
from the Q-Q plot indicated that it was possible to make the assumption that the data 
was normally distributed. Of course it can not be completely normal because the 
number of CAG repeats is a discrete value, but it is close enough to be able to perform 
the subsequent statistical tests. 
 
The t-test and Anova procedures were the initial steps of the analysis. The t-test or 
Student’s test is specifically designed to compare the mean values of two groups. The 
Anova test tells whether there are overall differences between the various groups of 
patients and the control group. If the Anova test shows that there are differences 
among those groups then a Dunnett’s test is performed. The Dunnett's test is a special 
case of means comparison in which the only comparison that need to be tested is 
between a set of treatments and a single control treatment. In a general multiple 
comparison between K treatments and one control there are (K+1) (K)/2 comparisons 
performed. In the Dunnett's procedure we restrict ourselves to only K comparison and 
hence obtain a more powerful test. 
 
In this study, firstly, the mean number of CAG repeats from infertile patients were 
compared to fertile controls using a two-sample independent t-test. Infertile patients 
were subsequently divided in azoospermic and oligospermic patients. Multiple 
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comparisons were then performed comparing the mean number of CAG repeats of 
azoospermic and oligospermic groups with the fertile control group using ANOVA 
and then Dunnett's test. 
 
The number of CAG repeats was then assessed as a continuous variable. Logistic 
regression analysis was performed using the number of CAG repeats as the predictor 
and clinical infertility as the outcome. Logistic regression is a standard method for 
regression analysis for cases when the response variable is not quantitative but 
dichotomous. It is a test commonly used in the field of health sciences.  
 
For the categorical analysis, the number of 26 CAG repeats was chosen as a cut-off 
point because this size is about two standard deviation above the mean. Having >26 
CAG repeats was taken as a reference group and examined if the risk of infertility 
decreased progressively with shorter CAG repeat lengths. From this analysis the odds 
ratios and corresponding confidence intervals were calculated. 
 
Statistical analyses were performed using the SPSS Version 9.01 (SPSS) computer 
software. Statistical significance was defined as obtaining a two-sided p-value less 










To investigate the relationship between AR-CAG length and male infertility, two case-
controls studies were designed. The first one comprised of subjects from a 
predominantly Caucasian population recruited at Baylor College of Medicine; 
Houston, and the second one included subjects of predominantly Chinese ethnic origin 
recruited at the National University Hospital in Singapore. 
 
1.   Analyses of patient population from the Baylor College of Medicine, Houston  
1.1 Characteristics of subjects 
The study examined 95 infertile subjects with various degrees of infertility from 
Baylor College of Medicine. 55 individuals of proven fertility were recruited as 
controls. The age of patients and controls was comparable, averaging 37 and 43 years 
respectively. The racial composition of controls and patients was similar and consisted 
of mainly Caucasians (68% and 71% respectively). The other two races were 
individuals of Hispanic and Arabic origin. The clinical characteristics of the patients 
are summarized in Table 1. 
 
1.2 Determination of the CAG repeat length 
The region comprising the CAG polyglutamine tract was amplified as described 
previously in the materials and methods, chapter 1; section 3 (page 24). Fragments 
were firstly resolved in a 2% agarose gel electrophoresis along with the 100bp DNA 
ladder marker for about 1 hour in order to verify the PCR reaction. Despite this being a 
difficult region to amplify due to the high CG content, most reactions yield a 


















             Table 1. Clinical characteristics of the infertile group of patients. 
 
 
Number of infertile patients 
 
95 
Number of patients with azoospermia 
 
23 






Mean sperm density for oligospermic patients 
(Normal : > 20 mil/ml) 
6.34+0.7 
Percentage of patients with varicocele 
 
41% 
Mean testicular volume  
























The size of the amplified fragment was dependent on the length of the CAG stretch, in 
the range from approximately 260 to 320 bp (Fig. 1).  
 
The precise size of the CAG repeat to a base pair level was achieved by GeneScan 
technology. Each PCR product was then mixed with the size standards of known sizes 
and resolved in the 4% acrylamide gel. The advantage of this analysis is that each 
sample has its own internal standard. Both the sample and the internal standards 
migrated across the gel at the same time and under the same electrophoresis 
conditions. 
 
The software analyzes the data and creates a gel file. In this study the PCR products 
were labeled with the green fluorescent dye and the commercially available internal 
markers with red color (Fig. 2). When the electropherogram was displayed in a 
horizontal way, it was observed not to be composed of a single peak but of several 
overlapping peaks. This is due to the stuttering effect, a well-known phenomenon in 
the amplification of trinucleotides repeat regions, believed to be due to PCR slippage. 
To elucidate which one of the three peaks corresponded to the correct size of the 
sample, some samples were sequenced and compared to the GeneScan profile. It was 
determined that the correct size was given by the peak corresponding to the largest 


















Figure 1.  Agarose gel electrophoresis with the PCR products comprising 
the polymorphic CAG repeats region in the AR gene. 
 
A 2% agarose gel was run for about 1 hour at 100 V to verify the PCR reaction. 
The first lane corresponded to the 100 bp DNA ladder marker, and the rest of 
the lanes to the different PCR products. Each PCR yielded only one PCR 
product. Their sizes were located between the 200 and 300 bp lanes of the 







































Figure 2.   Gel image of the GeneScan polyacryamide gel. 
The gel contained 36 lanes (not all the lanes are shown in the picture). Each 
lane was loaded with the fluorescently labeled PCR products (green color) 
along with the commercially available size standards GeneScan 500 (ROX), 
(red color). The gel image provided a qualitative overview of the run. 
The picture in left corner shows the image of the first sample loaded on the 









































Figure 3.   Confirmation of the fragment size that flanks the CAG region 
by sequence analysis. Sample 1 
A) GeneScan profile of the sample, and B) sequence 
To confirm the accuracy of the GeneScan analysis for some of the samples 
the same region was sequenced. The size indicated by the third peak of the 
GeneScan electropherogram, highlighted peak, (in this sample of 273 bp) 
match with the number of base pairs obtained from the sequencing reaction. 





































Figure 4.   Confirmation of the size of the fragment that flanks the CAG 
region by sequence analysis. Sample 2 
A): GeneScan profile of the sample, and B): sequence. 
To confirm the accuracy of the GeneScan analysis some samples were 
sequenced. The size indicated by the third peak of the GeneScan profile, 
highlighted peak (303 bp) corresponds to the number of base pairs obtained 

























1.3 Statistical analysis 
The number of CAG repeats ranged in infertile males from 14 to 31 whereas the 
number in fertile controls ranged from 8 to 27. 
A Q-Q plot was performed to assess if the data could be analyzed as normally 
distributed because despite the fact that the number of CAG repeats is a discrete 
variable it takes values over a reasonably large range and so it may be taken as a 
continous variable. The Q-Q plots in Fig. 5 indicate the assumption that the data is 
normally distributed could be made for each one of the three groups, normal fertile, 
oligospermic and azoospermic patients. The normal fertile controls appear less 
normally distributed that the other two groups of infertile patients but since it not too 
far away from normality is was possible to apply the statistical analysis based on 
ANOVA and t-test for all the groups 
 
Mean values for the number of CAG repeats were obtained and a t-test was performed 
to compare them. Results indicated that the mean AR-CAG length of infertile subjects 
was significantly longer than fertile controls, 21.95±0.31 versus 20.72±0.52 
respectively (p=0.034). 
 
For further analysis, infertile patients were then classified according to their sperm 
count into two categories, oligospermic (<20 million sperm per ml) and azoospermic 
(no spermatozoa present). The oligospermic category included those cases with severe 
oligospermia and mild oligospermia. For this study they were combined because the 
number of patients with severe oligospermia was 16, quite low, and the mean value of 
the number of CAG repeats fairly similar to those patients with mild oligospermia, 













Figure 5.   Q-Q plots to evaluate if the sample was normally distributed. 
To perform the Q-Q plot analysis subjects were divided into the categories: 
normal fertile, oligospermic and azoospermic. 
The observed quantiles values for the number of CAG repeats in each 
category were plotted against the expected quantile values. The straight line 
resulting from the plot indicates that the variable number of CAG repeats is 





























































































Anova and Duneett's tests were performed to establish multiple comparisons between 
the azoospermic and the oligospermic group against the fertile control group. Results 
are summarized in Table 2. Longer CAG repeat tracts corresponded to greater severity 
of spermatogenic defects, with the CAG repeat length increasing in the order: fertile 
controls <oligospermic < azoospermic. Azoospermic patients had the higher number of 
CAG repeats and the mean value was statistically different to that of the fertile control 
group (22.91 versus 20.72, p=0.019). Oligospermic patients also had an increased 
number of CAG repeats in their AR compared to the fertile population (21.65 versus 
20.72, p=0.226), although this difference did not reach statistical significance. 
 
1.3.1 Distribution of the CAG repeat length 
Percentage values of the CAG repeat length in the infertile population were calculated 
and compared to those in the normal fertile group (Fig. 6, 7 and 8). The histogram in 
Fig. 8 shows the two samples, normal and azoospermic patients. The distribution of the 
azoospermic patients is shifted to the right of the distribution of normal patients. 
Moreover the distribution of azoospermic appears to be bimodal, whereas the sample 
of normal patients appears unimodal. The first mode of the azoospermic patients is 
close to the mode of the normal patients, whereas the second mode is at a higher 

















  Table 2. Results of the Dunnett's test. 
Comparison of the number of CAG repeats were established between 





No. of cases Mean±SE  
(CAG length) 
Range P-value a
Fertile controls 55 20.72±0.52 8-27  
Oligospermic b 72 21.65±0.34 14-29 0.226 
Azoospermic 23 22.91±0.73 17-31 0.019 
 
 
a Dunnett's test , in comparison to fertile control subjects 
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Figure 6. Allelic distribution of the AR(CAG)n in the fertile and 
infertile group of subjects. 
Representation of the CAG repeat number allelic distribution in the 
normal fertile group (white bars), and the infertile group comprised of 
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Figure 7.   Allelic distribution of the AR(CAG)n in the normal fertile and 
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Figure 8. Allelic distribution of the AR (CAG)n in the normal 
fertile and azoospermic group. 
The azoospermic group of patients (black bars) shows a bimodal 
distribution, whereas in the normal fertile group (white bars) the 










1.3.2 Logistic regression analysis using the number of CAG repeats as the predictor, 
and clinical infertility or azoospermia as the outcome. 
When logistic regression was performed using the number of CAG repeats as a 
continuous predictor variable, the odds ratio for each unit increase in CAG was 
exp(β)= 1.11 (95% CI:1.05-1.23; p=0.038) for the outcome of clinical infertility, 
defined as a composite of oligospermic and azoospermic subjects. When the outcome 
was the azoospermic group of patients, exp(β) increased to 1.20 (95% CI:1.02-1.40; 
p=0.0277). Thus, each unit increase in CAG length was associated with a 20% 
increase in the odds of being azoospermic. 
 
1.3.3 Number of CAG repeats assessed as a categorical variable. 
For the categorical analysis, the threshold of 26 CAG repeats was chosen because this 
size was about two standard deviation above the mean. When the subjects were 
divided using 26 CAG repeats as the cut off point normal, and the infertile group of 
patients compared no significant differences were encountered (OR=2.75, 95%CI: 
0.747-10.108, p=0.128). However, when the normal versus the azoospermic groups 
were compared the differences between them were significant. Patients with >26 CAG 
repeats were 7-fold more likely to be azoospermic compared to those with < 26 CAG 
repeats (OR= 7.52, 95%CI: 1.75-32.78, p=0.006). The results imply that only those 
patients with azoospermia have significantly longer CAG repeats. 
 
1.3.4 Protective effect of having short CAG repeats towards azoospermia. 
From our previous tests we conclude that long CAG repeats increase the odds of being 
infertile. Another way to analyze this data is to study the protective effect towards 
infertility of having short CAG repeats. Using CAG repeats > 26 as a reference group, 
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Table 3A compares the proportion of azoospermic versus normal patients between two 
ranges of CAG repeats. The first range is CAG repeats > 26 compared to CAG repeats 
< C, where the values of C are taken as 22, 21, 20, and 19. As we reduce C we 
observed smaller OR and smaller p values for the chi square test. 
 
As we can see from Table 3A the odds of being azoospermic decreased with the 
number of CAG repeats. For instance, if the number of CAG repeats is < 19, the OR of 
being azoospermic was 0.100 compared to those with > 26 CAG repeats, (p=0.009). 
Similar results were obtained when the infertile population as a whole was considered 
and compared to the fertile group although the values did not reach statistical 

































Table 3.  Protective effect of short CAG repeats on the risk of male    
infertility.  
A) Only the group of azoospermic patients was considered. 
B) The whole group of infertile males was considered. 
Results in both tables show the same pattern, the risk of infertility decreases as 
it does the number of CAG repeats. Only when azoospermic patients were 






















>26 <22 <21 <20 <19 
OR a 
 
1 0.194 0.150 0.102 0.100 
















>26 <22 <21 <20 <19 














P value  0.122 0.144 0.084 0.06 
 
 
   a Odds Ratio 
                b 95% Confidence Intervals 
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1.3.5 Varicocele and male infertility 
The relationship between the presence of varicocele and male infertility has been 
studied, but the causes that originate varicoceles still remain controversial. The  
proportion of patients with varicocele was exceptionally high because Baylor is a 
referral center for this condition and therefore it was possible to study if there was any 
relationship between the number of CAG repeats and the presence of varicocele. 
In order to address this question the following t-tests and logistic regression analysis 
were performed. 
1. Mean CAG repeat values were compared between patients with and without 
varicocele. The mean value for the patients without varicocele was 22.07+0.39 and for 
those with varicocele was 21.97+0.53 (p=0.875), suggesting that the number of CAG 
repeats does not play a role in the aetiology of varicocele in infertile patients. 
 
2. When the same test was performed among azoospermic patients, again no 
significant differences in the number of CAG repeats were found between patients 
with and without varicocele (23.75 versus 22.88, p=0.652). However, the number of  
azoospermic patients with varicocele was very small, only four. 
 
3. When the number of CAG repeats was assesed as a continuous variable and the 
condition of varicocele as the outcome, a logistic regression test showed no significant 
correlation between the number of CAG repeats and the presence of varicocele, OR= 
0.97, (95% CI:0.87-1.08, p=0.6028). 
 
In line with other studies (Famiglietti et al., 2002; Schoor et al., 2001) a strong 
correlation was found between the presence of varicocele and the condition of 
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subfertility, being the OR= 2.55, (95% CI:1.13-5.791,p=0.027). When the azoospermic 
group was analyzed the OR increased to 7.79, (95%CI: 2.13-28.49; p=0.002). 
 
1.4  Clinical characteristics of patients with ≥ 26 CAG repeats. 
To determine if any particular phenotype would be related to long CAG repeats, the 
clinical characteristics of patients whose CAG length was 26 or more were analyzed. 
About 27% of Baylor patients had > 26 CAGs, the point at which risk of infertility 
significantly increased. None of the patients with long CAGs had any neurological 
deficit or abnormal secondary sexual development. In particular, none were noted to 
have hypospadius, microphallus, gynaecomastia or abnormal sexual hair distribution. 
Among patients having > 26 CAGs, 54% were azoospermic. The mean sperm counts 
of non-azoospermic patients were 6.5 mil/ml. Varicoceles were present in 46% of 
Baylor patients. This parameter was however not significantly associated with CAG 
length. The high prevalence of varicoceles in Baylor patients was due to the clinic 
being a quaternary referral centre for urological problems. The testicular volume of 
infertile patients with > 26 CAG repeats was significantly smaller than that of the 
fertile controls and the mean FSH values were above the normal range. Table 4 
summarises these results. 
 
2.   Analyses of patient population from the National University of Singapore  
2.1 Characteristics of subjects 
To compare differences in CAG repeat length between ethnic groups, 120 infertile and 
87 control males from the Singapore Hospital were analyzed. The racial composition 
was predominantly of Chinese origin. The clinical characteristics of the patients are 















Table 4.  Clinical characteristics of the patients with >26 CAG 





   
Number of patients = 13  
Azoospermia      54%  
Non-azoospermic patients   
      Sperm Density (N: >20  mil/ml) 
      Motility (Normal: >50%) 
 
    6.5±3.0 
    38.4±9.9 
Testicular volume  
(Normal:17.82±0.61ml). 
13.0±1.6    
Varicocele 46% 
Mean FSH (Normal: 0.8-4.7 IU/L)     16.4±2.9 
 
    
 
 
































                      Table 5. Clinical characteristics of the infertile group of patients. 
 
 
Number of infertile patients 
 
120 
Number of patients with azoospermia 
 
33 






Mean sperm density for oligospermic patients 




















2.2 Statistical analyses 
The number of CAG repeats ranged from 14 to 33 CAG repeats in the infertile group 
and from 11 to 29 in the fertile controls. 
 
To assess if the variable number of CAG repeats was normally distributed we 
performed a Q-Q plot. As in the case of the Baylor population the assumption that it 
was normally distributed was made. Results of the Q-Q plot are shown in Fig. 9 
 
The mean value of the number of CAG repeats in the infertile population was 
23.13+0.28, slightly higher that the mean value of the normal fertile group which was 
22.38+0.32. In contrast with the American population this difference was not 
statistically significant, (p=0.088), although it was quite close. 
 
Multiple comparisons using the Anova and Dunnett's tests were established to evaluate 
the differences among the different groups and to compare the oligospermic and 
azoospermic groups to the control one. Table 6 summarises these results. As in the 
case of the American population, no significant differences in the number of CAG 
repeats were encountered between oligospermic patients and fertile controls and were 
only observed when the azoospermic group of patients was compared to the control 
fertile group. 
 
2.2.1 Distribution of the CAG repeat length 
Percentage values of the CAG repeat length in the infertile and normal populations are 














Figure 9.   Q-Q plots to evaluate if the sample was normally distributed. 
To perform the Q-Q plot analysis subjects were divided into the categories:  
normal fertile, oligospermic and azoospermic. 
The observed quantiles values for the number of CAG repeats in each 
category were plotted against the expected quantile values. The straight line 
resulting from the plot indicates that the variable number of CAG repeats is 
















































































































 Table 6.  Results of the Dunnett's test. 
 Comparison of the number of CAG repeats were established with the 
oligospermic and azoospermic group against the fertile control one. 
 
 
   
SINGAPORE No.of cases Mean±SE  
(CAG length) 
Range P-valuea
Fertile controls 87 22.38±0.32 11-29  
Oligospermic b 87 22.85±0.33 14-32 0.514 
Azoospermic 33 23.82±0.52 18-33 0.043 
 
 
                       a Dunnett's test after ANOVA, in comparison to fertile control subjects 
     b Sperm counts less than 20 mil/ml 
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Figure 10.   Allelic distribution of the AR(CAG)n in the control 





















8 10 12 14 16 18 20 22 24 26 28 30 32











Figure 11.  Allelic distribution of the AR(CAG)n in the control 
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Figure 12.  Allelic distribution of the AR(CAG)n in the control fertile 
group and the azoospermic group of patients. 
There was a shift towards the right in the azoospermic group (black bars) 
respect to the control fertile sample (white bars), although the shift was less 





Fig.12 shows that there is a shift towards the right of the azoospermic sample with 
respect to the normal sample, although the observed shift is smaller than the shift that 
was observed for the Baylor population. The bimodality of the azoospermic sample 
was also less pronounced than that observed for the Baylor population. 
 
2.2.2 Logistic regression analysis using the number of CAG repeats as the exposure 
and clinical infertility as the outcome. 
When we performed the logistic regression method to establish any possible 
correlation between the number of CAG repeats and the condition of infertility the 
value of exp(β) was 1.083 (95% CI:0.99-1.19; p=0.09). In contrast with the American 
population, when the group of infertile patients were analyzed as a whole, no 
significant relationship was observed between the number of CAG repeats and the 
condition of infertility. The logistic regression analysis when only the azoospermic 
patients was considered showed a value of exp(β) of 1.18 (95% CI:1.01-1.37;p=0.032). 
This result indicates a relationship between the number of CAG repeats and the 
condition of azoospermia and it is possible to predict that there is an increased risk for 
azoospermia of 18% for each unit increase in CAG length.  
 
2.2.3 Categorical analysis 
Results from the categorical analysis indicated that for the Singaporean population 
there was no single cut-off point at which the risk of being azoospermic increases 
significantly. Table 7 summarizes the results obtained from the various cut-off points 


























           
    
Table 7.   Different cut off points considered in the 
categorical analysis. For the Singapore study there 
was not any statistically significant CAG repeat 
number cut off point at which the risk of being 
azoospermic was significant 
 
           
    
Cut off point Exp(β) 95% CI P-value 
n25 1.75 0.73 - 4.14 0.20 
n26 1.91 0.67 - 5.45 0.23 
n27 1.90 0.50 - 7.25 0.34 












2.3 Clinical characteristics of patients with ≥ 26 CAG repeats. 
20% Singapore patients had >26 CAG repeats. None of the patients had any abnormal 
secondary sexual development. In particular none of them had gynaecomastia, 
hypospadius, microphallus or abnormal hair distribution. Amongst patients having 26 
CAG repeats or more 33% were azoospermic. The mean sperm counts of non-
azoospermic patients were 4.1 mil/ml for Singapore patients and the mean testicular 
volume was significantly reduced to 13 mls. Varicoceles were present in 25% of 
Singapore patients, this parameter was however not significantly associated with CAG 
length as described previously. The mean FSH value of these patients was also slightly 
raised to 5.2±0.9 IU/ml. These results are summarised in Table 8. 
 
Testicular biopsies of 14 patients with long CAG tracts were available. Histology was 
non-specific and included incomplete spermatocytic arrest, paucity of mature sperm, 
Sertoli cell only syndrome, tubular atrophy, hyalinization and fibrosis of seminiferous 
tubules. In one patient, all the above were observed in seminiferous tubules biopsied 
from different parts of the testes. Of the 7 azoospermic Singapore patients with 
biopsies, three had complete absence of spermatogenesis, while 4 others had some 
evidence of spermatogenesis. Azoospermia associated with long CAGs therefore does 




















     
 
Table 8.   Clinical characteristics of infertile patients with 





Number of patients = 24  
   Azoospermia  33%  
Non-azoospermic patients   
      Sperm density (N: >20  mil/ml) 




Testicular volume (Normal:17.82±0.61ml). 13.1±0.8 
Varicocele 25% 

























Analyses of over 350 patients and controls show a significant direct correlation 
between CAG length in the AR gene and severity of spermatogenic defect. The major 
observation in this study is that there is a subgroup of azoospermic men than have 
significantly longer AR-CAG alleles compared to fertile controls. The CAG length 
was measured accurately with the use of internal size standards in every lane, and 
allelic size assigned objectively by the GeneScan software. Subjects with >26 CAGs 
have a 7-fold higher risk of azoospermia compared to those with < 26 CAGs. 
Conversely patients with short AR-CAG alleles had a lower risk of male infertility. 
The shorter the tract, the lower the risk. Thus men with <19 CAGs had only 10% the 
risk for infertility compared to those with >26 CAGs. No clear phenotype was 
observed in patients with long AR-CAG alleles. About 25% of Singapore patients with 
long AR-CAG alleles had moderate to large varicoceles, consistent with occurrence 
rates reported for infertile men (De Kretser et al., 1999). A high incidence of 
varicoceles where observed in the Baylor population, both for patients with long and 
normal CAG lengths, because the Baylor clinic is a referral center for such conditions. 
Overall our data indicate that long CAG tracts were not significantly associated with 
varicoceles. Serum FSH was raised slightly in the Singapore population and more so in 
the Baylor population, these differences most likely arising because of referral patterns 
to the two centres. Although about 33-46% of patients with long CAGs were 
azoospermic, spermatozoa were present in the seminiferous tubules in the majority of 
azoospermic men, suggesting that basal spermatogenic function was preserved in even 
the most severely affected patients. It is tempting to speculate that boosting intra-
testicular levels of androgens could be one method to improve spermatogenesis in 
these patients (Yong et al., 1994). 
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Ethnic differences in CAG length are well known; for instance, African-Americans 
have shorter CAG repeats compared to White-Americans (Edwards et al., 1992).  
The present study compared AR-CAG allele distribution in two different ethnic 
groups, one predominantly Caucasian and the other Chinese. There was a clear ethnic 
difference in CAG length, with the mean CAG lengths in the Singapore subjects being 
0.91 to 1.66 longer than the one corresponding American subjects. However, long 
CAG tracts were significantly associated with azoospermia in both populations, 
indicating that these differences were independent of ethnicity. 
 
It is well known that prostate cancer is an androgen-driven tumour and androgen-
ablation therapy is a commonly used treatment modality. There is evidence that 
spermatogenesis requires high concentrations of androgens (Zirkin et al., 1989). 
Patients with AR mutations that reduce intrinsic receptor activity have impaired 
spermatogenesis (Tsukada et al., 1994, Wang et al., 1998, Ghadessy et al., 1999). 
Conceptually prostate cancer and defective spermatogenesis may represent opposite 
ends of a spectrum of AR activity.  In combination, these studies suggest that 
polymorphic changes in CAG length inversely regulate the function of the AR. This 
hypothesis would imply that lower risk of defective spermatogenesis would be 
associated with increased severity and earlier age of onset of prostate cancer, and vice-
versa. Long-term cohort studies are required to validate this model of AR function. 
 
Long AR-CAG alleles encoding long AR polyglutamine tracts are associated with low 
intrinsic AR activity in reporter gene assays (Mhatre et al., 1993, Chamberlain et al., 
1994). A possible molecular mechanism as to how a change in polyglutamine length 
can affect the activity of the receptor has been suggested with the identification a novel 
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nuclear G-protein, Ras-related nuclear protein/ARA24, that acts as a coactivator with 
the AR and can bind differentially with different lengths of AR polyglutamines (Hsiao 
et al., 1999). AR-CAG/ARA24 interactions become stronger as the number of 
glutamines decreases, thereby increasing coactivation and AR transactivation 
capability. Recent studies have provided more insights into the molecular mechanism 
of how the CAG tract affects the functional competence of AR. The transactivation 
domain of AR is important for normal AR function, providing the essential AF-1 
function and coactivator interactions. Irvine et al showed that with increasing CAG 
repeats length, p160-mediated coactivation (such as AIB1, SRC-1a, GRIP1) of AR is 
repressed (Irvine et al., 2000). It was further demonstrated that the partial loss of AR 
function (with 65 CAG repeats) is due to decreased mutant AR protein that has been 
preferentially targeted for degradation via the ubiquitin-proteasome pathway 
(Lieberman et al., 2002). The mutant receptor also undergoes altered post-translational 
modifications such as hyperacetylation and phosphorylation, thereby targeting AR for 
ubiquitylation and degradation (Lin et al., 2002). 
 
Although the likely increase in AR intrinsic activity with each reduction in AR-CAG 
length is relatively small, these effects are genetically determined and therefore exert 
its effects over the entire lifetime of the individual. Small changes can over time have 
significant cumulative pathological effects. 
 
Collectively, the evidence supports the hypothesis that the glutamine repeat has a role 
in AR function by fine-tuning the balance between excess and deficient receptor 
function. The highly polymorphic nature of the glutamine repeat would imply a subtle 
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gradation of AR function among individuals, possibly allowing alleles with 
evolutionary advantages to be rapidly selected and transmitted to future generations.  
 
Recently, a number of studies have addressed the question of the importance of an 
expanded CAG repeat track and male infertility. Not all their conclusions are in 
agreement with the findings of the study presented in this thesis. Strikingly different is 
that of Komory et al. (1999) in which their researchers described that infertile males 
have higher chances of having less than 16 CAG repeats in the AR gene than the 
normal fertile individuals. This study was done on a small number of patients, only 59, 
without specifying how many of the infertile patients were azoospermic or 
oligospermic. Recently Sasagawa et al. (2001) reported in a Japanese population that 
no significant differences were found in the number of CAG repeats, when they 
compared the AR of 30 men with idiopathic azoospermia and 51 fertile males. 
 
Other studies performed by Dadze et al. (2000), conducted on a Caucasian population, 
did not find significant differences in the number of CAG repeats between the infertile 
and the fertile group, although the sample size was reasonable large (119 patients and 
22 controls). This study included only 22 controls and therefore may not had the power 
to prove significance. Likewise von Eckardstein et al. (2001) did a study in a German 
population and no differences where encountered in the number of CAG repeats 
between infertile and fertile. Nevertheless in a multivariate analysis the CAG repeat 
length was significantly correlated to sperm concentrations with a coefficient of –0.25 
only in the fertile group. In a Swedish population (Giwercman et al. 1998) there was 
no association between the number of CAG repeats and impaired sperm production, 
neither did a study performed in the Netherlands by Van Golde et al., (2002). It is 
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worth mentioning that in this last study the number of azoospermic patients was only 
of ten, from a total of seventy-five subfertile patients. Combined data from previously 
published European studies also did not find any difference in the CAG repeat length 
distribution between fertile and infertile males (Rajpert-De Meyts et al., 2002). 
However there were discrepancies in the various studies analyzed. For instance two 
studies of German populations (Dadze et al., 2000; Hiort et al., 1999) reported quite 
markedly different means of CAG repeat length in their small control groups (20.8 and 
24.0). Since the significant differences between patients and controls were usually one 
to two CAG lengths, it is possible that differences in analytical techniques and patient 
selection have contributed to the discrepancies observed between the European meta-
analyses (Rajpert-De Meyts et al., 2002) and our data. Other investigators suggest that 
differences observed could be due to the ethnic origin (Van Golde et al., 2002;), since 
the majority of the studies performed on European populations did no found an 
association between the CAG repeat length and subfertility.  
 
Nevertheless, the data presented in this thesis suggest that the differences encountered 
are not so much dependent on the ethnicity but on the design of the study. We had 
obtained significant results from our two ethnically diverse populations, one a 
Caucasian population from the US and the other a predominantly Chinese one from 
Singapore. The selection criteria employed to choose the cohort of patients in our 
studies was very selective. We excluded patients whose cause of infertility might be 
other that the one being investigated. In the study presented in this thesis, the exclusion 
criteria were patients diagnosed with chromosomal disorders, deletions in the Y-
chromosome, AR mutations, infective or obstructive syndromes of the genital tract, 
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hypopituitarism and hyperprolactinemia. The significant association between long 
CAG and azoospermia was found in both US and Singapore subjects.  
 
In line with our study, is that of Dowsing et al. (1999) performed on an Australian 
population composed of mainly Caucasians. The researchers also found significant 
differences in the number of CAG repeats between infertile patients and the fertile 
controls (24.0+0.7 versus 20.5+0.3) despite the sample size being very small, 
composed of only 30 patients with idiopathic infertility and 32 controls. The large 
difference found in the number of CAG repeats between the fertile and infertile group 
could be due to the fact that the infertile population was composed of 23 patients with 
severe oligospermia and azoospermia, while only 7 of those infertile patients had 
oligospermia. In a previous study, Tut et al. (1997) in a predominantly Chinese 
population from Singapore demonstrated that the longer the CAG tract the greater the 
severity of the spermatogenic defect. This is also in concordance with our study, which 
demonstrated that longer CAG tracts were mainly associated with azoospermia. 
Likewise, a study performed on a Japanese population by Yoshida et al. (1999) 
showed that patients with azoospermia had longer CAG tracts in their AR gene. The 
study included 41 patients with idiopathic azoospermia and 48 normal fertile males, 
and concluded that the mean values were 26.5+3.5 and 23+2.9 for infertile and fertile 
males respectively, (p=0.0013). They also reported that 4 of the patients with 
idiopathic azoospermia had 34 CAG repeats and in contrast none of the fertile males in 
the control group had more than 31 CAG repeats in their AR gene. Patrizio et al., 
(2001) performed a study in a Caucasian population from US and also reported that 
there were significant differences in the number of CAG repeats when the fertile and 
infertile groups were compared (p=0.03). Likewise longer CAG repeats tracts were 
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encounter in infertile Israeli men when compared to their fertile counterparts (18.6 + 
3.0 vs 16.6 + 2.7). It is important to notice that out of 61 patients 46 were azoospermic 
and 15 were severe oligospermic. In a French study by Wallerand et al. (2001), the 
authors found an association between the CAG length and infertility. The selection 
criteria to include patients in the study was very strict and excluded those with 
hypogonadotropic hypogonadism, hyperprolactinemia, obstructives syndromes of the 
genital tract, microdeletions of the long arm of the Y chromosome, mutations of the 
CFTR gene and karyotypic abnormalities. Moreover the proportion of azoospermic 
males was of 76% from a total of thirty-seven infertile males. In a Spanish population 
Mengual et al., (2003) measured the AR CAG repeat length of 102 patients with 
azoospermia and compared it to that of 96 fertile controls being significantly longer in 
azoospermic patients than in the control group. In line with our study, these 
investigators indicated that the number of 26 CAG repeats could be used as a cut-off 
point and showed that men with more than 26 CAG repeats have 4.09 greater risk of 
being azoospermic. Other investigators such as Kukuvitis et al., (2002), in a Greek 
population, performed a study on the contribution of genetic polymorphisms in the 
oestrogen receptor alpha gene (XbaI) as well as the AR CAG tract on male infertility. 
Although they did not find a difference in the number of CAG repeats between the 
fertile and azoospermic population, they did encountered a higher frequency of larger 
CAG repeats in patients with idiopathic oligospermia and azoospermia than those of 
the fertile group. The authors suggested that a possible synergy might exist between 
unfavourable genotypes between these two genes (ER and AR) in male infertility. In a 
recent report by Casella et al., (2003) in a predominantly white population, the CAG 
repeat tract was analyzed in seventy severely infertile patients without genital 
obstruction who were undergoing testicular biopsy (37 with Sertoli-cell-only 
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syndrome, 15 with maturation arrest, and 18 with hypospermatogenesis) Results 
indicated that only patients with hypospermatogenesis had longer CAG repeats than 
the fertile controls, suggesting a contributory role of these expanded polyglutamine 
tracts in the aetiology of hypospermatogenesis. Strikingly, longer AR CAG repeats are 
also associated with moderate to severe undermasculinization in male infants 
(undermasculinized: n=78, median 25, range 23-26; control: n=850, median 23, range 
22-26, P = 0.002) (Lim et al., 2000). The last piece of data from an entirely different 
paediatric patient population unrelated to male infertility strongly suggests the concept 
that CAG repeat length has a role in the intrinsic activity of the androgen receptor. 
Table 9 displays a list of publications that investigated the role of the CAG tract length 
and male infertility.  
 
It is likely that the genetic background and other environmental influences may 
contribute to AR activity and sperm production. Spermatogenesis is a very dynamic 
biological process and can be affected by a wide number of factors such as reactive 
oxygen species (ROS), which could damage not only the sperm plasma membrane but 
also sperm DNA (Aitken et al., 1998), exposure to toxins, fertilizers and herbicides 
(Kenkel et al., 2001). Expansions of unstable trinucleotide repeats in a number of other 
gene loci also lead to many other non-reproductive hereditary disorders. Examples 
include CGG or CCG expansion in fragile X syndrome (O’Donnell et al., 2002), CTG 
expansion in myotonic dystrophy type 1 (DM1), CAG expansions in Huntington 
disease (HD), dentatorubral-pallidoluysian atrophy (DRPLA), spinocerebellar ataxias 




Table 9. Studies to determine if the CAG polymorphic tract predisposes 
to male infertility 
 







MEAN CAGs  
INFERTILE 
Mean (range) 









153/72 No determined No determined No 
determined 
Tut et al., 1997 Patients with 




Swedish 33/294 21.9(16-27) 23.2(8-30) NS Giwercman et 
al.; 1998 
 
Australian 35/32 23.2(15-34) 20.5(17-25) S (0.0001) Dowsing et al., 
1999 
 
Belgian 223/181 21(15-30) 21(14-29) NS Legius et el., 
1999 
 
Japanese 41/48 26.5(20-34) 23.9(17-30) S (0.0013) Yoshida et al., 
1999 
 
German 119/22 22(16-34) 20.8(15-26) NS Dadze et al., 
2000 
 
UK 78/850 25(23-26) 23(22-26) S (0.002) Lim et al., 2000  















sperm count in 
normal males 
Japanese 30/51 23.4(19-30) 23.7(17-28) NS Sasagawa et al., 
2001 
 




French 37/50 23.91(13-28) 22.2(17-27) S (0.008) Wallerand et al., 
2001 
 
Danish 119/110 21.5(15-29) 21.8(14-33) NS Rajpert-De 
Meyts et al., 
2002 
 
Dutch 75/70 22.2 21.7 NS Van Golde et 
al., 2002 
 










Although exactly how these repeat expansions cause disease is not clear, a hallmark of 
these diseases is `anticipation'; i.e. the severity is greater and/or the age of onset 
becomes earlier in successive generations within the family (Timchenko and Caskey, 
1996). The clinical severity of these diseases is positively correlated with the length of 
the expanded trinucleotide repeats. Since the repeat length increases as it is transmitted, 
it is thought that the molecular basis of anticipation is meiotic instability of the 
trinucleotide repeat. In addition to instability during gametogenesis, these trinucleotide 
repeats are also unstable in somatic cells, resulting in somatic heterogeneity 
(Timchenko and Caskey, 1996).  
 
Taking these observations into consideration, Pan et al. (2002) examined the number 
of repeats at the loci DM1, MJD, DRLA, AR, and SCA8 of 48 patients with 
azoospermia, and compared them to 47 control subjects. Results indicated that the 
median CAG length in the AR gene was significantly longer in azoospermic patients 
than in controls (23 vs 21, p=0.001) and in addition increased (CTG/CAG) length were 
encountered at DM1 and MJD loci in a subset of azoospermic patients. Thus, it is 
noteworthy to evaluate whether offspring of these azoospermia patients, if born by 
assisted reproductive technologies, have an increased risk of trinucleotide repeat 
diseases. 
 
The important role of the genetic component in and male infertility has in recent years 
become clearer. Congenital bilateral absence of the vas deferens (CBAVD) is a form of 
male infertility in which mutations in the cystic fibrosis transmembrane conductance 
regulator (CFTR) gene have been identified. The molecular basis of CBAVD is not 
completely understood. Although patients with cystic fibrosis have mutations in both 
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copies of the CFTR gene, most patients with CBAVD have mutations in only one copy 
of the gene. Cystic fibrosis is important in the European population accounting for at 
least 6 percent of cases of obstructive azoospermia and being responsible for 1 to 2 
percent of cases of infertility in men (Jequier et al., 1985) 
 
Y-chromosome microdeletions were detected and confirmed in 6.8% of azoospermic 
and in 3.5% of severely oligozoospermic patients in our local population (Liow et al., 
1998).  However these patients with Y-deletions and long CAG patients in our study 
did not overlap. Thus our studies on CAG repeat length adds to the armamentarium of 
tests available to pinpoint the diagnoses in cases previously labelled as “idiopathic”. 
 
The additional data increases information for patients and enable them to understand 
the cause of male infertility and low sperm counts in subjects with azoospermia or 
severe oligospermia. Modern assisted reproductive technologies, utilising sperm 
obtained by testicular biopsies and the intra-cytoplasmic sperm injection procedure 
(ICSI), could result in viable pregnancies and the transmission of this trait. Screening 







CHAPTER 2: CAG REPEAT POLYMORPHISM IN THE AR GENE AND 
POLYCYSTIC OVARIAN SYNDROME (PCOS) 
 
INTRODUCTION 
1.   Oogenesis 
Reproduction in humans depends on the production of fertilizable oocytes by 
oogenesis. This is a discontinuous process that begins in the foetus and ends once 
puberty is reached. Oogenesis takes place in the ovary. The ovary is composed of three 
separate functional units, the stroma, the follicles and the corpus luteum. Follicles at all 
stages of development are present in the ovaries at any time until menopause. They 
contain the oocytes and serve as the vehicles for ovulation as well as producing steroid 
hormones. The mature Grafian follicle is composed of several layers of cells 
surrounding the oocyte. Two type of cells are present: the granulosa cells that maintain 
the conditions in the antral cavity which permit development of the oocyte, such as the 
transfer of nutrients and hormones, and the theca cells located in the outermost layers. 
The theca cells are supplied by a rich network of capillaries and synthesise mainly 
androgens. 
 
2.   Hormones involved in folliculogenesis 
Under stimulation by LH, the theca cells synthesize mainly androgens. Granulosa cells 
of mature follicles have a very high aromatase activity and convert most of the 
androgens produced by theca cells into oestrogens. In this way the intrafollicular 
enviroment of the follicle is kept highly oestrogenic. The activity of the aromatase 
enzyme is stimulated by FSH. LH and FSH are both secreted by the same cell in the 
anterior pituitary gland in response to stimulation by the gonadotropin-releasing 
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hormone (GnRH). The secretion of GnRH by the hypothalamic neurons is intermittent 
and hence the release of gonadotrophins is pulsatile in nature. The rising level and 
increased frequency of LH discharge that occurs throughout the follicular phase of the 
cycle is responsible for stimulating this increase in estrogen secretion from the 
dominant follicle. The levels of FSH decrease as the pre-ovulatory follicle matures. 
When the dominant follicle has reached maturity, the secretion of oestradiol is 
sufficient to induce a positive feed back effect and a massive discharge of pituitary LH 
occurs. LH then induces a series of changes in the structure of the follicle as well as 
the termination of the meiosis by the oocyte. 
 
3.   Definition of PCOS and selection criteria of patients 
Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine disorder, which is 
considered to be the most common cause of anovulatory infertility and hirsutism 
(Adams et al., 1986). It occurs in approximately 4% of women of reproductive age. It 
was first described by Stein and Leventhal in 1935, although the association between 
masculinization and abnormal carbohydrate metabolism was first described by Achard 
and Triers in 1921, who called it “The diabetes of bearded women”.  
  
There are many clinical, biochemical and metabolic manifestations of this disorder that 
make the criteria for disease diagnosis a very complex issue. The most widely accepted 
definition of (PCOS) is the association of anovulation (manifesting itself as irregular 
menses, oligomenorrhoea or amenorrhoea), hyperandrogenism, (with variable degrees 
of cutaneous symptoms such as acne, seborrhea and hirsutism) and ultrasonic evidence 
of polycystic ovaries. The last criteria has become important and many researchers 
now use it as a powerful tool to establish a diagnosis. Sonographically diagnosed 
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polycystic ovaries are enlarged, contain an increased number of follicles, or exhibit an 
increased amount or density of stroma (Takahashi et al., 1993). Patients with PCOS 
may not show all the symptoms described above and normal healthy individuals may 
have some of these characteristics. 
 
Since the definition of PCOS is very controversial, epidemiological studies on PCOS 
patients should clearly specify the selection criteria followed when selecting the 
patients as well as the ethnic background. It appears that there is some variability of 
clinical manifestations among races. For instance obesity and hirsutism are not 
pronounced in Japanese PCOS patients (Taketani, 1990). 
 
Some specialists have attempted to establish subgroups among PCOS patients to 
explain the variety of symptoms encountered. For instance, Balen et al. (1995) 
proposed two main groups based on the clinical phenotype that encompasses about 
85% of the wide range of manifestations. Among the first group the main clinical 
manifestations are hyperinsulinaemia, oligomenorrhea, obesity and 
hyperandrogennaemia. The women in the second group have high levels of LH, tend to 
be slim, with regular menses, but they have increased infertility and rate of 
miscarriage. Several authors failed to divide their PCOS patients into these two distinct 
groups (Grulet et al., 1993; Tropeano et al., 1994) because the gonadothrophic and 
metabolic disturbances are inter-linked. For instance, in vitro, the hormone insulin has 
been shown to stimulate androgen secretion directly and to enhance LH-mediated 
responses in isolated theca cells to a greater degree than in normal ovaries (Bergh et 
al., 1993). In vivo, the frequent coexistence of elevated LH and insulin concentrations 
leads to more severe expression of the syndrome (Fulghesu et al., 1999). 
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4.   The polycystic ovary (PCO) and the mechanism of anovulation. 
The polycystic ovary (PCO), on macroscopic appearance, typically contains 10 or 
more follicles ranging in size between 2-10 mm. In addition to the increased number of 
antral follicles there is twice the number of primary and secondary follicles in the PCO 
compared with the normal ovary. This suggests that there is an underlying disorder of 
folliculogenesis with increased follicular recruitment, but an arrest of follicular 
development at small antral stages  
 
The mechanisms of anovulation in PCOS still remain obscure in spite of being the 
most common cause of anovulatory infertility. Anovulation is characterised by the 
arrest of antral follicle development at the 5-10 mm stage and the failure to enter the 
preovulatory phase of the cycle (Franks et al., 1988). Spontaneous ovulation can 
occasionally occur and the disorder can be reversed in most cases by treatment that 
increases serum concentrations of FSH, such as antiestrogens or exogenous 
gonadotrophins (Hamilton-Fairley et al., 1991).  
 
The granulosa cells of follicles from anovulatory women with PCOS remain 
steroidogenically active and actually show increased aromatase activity when 
compared with folicles of similar size from women with normal ovaries. The 
production of oestradiol is therefore increased. Steroidogenesis by theca cells is 
abnormal in both anovulatory and ovulatory PCOS subjects. They produce higher 
levels of androestenedione, 17α hydroxyprogesterone and progesterone (Gilling-Smith 
et al., 1994). 
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Other forms of chronic anovulation not associated with hyperandrogenism can result in 
cystic ovaries, like multifollicular ovaries. The differences are that such ovaries do not  
have the peripheral distribution of ovarian cysts or the increased stroma characteristic 
of  PCOS. 
 
There are also differences between the presence of ultrasound-detected multicystic 
ovaries and PCOS (Hamilton-Fairley et al., 1991). The former occurs when 
characteristic ultrasound features are detected in a woman with a regular menstrual 
cycle and there are no symptoms or signs of hyperandrogenism. Actually up to 22% of 
the population may show ultrasound evidence of PCO although the majority will have 
regular ovulatory cycles. The latter exists when the ovarian ultrasound appearance is 
detected in a woman with menstrual irregularities, hyperandrogenism and perhaps 
obesity. Moreover, approximately 10% of women with all the features of the endocrine 
syndrome have normal ovaries as evidenced by ultrasound examination.  
 
5.   Several markers of the condition that can be considered as diagnostic criteria 
5.1 Excess of androgens 
The ovaries and the adrenal glands secrete androgens in response to their respective 
hormones, LH and ACTH. Ovarian hyperandrogenism is found in about 70% of 
patients with PCOS while adrenal hyperandrogenism is found in about 50% of the 
patients. If they are elevated serum T levels are between 2.4 and 4.1 nmol/L. The most 
likely cause of increased production of androgens from both glands seems to be the 
abnormal regulation of the 17-hydroxylase and the 17,20-lyase activities of P-450c17, 
the rate-limiting enzyme in the biosynthesis of androgens. The deregulation does not 
appear to be the result of a mutation in the gene as was suggested by Carey et al. 
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(1993), and it is likely to be due to hyperinsulinaemia, elevated LH levels and/or 
serine/threonine phosphorylation of the receptor itself, which increases its 17, 20-lyase 
activity (Ehrmann et al., 1995). 
 
Hyperandrogenism manifests itself in the presence of acne, excessive hair growth and 
sometimes acanthosis nigrans, which is characterized by symmetric gray-brown 
hyperpigmentation of the skin affecting the nape of the neck and axillae. The presence 
or absence of hirsutism depends on whether androgens are converted peripherally by 
5-alpha reductase to the more potent androgen dihydrotestosterone (DHT) and 3 alpha 
diol-G . 
 
5.2  Changes in concentrations of LH and FSH and prolactin. 
Altered gonadotrophin secretion, which in the past was considered to be the causal 
factor in the pathogenesis of the syndrome (Mais et al., 1986), is no longer considered 
a universal finding in PCOS although it helps physicians in establishing the diagnosis. 
The basal levels of LH and the frequency and amplitude of LH pulses are increased to 
levels usually above 20 IU/L. In contrast, the level of FSH is in the low-normal range. 
Actually additional amounts of FSH given to PCOS patients are sometimes sufficient 
to induce ovulation. It has been found that a LH/FSH ratio greater than 3, provided the 
LH level is not lower than 8mIU/ml, may be used for the diagnosis of women with 
clinical features of PCOS. Women with PCOS have mildly elevated levels of prolactin 
(20-30ng/ml), possibly related to the increased pulsatility of GnRH. 
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5.3 Pituitary abnormalities 
Abnormalities of GnRH secretion exist in a significant subset of patients and leads to 
persistent hypersecretion of LH, which seems to be an important component of the 
syndrome, particularly in non-obese patients (Marshall et al., 1999). Suppression of 
the pituitary-ovarian axis by the chronic administration of agonist and analogues of 
GnRH results in a fall in circulating androstenedione and testosterone. 
 
5.4   Metabolic disturbances. Hyperinsulinemia 
In addition to the abnormalities of the pituitary ovarian axis, PCOS is characterized by 
significant metabolic abnormalities. These include fasting and glucose-stimulated 
hyperinsulinaemia, peripheral insulin resistance (affecting predominantly muscle and 
adipose tissue), abnormalities of energy expenditure and dyslipidaemia. 
Hyperinsulinemia in PCOS is the result of insulin resistance as well as decreased 
insulin clearance. These abnormalities, together with obesity, explain the increased 
prevalence of glucose intolerance in PCOS patients. 
 
Obesity is present in about 25-50% of the PCOS population, while hyperinsulinemia 
associated with insulin resistance is present in more than 50% of PCOS patients. It is 
well known that obesity, and especially the accumulation of abdominal fat (android fat 
distribution), is associated with insulin resistance and when the pancreatic function is 
intact, insulin resistance will result in compensatory hyperinsulinaemia. PCOS 
represents a major risk factor for non-insulin dependent diabetes mellitus (NIDDM). 
The prevalence of impaired glucose tolerance or frank diabetes in young obese women 
with PCOS ranges (depending on the population studied) between 11% and 38% 
(Dunaif et al., 1993). Controversy exists as to whether women with PCOS have an 
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increased prevalence of gestational diabetes mellitus and larger studies are required to 
address this issue (Lanzone et al., 1995).  
 
6.  Genetic component in PCOS. Candidate genes studied 
If a woman in a family has PCOS, the risk of the syndrome in her sister is about 50% 
as compared to a prevalence of only 5-10% in a population for such risk. This familial 
clustering suggests a major genetic component to the aetiology of PCOS, although it 
seems unlikely that there is a single cause for the syndrome (Franks et al., 1988). 
There are of course obvious problems, which make genetic studies of PCOS difficult 
to perform. For instance, the heterogeneity and the lack of universally acceptable 
clinical or biochemical diagnostic criteria are a major problem. Another issue is that 
PCOS is a disorder that primarily affects women of reproductive age and it is therefore 
very difficult to analyze more than one generation. In addition to this, there is no 
commonly accepted male phenotype, although premature balding has been suggested 
as the likely manifestation of affected status in males (Lunde et al., 1989). 
 
To date, there has been no consensus about the mode of inheritance of PCOS. Certain 
segregation analyses gave results that were consistent with an autosomal dominant 
mode of inheritance (Lunde et al., 1989; Carey et al., 1993) however one study 
suggested an X-linked mode (Jahanfar et al., 1995). Only a few clinical studies have 
been performed over the last 20 years. Evidence that any of the candidate genes 
researched play a role in PCOS has not been replicated extensively. These 
uncertainties are common in “complex” genetic diseases, where identifying the 
contributing genes is difficult because of the multiple aetiologies and the 
 85 
environmental contributions (Urbanek et al., 1999). A description of the genes that 
have been studied is listed below. 
 
6.1   Genes coding for steroidogenic enzymes 
6.1.1 The 17-hydroxylase/17,20-lyase gene (CYP17) 
This gene encodes P450c17α, which is a rate-limiting enzyme in the biosynthesis of 
androgens. Carey et al. (1994), identified a single base change (a T to C substitution) 
at –34 bp from the starting point of translation. This variant allele includes a restriction 
site for the enzyme Msp-1, thus allowing the DNA screening by restriction fragment 
length polymorphism (RFLP) analysis. Preliminary case-control data suggested an 
association between the variant allele of CYP17 and PCOS. These findings were based 
on a small population of subjects (71 patients and 33 controls) and other research 
groups have been unable to replicate this association (Gharani et al., 1996; 
Techatraisak et al., 1997; Franks et al, 1997). 
 
6.1.2 Cholesterol side chain cleavage gene, CYP11a 
Based on the observation that ovarian theca cells in culture produce an excess of both 
androgens and progesterone (Gilling-Smith et al., 1994; Franks et al., 1996), Gharani 
et al. (1997) examined the CYP11a gene as a possible candidate gene for abnormal 
steroidogenesis. The CYP11a gene encodes P450 side chain cleavage (P450scc), an 
enzyme which catalyzes the conversion of cholesterol to pregnenolone, the first rate-
limiting step at the start of the steroid hormone biosynthesis pathway. The promoter 
region of the CYP11a gene contains a polymorphic region, a pentanucleatide repeat 
(tttta)n located at –528bp from the AGT start of translation site. They examined the 
segregation of CYP11a in 20 families and performed association studies in 
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premenopausal European women with PCOS. Patients and controls were classified 
according to the presence or absence of this repeat (at least one copy). Results showed 
that variation at the CYP11a gene were associated with both PCOS and serum 
testosterone levels.  
 
6.2   Genes involved in the secretion and action of insulin 
Numerous metabolic studies have revealed abnormalities of both insulin secretion and 
action in women with PCOS (Holte, 1996). The results of such studies raise the 
possibility that genes implicated in the secretion and action of insulin may have a role 
in the aetiology of PCOS. Some of them are described below. 
 
6.2.1  The insulin receptor gene 
There have been sporadic reports of a PCOS-like phenotype occurring in patients with 
severe insulin resistance associated with defects of the insulin receptor gene (Moller 
and Flier, 1988). Conway et al., (1994) were unable to detect any abnormalities of the 
tyrosine kinese domain of the insulin receptor gene in a population of 22 
hyperinsulinaemic women with PCOS. In another study, Talbot et al. (1996) scanned 
the entire coding region of the insulin receptor gene on DNA samples from 24 well-
characterized women with PCOS. Likewise, no missense or nonsense mutations were 
found concluding that mutations of the insulin gene were rare in women with PCOS. 
 
6.2.2. The insulin gene 
Abnormalities of the insulin secretion have been reported in studies of women with 
PCOS, with or without a family history of NIDDM (Ehrmann et al., 1995; Holte et al., 
1994; Dunaif and Fineggod, 1996). At the 5’ end of the insulin gene there is a 
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minisatelite region implicated in the regulation of insulin secretion. At this locus there 
is a bimodal distribution of repeats, class I alleles being short (average of 40 repeats) 
and class III alleles being much longer (average 157). Waterworth et al. (1997) looked 
for an association between the insulin gene VNTR (variable number tandem repeats) 
and PCOS in three different populations of European origin. They found that class III 
alleles were associated with PCOS in the three populations studied, and this 
association was stronger when only the cases with anovulatory PCOS were considered. 
They concluded that the VNTR of the insulin gene is a major susceptibility locus for 
PCOS, particularly anovulatory PCOS, and may contribute to the mechanism of 
hyperinsulinaemia and to the high risk of NIDDM in women with PCOS. 
 
6.3  The follistatin gene. 
Urbanek et al. (1999) studied 37 candidate genes for PCOS. The study was carried out 
in 150 nuclear families, mainly of European origin, with at least one affected case. The 
analysis included certain genes previously studied as candidate genes by others, such 
as the insulin gene, CY11a,  and the insulin receptor gene (INSR). They could not 
replicate the previously described association between the allele III of the insulin gene 
and PCOS. Neither could they replicate the association between the allele 5 in the 
promoter region of the CYP11a gene and PCOS after correction for multiple analyses, 
although without correcting for multiple analyses the association was found. 
Regarding the INSR, they found no mutations in the INSR coding region of patients 
with PCOS. The only association found was between the gene coding for follistatin 
and PCOS. Follistatin is an activin-biding protein which neutralizes the biological 
activity of activin. Both proteins are expressed in various tissues such as the ovary, 
pituitary, adrenal cortex, and pancreas. Activin promotes ovarian follicular 
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development, inhibits theca-cell androgen production, and increases pituitary follicle-
stimulating hormone production and insulin secretion by the pancreas (Shibata et al., 
1996). An increase in the level or functional activity of follistatin will overcome all 
those effects caused by activin. In fact overexpression of follistatin in transgenic mice 
results in suppression of serum levels of follicle stimulation hormone and arrested 





















SUBJECTS AND METHODS 
 
1.   Study population 
In this prospective study 91 patients with PCOS were recruited from the Subfertility 
and Reproductive Endocrinology clinics of the National University Hospital, 
Singapore. The women must not have taken any hormonal medication for at least 2 
months prior to the study. Inclusion criteria for patients were the presence of 
polycystic ovaries, infrequent periods with intermenstrual interval of >35 days, and 
involuntary infertility. An ovary with the ultrasound appearance of more than 10 
subcapsular follicles (< 10 mm in diameter) in the presence of prominent ovarian 
stroma was deemed polycystic. Patients with hyperprolactinaemia, thyroid and adrenal 
diseases; 21-hydroxylase deficiency and androgen-secreting tumours were excluded. 
The weight and height of all subjects were recorded. Hirsutism was not used as an 
inclusion criteria because was relatively rare (21%) in our predominantly Chinese 
patient population. Hormonal parameters measured in the patient include LH, FSH, 
PRL and T. 112 normal controls of proven fertility, no history of subfertility treatment 
and with normal menstrual cycles every 25-32 days were recruited from the 
contraceptive clinic. Ethical committee approval was received and informed consent 
was obtained from all subjects and controls.  
 
2.   DNA extraction, DNA amplification and GeneScan analysis 
The detailed procedures for DNA extraction, DNA amplification and GeneScan 
analysis are described in the materials and methods section 3 of Chapter 1 (page 24). 
The only difference with the male infertility study is that in this study the participants 
were women. Since the AR gene is located in the X chromosome, women have two 
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alleles if they are heterozygous for this locus. The number of CAG repeats for each 
allele was recorded. 
 
3.   Hormonal analysis 
Radioimmunoassays for serum LH, FSH, PRL and T were performed using standard 
reagents supplied by the WHO matched-reagent program (Yong et al., 1992). Free T 
was measured with the Coat-A-Count free T solid phase 125I radioimmunoassay 
(Diagnostic Products Corp). 125I-labeled T analog competes for a fixed time with free 
T in the patient sample for sites on testosterone-specific antibody immobilized to the 
wall of a polypropylene tube. The tube is then decanted, to isolate the antibody-bound 
fraction, and counted in a gamma counter, the counts being inversely related to the 
concentration of free T in the sample. The Coat-A-count Free T procedure is a direct or 
single-tube assay: the results are not calculated as a function of total T and SHBG or 
some other parameter, but interpolated from a standard curve calibrated in free T 
concentrations. In this respect it differs from conventional equilibrium dialysis 
methods and from so-called testosterone free index (TFI) determinations. It is also a 
single-stage assay, requiring neither a pre-incubation step nor preliminary isolation of 
the free fraction by dialysis, filtration or column chromatography. The assay can detect 
as little as 0.15pg/mL. The inter-and intra-assay coefficients of variation were less than 
15%.  
 
4.   Data analyses 
The mean values of AR-CAG alleles lengths of cases and the controls were compared 
using a two independent samples t-test. Since two X-linked CAG alleles are present in 
every subject, comparisons between subject groups were performed by firstly, 
 91 
considering the mean of the two AR-CAG alleles (biallelic mean) in each subject and 
secondly, the short and long alleles of each subject separately.  
 
To investigate whether CAG repeats are associated with any subset of anovulatory 
subjects, patients were categorised into “high T” and “low T” cases using a cut-off T 
value of 1.73nmol/L which corresponded to the mean value for fertile controls. Mean 
values of the number of CAG repeats of both subgroups were obtained and similarly 
compared. The mean AR-CAG lengths of patients with levels of FSH and LH above or 
below the respective means for normal subjects were similarly subjected to a t-test. 
 
Pearson’s correlation coefficient was calculated to assess the relationship between 
CAG length and T. 
 
The contribution of ethnic differences in AR-CAG alleles was evaluated by analysing 
the distribution of AR-CAG alleles among the subjects of the two ethnic groups of our 
study population.  
 
Statistical analyses were performed using the SPSS Version 9.01 (SPSS) computer 
software. Statistical significance was defined as a two-sided p-value of less than 0.05 









1.   Subjects characteristics 
203 participants were included in the study, comprising 91 patients (83% Chinese 
and 17% Indians) and 112 healthy controls (92% Chinese, 8% Indians). Patients with 
hyperprolactinemia were excluded from the study. The clinical characteristics of the 
patients are summarized in Table 1. Patients had a higher mean BMI of 26.9±0.73 
kg/m2 compared to 22.08±0.43 kg/m2 for control subjects. Hirsutism was not 
common, occurring in 21% of our patients. 
 
2.   Determination of CAG repeat length. 
The precise number of CAG repeats was determined by GeneScan technology in the 
same way as in the male infertility study. The only difference was that since the AR 
is located on the X chromosome each female has two AR alleles instead of one when 
women are heterozygous for this locus. Fig. 1 shows the two peaks corresponding to 
the two alleles from two subjects heterozygous for this locus. 
 
3.  Range of the number of CAG repeats and percentage of homozygous and 
heterozygous subjects. 
There were 28 AR-CAG different alleles in our population, ranging from 11 to 33 
CAGs in patients, and 14 to 38 in controls. The AR is located on the X chromosome, 
therefore each female has two AR alleles. Women can be then homozygous or 



























Figure 1.  GeneScan analysis of the androgen receptor CAG length in women. 
The polymorphic CAG repeat tract in exon 1 of the androgen receptor gene was 
amplified and internally labelled with the green fluorescent marker (dCTP, R6G) 
represented by the composed peaks in the picture. Its length was measured with the red 
internal size standard (ROX, 500) represented by the single peaks in the picture. The 
electropherograms from two different women show the two alleles with A) 15 and 22 















































































     Table 1.   Clinical and hormonal characteristics of PCOS patients 
 
 
 Mean + SE Range 
Age (years) 31.7 + 0.66 19-45 
BMI (Kg/m2) 26.93 + 0.73 18.2-39.9 
LH (IU/L) 9.50 + 0.80 1-30.4 
FSH (IU/L) 2.95 + 0.34 0.6-24.2 












The number of homozygous patients in our population was 12 (13.18%), ranging 
from allele 21 to 26. In contrast for fertile controls the number of homozygous was 
of 21(18.75%), ranging from allele 19 to 28. Among heterozygous the difference in 
the number of CAG repeats between alleles was quite similar in the control and 
patient population, being the average of the difference 3.21 (+2.81. SD) CAGs, and 
3.15 (+2.59 SD) CAGs respectively. 
 
4.   T-test to compare the means between patients and controls 
The biallelic mean was calculated for patients and controls, being 22.97±0.24 and 
23.09±0.23 respectively. A two-sided t-test was performed and the result indicated 
no significant differences between the biallelic means of patients and controls. 
 
Since all females have two AR genes and one of them is inactivated (Lyon et al., 
1988), analyses were performed on the short and long alleles separately. There were 
no significant difference on the long allele length between patients and controls. The 
respective mean lengths being 21.38±0.27 and 21.49±0.25 respectively. Similarly, 
there were no significant differences on the long allele between patients and controls, 
their mean lengths being 24.53±0.25 and 24.7±0.67 respectively. Table 2 
summarizes these results and also includes the corresponding values when both races 
(Chinese and Indian) were analyzed independently. No significant differences in the 
number of CAG repeats between patients are controls were found when the analysis 












 Table 2.   CAG repeats mean values for the short, long, and biallelic 
mean for patients and controls 
The number of CAG repeats was calculated and their values compared 
between patients and controls using a t-test. The corresponding P-values are 
indicated in the last column of the table. Firstly, the biallelic mean was 
calculated and subsequently the two alleles (short and long) were analyzed 
separately. The analysis was done for each race independently (Chinese and 











































      
 Patients Controls P-Value 
    CAG Repeat Biallelic Mean Value (SE) 
 
 
   Chinese    23.24+0.25    23.06+0.24    0.63 
   Indians    22.43+0.57    21.5+0.93    0.38 
   Total    22.97+0.24    22.97+0.23    0.68 
    
 CAG Repeat Short Allele Mean Value (SE) 
  
   Chinese    21.49+0.28    21.65+0.26    0.67 
   Indian    20.87+0.83    19.67+1.18    0.40 
   Total    21.38+0.27    21.49+0.25    0.78 
    
 CAG Repeat Long Allele Mean Value (SE) 
  
   Chinese    24.64+0.29    24.82+0.29    0.18 
   Indian    24.00+0.57    23.33+0.97    0.53 























5.   Frequency distribution of the CAG repeat sizes of the short allele and long 
allele.  
The frequency distribution when both alleles, short and long, were analyzed 
separately did not differ much between the patient and control groups. Fig. 2 and  3.  
 
6.   Testosterone levels divide patients with PCOS into two subsets of AR-CAG 
length. 
The clinical manifestations of patients with PCOS are very wide and since there is a 
subset of PCOS patients who are non-hyperandrogenemic (Conway et al., 1989), the 
relationship between AR-CAG length and serum androgen levels was investigated. 
As the mean T value in the normal population was 1.73nmol/L, the patients group 
was divided into two groups: “low T” subjects with T<1.73nmol/L and “high T” 
subjects with T>1.73nmol/L respectively. There were 57 patients with 
T>1.73nmol/L, and 34 patients with T<1.73nmol/L; no patient had a T of exactly 
1.73 nmol/mL. Their CAG ranges were 11 to 29, and 17 to 33 respectively. Total T 
was used in the analysis since there was a close correlation between total and free T 
in our patients (r= 0.82, p<0.0001) and because free T assays are also less readily 
available than total T. Furthermore there is evidence in the rabbit (Franks et al., 
1995) and human (Allen et al., 1997) that at least some of the albumin and sex-
hormone globulin bound T fractions may be bio-available. 
 
There was a trend for “low T” patients to have a lower average CAG biallelic mean 





Figure 2.   Frequency distribution of the short AR-CAG allele 
of PCOS patients and controls. No major differences were 
encountered in the allelic distribution of the number of CAG 
repeats between patients (black bars) and controls (white bars) 
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Figure 3.  Frequency distribution of the long AR-CAG allele of 
PCOS patients and controls No major differences were encountered in 
the AR-CAG allelic distribution between the patient (black bars), and 





















this difference did not reach statistical significance (p=0.09) but was marginally 
significant. This was not the case when only the short allele was considered. Results 
indicated that the mean length of the shorter allele for patients with “low T” was 
significantly lower than for patients with “high T”, being 20.38±0.51 versus 
21.98±0.29 respectively (p=0.004). Conversely, no significant differences were 
observed when the long allele was analyzed. The mean length value of the long allele 
for patients with “low T” was of 24.56 +0.38 CAGs, similar than that for patients 
with “high T”, being 24.53+ 0.35 (p=0.95). Table 3 summarizes the mean values of 
the number of GAG repeats when patients were divided according to their levels of 
T. Values are expressed considering the two racial groups separately as well as in the 
combined data. 
 
When the shorter allele was evaluated, differences in frequency distribution were 
observed, with 53% of patients with “low T” having ≤21 CAGs compared to 33% for 
“high T” ones (Fig. 4). 
 
7.   Sensitivity test to evaluate the T cut-off point. 
Different cut-off points above and below 1.73nmol/L were considered when the short 
allele was taken into account for analysis. Table 4 summarizes the results of such 
test. For instance, when the cut-off was increased to 1.91nmol/L, the p-value 
decreased to 0.058, value of borderline significance, which may be a result of the 













Table 3.   CAG repeats mean values were calculated and compared for 
patients with “low T” and “high T” respectively. 
Patients were divided into two groups depending on their T levels, named  
“low T” and “high T". The number of CAG repeats was compared 
among these groups with a t-test. The p-values are indicated in the last 
column of the table. Firstly the biallelic mean was calculated and 
subsequently the two alleles (short and long) were analyzed separately. 





















 Low T High T P-Value 
 CAG Repeat Biallelic Mean (SE) 
 
 
   Chinese  22.75+0.39 23.23+0.32 0.37  
   Indians  21.36+0.90 23.27+0.60 0.079 
   Total  22.47+0.36 23.25+0.29 0.098 
    
 CAG Repeat Short Allele Mean (SE) 
  
   Chinese  20.70+0.53 21.91+0.32 0.041 
   Indian  19.14+1.42 22.37+0.59 0.046 
   Total  20.38+0.51 21.98+0.29 0.004 
    
 CAG Repeat Long Allele Mean (SE)   
   Chinese 24.81+0.43 24.55+0.39 0.66 
   Indian 23.57+0.78 24.37+0.84 0.50 






























Figure 4. Frequency distribution of the short AR-CAG allele of PCOS 
patients with serum T levels below or above the normal laboratory mean 
value of 1.73nmol/L. There were differences in the AR-CAG allelic 
distribution of patients with low (black bars), and high levels (grey bars) of T 






































Table 4.  Sensitivity assay. 
Sensitivity assay showing the differences in the number of AR-CAGs 
(column 3) when the cut-off point values for T varied (column 1). The cut-
off values considered were bellow and above the original cut off point of 
1.73nmol/L (indicated in bold characters). The corresponding P-values 






































T cut-off point 
(nmol/L) 
 




1.21 <1.20  = 7 





1.38 <1.37  = 15 




1.56 < 1.55 = 28 






< 1.72 = 57 




1.91 < 1.90 = 40 




2.07 < 2.06 = 43 




2.25 < 2.24 = 49 




2.42 < 2.41 = 56 

















8.  Correlation between the number of CAG repeats and the levels of testosterone. 
Bivariate correlation analysis between CAG repeats and the T levels for each allele 
did not show any correlation when each of the alleles were analysed separately, 
values for the shorter and longer allele being (r=0.063, p=0.551) and (r=-0.113, 
p=0.285) respectively. This result suggests that the relationship is not a dose-
response or linear one, but is more closely approximated by a threshold response.  
 
9.   CAG repeat number and the levels of LH and FSH 
In order to elucidate if the differences in the number of CAG repeats when patients 
were classified according to their levels of testosterone were to be due to chance, 
patients were similarly classified according to their “high” or “low” levels of the 
hormones FSH and LH and their CAG number analyzed. The cut off point used in 
the analysis was the mean value obtained for the control group, being in the case of 
LH of 3.5(IU/L) and of 6.1(IU/L) for FSH. Results are summarised in Table 5. No 
differences in the number of CAG repeats were detected when those with low or high 
FSH and LH were analyzed, however when the hormone testosterone was used to 
divide the patients into two categories the difference in the number of CAG repeats  
was highly significant and not likely to be due to chance.  
 
10.   Ethnic differences in CAG length 
The average biallellic mean CAG length in Chinese subjects (patients and controls) 
was longer than for Indians, being 23.16±0.17 and 22.08±0.5 respectively (p=0.035). 
This result agrees with other studies where it has been reported than Chinese 
individuals have longer number of CAG repeats than those of other races (Edwards 













Table 5. Comparisons of the CAG repeats number when patients were 
classified according to the hormonal levels of LH and FSH below and 
above the laboratory mean value. 
The average number of CAG repeats in the shorter androgen receptor allele in 
patients with hormonal levels of LH and FSH below or above the normal 
laboratory mean was calculated and compared to the values obtained for T. 
*Independent 2-sample t-test was used for calculation of statistical 
significance (last column). Statistical differences in the number of CAG 
repeats were observed only when patients were classified according to the 
levels of T. This was not the case when patients were classified according to 



































































       























































The mean length of the short allele was also different between these two races, being 
21.5±0.19 and 20.4±0.68 for Chinese and Indians respectively (p=0.045). There was 
also a difference between “low T” Chinese and Indians when the short allele alone 
was considered, being 20.7±053 and 19.1±1.42 respectively, although this did not 

























PCOS is a heterogeneous endocrine disorder manifesting itself in a wide variety of 
symptoms that affects approximately 4% of women of reproductive age. Due to its 
heterogeneous nature, establishing a definition, which encompasses all the clinical and 
biochemical manifestations was a difficult task. The most widely accepted definition 
of PCOS is the association of anovulation (manifesting itself as irregular menses, 
oligomenorrhoea or amenorrhoea), hyperandrogenism, (with variable degrees of 
cutaneous symptoms such as acne, seborrhea and hirsutism) and ultrasonic evidence of 
polycystic ovaries (Takahashi et al., 1993). 
 
Due to the heterogeneity of symptoms encountered in PCOS patients the selection 
criteria when recruiting the patients was a very important issue. In this study to account 
for such a variety of clinical manifestations and to encompass the various subsets of 
patients of this complex disorder, the patients were selected using a broad criteria of 
menstrual cycles >35 days and ultrasound-diagnosed polycystic ovaries. Emphasis was 
not placed on hyperandrogenemia as we wanted to include the subset of patients whose 
serum androgens levels were not abnormally high and whose symptoms could possibly 
be due to intrinsic hyperactivity of the receptor apparatus. Moreover the Chinese 
patients that comprised the majority of our patients did not have high levels of 
hirsutism (a commonly used marker for hyperandrogenemia).  
 
Familial clustering of PCOS patients suggests a major genetic component involved in 
the aetiology of PCOS. As described previously in the literature review, a reduced 
number of genes have been implicated in the aetiology of PCOS, some of them related 
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to the insulin metabolism and others to the estrogenicsteroidogenic pathway, although 
the conclusions for the majority of genes studied remain controversial and further 
studies are needed. 
 
One of the genes that has been implicated in the excess of androgen action 
characteristic of PCOS patients is the CYP11a gene, which codes for the enzyme 
P450scc, a rate-limiting enzyme in the steroid hormone pathway and could possibly 
lead to an increase in androgen production. Variations at the promoter region of this 
locus were associated with an increase of total T levels and the development of PCOS 
(Gharani et al., 1997). Results of this study were replicated by another study by 
Urbanek et al. (1999) where the researchers analysed 37 candidate genes implicated in 
the aetiology of PCOS and concluded that only the CYP11a (before the correction for 
multiple analysis) and the follistatin gene were accountable for some of the symptoms 
characteristic of the disease. 
 
Taking into account the excessive androgen action characteristic of PCOS patients, the 
AR gene was selected as a candidate gene for our study. The mode of action of 
androgens is through binding to the AR followed by a cascade of events that ultimately 
leads to the activation of target genes. Therefore, not only the levels of circulating 
androgens are important but also the activity of the complex AR and hormone as a 
whole and the question raised was if the AR-CAG microsatellite tract, located in the 
exon 1 of the AR gene, contributes to the hyperandrogenism in patients with PCOS.   
 
Since the AR is located in the X chromosome, each woman has two AR alleles, which 
may be of different sizes possibly due to different AR-CAG repeat lengths. We 
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therefore proceeded to measure both CAG repeat tracts in women with PCOS and 
compared them to those of normal fertile women. The average biallelic mean AR–
CAG length did not differ between controls and patients. Further we found no 
statistically significant differences when the long and short alleles of patients and 
controls were analyzed separately and compared. However it was ascertained that the 
short allele contained slightly fewer tracts in the patient group as opposed to the fertile. 
 
Subsequently, patients were divided into two subgroups, those with T levels below 
1.73nmol/L, ("low T") and those with T values above 1.73 nmol/L ("high T") (the cut-
off point of 1.73nmol/L was selected because it was the mean T value obtained in our 
laboratory for the normal fertile group). It was highly significant that patients with 
“low T” levels had shorter CAG repeats tract compared to patients with “high T” when 
the short allele was taken for the analysis. 37% have serum T levels below the normal 
laboratory mean and these cases have a significantly lower mean CAG length 
compared to patients whose T levels were above the laboratory mean. The association 
between short AR-CAG alleles and patients with “low T” was regardless of ethnic 
origin, and found in both Chinese and Indian subjects.  
 
A similar analysis was performed by dividing the patients into those with “high”, and 
“low” levels of LH and FSH, respectively. The cut-off point was the mean value of the 
control population for these hormones. The aim of this analysis was to determine if the 
differences found in the number of CAG repeats between patients with “low T” and 
“high T” were due to chance. No differences in the number of CAG repeats were 
observed between patients with “low” and “high” LH or FSH indicating that the 
differences appear only when the hormone T was used in the analysis. 
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More than half of “low T” patients have at least one AR-CAG allele of ≤21 (Fig. 4), 
section 7 of results ( page 105), and could potentially be at risk of hyperandrogenism 
due to the greater intrinsic activity of the short AR-CAG allele. The data supports the 
conclusion that there is a subset of PCOS patients with normal circulating androgen 
levels that have shorter CAG stretches in the AR gene, at least in one of the alleles, 
compared to patients with high levels of androgens. One will tend to think that due to 
the inactivation of one of the X chromosomes, this subset of patients could have active 
the AR allele containing the shorter number of CAG repeats in important target organs, 
such as the ovaries, and therefore responding to a greater degree to androgen action. 
This study is consistent with the findings of a recent study, which did not find any 
difference in the number of CAG repeats between hirsute patients and controls 
(Vottero et al., 1999). The authors suggested that significant skewing of X-
chromosome inactivation occurred, allowing the shorter of the two AR-CAG alleles to 
be expressed in cases of non-hyperandrogenic hirsutism.  If so, the effects of the short 
AR allele would be accentuated, increasing the chances of hirsutism in those with both 
long and short alleles in their X-chromosomes.  
 
Other studies support the hypothesis that short CAG tracts in the AR gene may account 
for the development of PCOS. For instance Carey et al. (1993) studied the mode of 
inheritance of PCOS in families, and the affected status was assigned on the basis of 
ultrasound evidence of polycystic ovaries in the women, and male pattern baldness, 
before age 30 in male. Coincidentally, Sawaya et al. (1988) found an association 
between shorter CAG tracts in the AR and the condition of male pattern boldness. In 
another study by Legro et al. (1994) on a Hispanic population, the researchers found 
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that normoandrogenic patients with idiopathic hirsutism had an inverse relation 
between the Ferriman Gallway score and the number of CAG repeats (r=-0.60, 
p=0.014). This correlation was not observed when the patients with high levels of T 
were taken into consideration. Furthermore low androgen action associated with long 
CAG repeat tracts had been correlated with increased incidence of breast cancer.  
Using a sample of women who inherited germline mutation BRCA1, Rebbeck et al. 
(1999) found that these women were at significantly higher risk of developing breast 
cancer if they carried at least one AR allele with >28 CAG repeats, possibly due to the 
lack of androgen inhibition in the tumor. 
 
Ethnic differences were evident in our data, Indian subjects having a shorter biallelic 
mean AR-CAG length compared to Chinese. This ethnic difference was also observed 
when only the shorter AR allele was analyzed.  Data from Table 3, section 7 of results 
(page 104), shows that Indian women with “low T” have an average of 19.14+1.42 
CAG repeats in their AR gene compared to 22.37+0.59 CAG repeats in those with 
“high T”. This difference in the number of CAG repeats was not as acute in the 
Chinese population where women with "low T" have an average value of 20.70+0.53 
CAG repeats versus 21.91+0.32 in the “high T” group. These results provide, at least 
in part, a physiological basis for the observation that the prevalence of PCOS in Indian 
women is very high, about 52% compared to <10% in other populations (Rodin et al., 
1998). Interestingly Indians have a higher age-standardized incidence rate of the 
androgen-driven tumor prostate cancer, compared to Chinese (11.0 versus 7.6 per 
100,000/year) (Chia et al., 1996). It would be very interesting in the future to include a 
higher number of Indian patients since in this study the majority of patients and 
controls were of Chinese ethnic origin. 
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An ethnic difference in AR-CAG distribution was also observed when patients and 
controls were grouped together. The most common allele length for our Chinese 
subjects was 23, similar to the Asian population described by Edwards et al. (1992). 
The AR-CAG allele has well-established population differences. The most frequent 
allele in African-Americans is 18 CAGs compared to 21 for White-Americans, and 23 
for the Chinese population.  
 
In summary, this study has identified a subset of PCOS patients with normal 
testosterone levels and shorter CAG tracts, in at least one of the alleles of the AR gene. 
PCOS is a complex genetic disease and it is likely that more than one gene would be 
involved. The complexity of this disease makes it difficult to define exactly how this 
locus interacts with other genetic factors Besides the genetic components, 
environmental influences such as fat and carbohydrate consumption, exercise level, 
peripubertal stress and hormonal exposure may contribute to the development of this 
complex disorder (Kashar-Miller et al., 1999). Nevertheless, this study adds to a 
growing list of conditions that are related to variations in the AR-CAG tract. We have 
examined a subpopulation of Singaporean PCOS subjects with normal testosterone 
levels whose disease was previously puzzling. Our data suggest the novel concept that 
the cause of hyperandrogenism in these subjects could be related to intrinsic 
hypersensitivity of the AR due to short CAG tracts. If this hypothesis is confirmed in 
other populations, our study would have made a significant contribution to the 
understanding of the disease etiology in the previously inexplicable subset of subjects 
with all the features of PCOS except for raised androgen levels. Increased 
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understanding of the mechanism of pathogenesis could lead to improved therapeutic 





















 CHAPTER 3: RELATIONSHIP BETWEEN PROSTATE-SPECIFIC 
ANTIGEN, SEX-HORMONE BINDING GLOBULIN AND ANDROGEN 






Prostate cancer is the most diagnosed malignant tumour, the second leading cause 
of cancer death in American men, (Boring et al., 1994.) and the sixth commonest 
cancer among men in Singapore (Koh et al., 2001). It is as well-known fact that 
androgens are required for the development of a normal prostate and also for the 
development of prostate cancer. The depletion of androgens by surgical or 
chemical treatments slows cancer growth (Cunha et al., 1987). Serum prostate 
specific androgen (PSA) levels are a common oncogenic marker for prostate cancer 
because the serum PSA levels parallel oncogenic growth in the initial androgen-
dependent and in early stages of androgen independent phase of the cancer.  
 
The AR activates the transcription of the PSA. The hormones playing an important 
role in prostate cancer are T, its more potent form dihydrotestosterone (DHT), and 
sex hormone binding globulin (SHBG) The levels of these hormones and PSA are 
biologically related to each other. A preliminary description of PSA, SHBG and 
the androgens T and DHT in addition to a short review on how these factors are 
related to each other is listed below.  
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 1. Androgenic parameters important for prostate cancer 
1. 1 Prostate specific antigen  
Prostate specific antigen (PSA) is a single chain glycoprotein enzyme (serine 
protease) of 33-Kd. In males it is found within the cytoplasm of prostatic duct cells 
and in the lumina of prostatic ducts. It is present in urine, seminal plasma, and 
serum (Warhol & Longtine, 1985). PSA concentration in male serum is a valuable 
tumour marker for diagnosis and management of prostate cancer. The expression 
of the PSA protein is an AR-mediated process (Young et al., 1991). 
 
PSA was believed to be a highly specific marker for normal or cancerous prostatic 
tissue, but recent studies have also found PSA in female tissues and fluids such as 
milk breast, ovary, and amniotic fluid, (Diamandis et al., 1995). The protein 
production of PSA in nonprostatic tissues is under regulation of steroid hormones, 
such as androgens, glucocorticoids, and progestins. Estrogen itself seems to have 
no effect on PSA regulation, but it can impair androgen-induced PSA production 
(Diamandis et al. 1997). 
 
PSA occurs in three major forms in blood. The major immunodetectable form is PSA 
complexed with the serine protease inhibitor, alpha-1-antichymotrypsin (PSA-ACT). 
Uncomplexed, or free PSA, is another immunodetectable form of PSA in serum. The 
majority of free PSA in serum appears to be an inactive form that cannot complex with 
protease inhibitors and may be either a PSA zymogen or an enzymaticaly-inactive 
cleaved form of PSA. A third form of PSA, a complex with alpha-2-macroglobulin, is 
not detectable with current immunoassays due to the engulfment and subsequent 
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masking of PSA epitopes by the alpha-2-macroglobulin molecule (McCormack et al., 
1995). The sum of the first and second forms of PSA constitute the total PSA. 
 
It has been postulated that PSA is more extensively complexed in prostate cancer cells 
than in nondiseased prostatic or benign prostatic hyperplasia cells. A lower ratio of 
free PSA to total PSA (fPSA/tPSA) in patients with prostate cancer has been 
demonstrated in numerous studies (Stephan et al., 2000); (Basso et al., 2000).  This 
ratio has been considered as a helpful tool for distinguishing between prostate cancer 
and benign prostatic hyperplasia (BHP).  
 
1.2 Sex hormone-binding globulin  
Sex hormone-binding globulin (SHBG) is a plasma glycoprotein that binds certain 
estrogens and androgens with high affinity. SHBG is synthesized in the liver. It 
binds T and DHT with high affinity and estradiol with a lower affinity. The 
function of SHBG still remains controversial, and one view is that only the non-
protein bound steroid hormones are capable of entering the cells from the 
bloodstream, and thereby initiating their biological responses. Another biological 
function is that SHBG binds specifically to cell membranes through its membrane 
receptor, and stimulate the production cyclic adenosine monophosphate (cAMP). 
When the steroid binds to the SHBG, this inhibits the binding site for the SHBG 
receptor (Rosner et al., 1999) 
 
T circulates primarily protein-bound, principally to SHBG, but also to albumin and 
cortisol binding globulin. Since variations in the carrier protein levels may affect 
the concentration of T in circulation, SHBG levels are commonly measured as a 
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supplement to total T determinations (Cunningham et al., 1985). The free androgen 
index (FAI) is the ratio of total T to SHBG and is sometimes an indicator of 
abnormal androgen status. 
 
1.3 Testosterone and dihydrotestosterone 
Androgens affect a multitude of physiological parameters, including muscle mass, 
bone density, central nervous system function, bone marrow production and sexual 
function.  
 
Testosterone (T) is the predominant circulating androgen in men. It is secreted by 
the Leydig cells of the testis in response to the hormone LH. T circulates almost 
entirely bound to transport proteins and normally less than 1% is T free. The 
principal transport protein for T is SHBG. Albumin and cortisol binding globulin 
(CBG) are the other T transport proteins.  
 
Dihydrotestosterone (DHT), a reduced form of T and a much more potent 
androgen, is essential for normal growth and development of the prostate gland. 
Greater than 95% of intracellular T is converted to DHT within the prostate gland 
by the enzyme 5α-reductase. 
 
2.   Relationships among the various androgenic parameters analyzed  
2.1 Association between the levels of testosterone and prostate specific antigen. 
A number of studies have shown that androgens are necessary for the development 
of prostate cancer, at least in the initial stages, before the tumour escapes its 
androgenic regulation. In this initial androgen-dependent stage appears to be a 
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correlation between the levels of T and those of PSA. However, there is limited 
data on the correlation between T and PSA in a normal healthy population, and 
people with low androgen status such as hypogonadism, during male puberty, and 
in women.   
 
Monath et al. (1995) measured the levels of T and PSA of 150 males without 
previous history of prostate cancer. They found no correlation between T and PSA 
(r= 0.054; P = 0.515), even when corrected for age and weight. No significant 
correlation was found between T and age, but a significant correlation was found 
between increasing age and PSA. In another study, MacIndoe et al. (1995) reported 
that serum PSA levels did not change significantly in 11 healthy young men 
receiving exogenous T administration. They concluded that the expression of PSA 
appeared to be dependent on the presence of androgens in patients with prostate 
cancer. On the contrary, in men without prostate cancer or with benign hyperplasia 
of the prostate gland (BHP) a correlation between the expression of PSA and the 
administration of exogenous T was not found. Similarly, Copper et al. (1998) 
studied 31 young healthy males following 15 weeks of T injection. They concluded 
that no detectable significant change occurred in their serum PSA levels or prostate 
volume after therapy. 
 
In the study by Kim et al. (1999) 77 normal boys in Tanner stages I to V, from 10 
to 18 years, were analyzed for PSA levels, SHBG, insulin like Growth factor (IGF-
I), IGF binding protein 3 (IGFBP-3) and T. A positive correlation was found 
between PSA and T during puberty (r=0.86, p<0.001). Behre et al (1994) studied 
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78 hypogonadal males undergoing T treatment for 6 months. They reported an 
increase in PSA levels and prostate volume as a response to the T treatment.  
 
Similarly, Douglas et al. (1995) studied the effect of exogenous T replacement on 
PSA levels in 10 hypogonadal men ranging in age from 40 to 76 years. These men 
had no clinical signs or symptoms of BHP, prostatitis, or carcinoma of the prostate 
and had normal PSA levels. Surprisingly they found no significant correlation 
between PSA and total T levels. The researchers found this lack of correlation 
unusual, and attributed it to the short duration of their study or to the small sample 
size used. Weber et al. (1989), reported a strong correlation between serum PSA 
and serum T levels in seven BHP patients undergoing a period of androgen 
deprivation. Aus et al. (1994), demonstrated no correlation between serum T and 
serum PSA in 120 men undergoing transurethal prostatectomy for symptomatic 
BHP. 
 
Since the discovery that women also have detectable levels of PSA, Escobar-
Morreale et al. (1998) studied the relationship between hirsutism and elevated 
levels of serum PSA. Their study included 37 patients and 11 controls. Serum PSA 
concentrations were clearly elevated in hirsute women compared to those in the 
control group. When patients and controls were studied as a whole, serum PSA 
values showed positive correlation with basal T, and a negative correlation with 
basal SHBG levels and age. In another study, Goh (1999) used  as a model of PSA 
regulation female transsexual patients whom were given exogenous doses of T. 
Serum levels of PSA were significantly raised in female transsexuals after long-
term androgen therapy. His study showed that high levels of T were able to up-
 124
regulate PSA production in transsexual women in a time and dose dependent 
manner. 
 
2.2 Association between the levels of testosterone and sex hormone-binding 
globulin 
The correlation between the levels of T and SHBG remains a controversial subject. 
Carlstrom et al. (1990) measured the levels of T and SHBG in 80 healthy males 
aged from 25 to 80 years and found that there was a positive correlation for all 
different age groups analyzed. Similarly, Gann et al. (1996), described a strong 
correlation (r=0.55) between the levels of T and SHBG measured from the plasma 
of 190 healthy individuals. On the contrary, Plymate et al. (1983) described that 
the levels of SHBG decreased in normal males after treatment with external doses 
of T. Cell culture experiments, using the human hepatocarcinoma cell line HepG2 
demonstrated that the secretion of SHBG was stimulated by increasing levels of T 
(Edmunds et al., 1990). 
 
2.3 The number of CAG repeats in the androgen receptor gene and prostate cancer. 
Some studies have analyzed whether there is a relationship between the number of 
CAG repeats in the AR gene and the development of prostate cancer. Hardy et al. 
(1996) reported that there was a significant correlation between CAG repeat length 
and age of onset of prostate cancer, suggesting shorter CAG repeats may be 
associated with the development of prostate cancer at a young age. The authors 
failed to find a correlation between the number of CAG repeats and other 
parameters such as PSA levels once the tumour was diagnosed. In a larger study 
comprising of 587 cases of prostate cancer and 588 control males, Giovannucci et 
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al. (1997) demonstrated that men with shorter number of CAG repeats in the AR 
gene had higher grade and advanced stages of prostate cancer at diagnosis, 
metastasis of the tumour, and mortality from the disease. Stanford et al. (1997) 
evaluated the number of CAG repeats of 301 cases of prostate cancer and 277 
controls in a population-based case-control study. Their results also supported the 
hypothesis that the number of CAG repeats is a predictor of risk for prostate 
cancer. In a recent study by Hsing et al. (2000), the researchers measured the 
number of CAG repeats in the AR gene from 190 prostate cancer patients and 304 
healthy controls in a population of Chinese ethnic origin. Results indicated that the 
median value of CAG repeats for their subjects was of 23, and that men with a 
CAG length of less than 23 repeats had a 65% increased risk of prostate cancer. 
 
In this study we wanted to gain information about how some of the androgenic 
factors relating to prostate cancer, such as the serum levels of free and total T, free 
PSA, total levels of PSA, and SHBG change with respect to each other in our 
population. Specifically, this study aimed to determine whether the levels of PSA 
were related to the number of CAG repeats in the AR gene, and therefore obtain a 









MATERIALS AND METHODS 
 
1.   Study population 
112 subfertile males were recruited from the infertility and andrology clinics of 
National University Hospital, Singapore. A complete history and physical examination 
were performed, and the use of any medications or previous surgery was recorded. 
Patients who had chromosomal abnormalities, hypopituitarism, hyperprolactinemia, 
undescended testes, obstructive syndromes of the genital tract, and hypogonadism 
secondary to surgery, trauma, or chemotherapy were excluded from this study. Sperm 
parameters were assessed according to standard criteria and were the mean of at least 
two analyses done 3 months apart. Azoospermia was defined as the absence of any 
spermatozoa despite centrifugation of the semen specimen, severe oligospermia was 
sperm density <5 mil/ml, and oligospermia defined as the mean sperm density being 
<20 mil/ml. 91 control men of proven fertility with no previous infertility history or 
treatment, and without any genetic disease were included in the study. Ethical 
committee approval was received and informed consent was obtained from all subjects  
 
2.    Hormonal analysis and determination of the number of CAG repeats 
Assays for serum total and free T, SHBG, total and free PSA were performed. 
Free T was measured with the Coat-A-Count free T solid phase 125I radioimmunoassay 
(Diagnostic Products). 125I-labeled T analog competes for a fixed time with free T in 
the patient sample for sites on testosterone-specific antibody immobilized to the wall 
of a polypropylene tube. The tube is then decanted to isolate the antibody-bound 
fraction, and counted in a gamma counter. The counts are inversely related to the 
concentration of free T in the sample. The Coat-A-count Free T procedure is a direct or 
single-tube assay. That means the results are not calculated as a function of total T and 
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SHBG, but interpolated from a standard curve calibrated in free T concentrations. In 
this respect it differs from conventional equilibrium dialysis methods and from so-
called testosterone free index (TFI) determinations. It is also a single-stage assay, 
requiring neither a pre-incubation step nor preliminary isolation of the free fraction by 
dialysis, filtration or column chromatography. The assay can detect as little as 
0.15pg/mL. 
 
Total T was measured by the ARCHITECT assay (Abbott Laboratories). This is a one-
step immunoassay to determine the presence of T in human serum and plasma using 
Chemiluminescent Microparticle Immunoassay (CMIA) technology. Sample, anti-
testosterone (mouse, monoclonal) coated paramagnetic microparticles, T, acridinium-
labeled conjugate, and assay diluent, were combined to create the reaction mixture. T 
present in the sample competes with the T acridinium-labeled conjugate for binding 
with anti-testosterone (mouse, monoclonal) coated particles to form an antigen-
antibody complex. An inverse relationship exists between the amount of T in the 
sample and the RLUs detected by the ARCHITECT optical system. 
 
The total levels of PSA were measured by the ARCHITECT Total PSA assay (Abbott 
Laboratories). This is a two-step immunoassay to determine the presence of total PSA 
(both free PSA and PSA complexed to alpha-1-antichymotrypsin) in human serum.  
 
In the first step, sample and anti-PSA coated paramagnetic microparticles are 
combined. PSA present in the sample binds to the anti-PSA coated microparticles. 
After washing, anti-PSA acridinium-labeled conjugate is added in the second step. The 
"Trigger" solutions are then added to the reaction mixture. The resulting 
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chemiluminescent reaction is measured RLUs. A direct relationship exists between the 
amount of total PSA in the sample and the RLUs detected by the ARCHITECT optical 
system. 
 
Free PSA was measured also by the Chemiluminescent Microparticle Immunoassay 
ARCHITECT assay (Abbott Laboratories). In the first step, sample and anti-free PSA 
coated paramagnetic microparticles are combined. Free PSA present in the sample 
binds to the anti-free PSA coated microparticles. After washing, anti-PSA acridinium-
labelled conjugate is added After the addition of the "Triger" solutions, the resulting 
chemiluminescent reaction is measured as RLUs. A direct relationship exists between 
the amount of free PSA in the sample and the RLUs detected by the optical system. 
The sensitivity of the ARCHITECT free PSA assay was calculated to be better than 
0.008ng/mL. This sensitivity is defined as the concentration at two standard deviations 
above the mean RLU at level 0. 
 
Levels of SHBG were measured with the IMMULITE SHBG assay (Diagnosis 
Products). The assay tube is coated with a monoclonal antibody specific for SHBG, 
which is coupled to the enzyme alkaline phosphatase. The chemiluminescent substrate, 
a phosphate ester of adamantyl phosphate, undergoes hydrolysis in the presence of 
alkaline phosphatase. The emission of light is proportional to the concentration of 
SHBG in the sample. The sensitivity of the assay was 0.2nmol/L. For all the tests 




The number of CAG repeats in the AR gene was calculated by GeneScan analysis after 
amplifying by PCR the region of interest following the same procedure as described in 
the materials and methods section 3 of chapter 1 (page 24) 
 
3.   Statistical analysis 
The mean values of the various parameters studied were calculated and compared 
between the infertile and fertile group using a two independent samples t-test. 
The correlations among the different variables were analyzed using Pearson's 
correlation coefficients (r) and when appropriate, adjustments for potentially 
confounding variables were made by multiple regression analysis. P values less than 
0.05 were considered statistically significant. 
 
Statistical analyses were performed using the SPSS Version 9.01 (SPSS) computer 
software. Statistical significance was defined as a two-sided p-value of less than 0.05 














1.   Differences between fertile and subfertile men 
Endocrine parameters important for androgen action and metabolism were measured in 
91 subjects with proven fertility, and 112 subfertile men with varying degrees 
(azoospermic, 29.4%; severe oligospermic, 54.1%; oligospermic, 16.5%) of 
spermatogenic defects. The mean ages for the fertile and subfertile men were 
35.57±0.58 and 33.98±0.50 years respectively. The racial composition of both groups 
was similar, being predominantly of Chinese ethnic origin.  
 
The mean values of PSA (free and total), SHBG, AR CAG repeat lengths, and T (free, 
total, and corrected for SHBG) between the fertile and subfertile males were compared 
using the two sided t-test. Results are summarised in Table1. 
 
The main observation when the mean values were compared between the two groups 
was that T levels were lower in subfertile males compared to fertile males. The 
majority of T is bound to carrier proteins and normally less than 1% is free T, which is 
considered the active form. One of the main protein carriers of T is SHBG. An indirect 
method to estimate the levels of free T is to calculate the ratio T/SHBG. Total T, T 
adjusted for SHBG, and free T were about 17-20% lower in subfertile men compared 
to their fertile counterparts. Differences in free T and T/SHBG were highly significant 
at the P<0.001 level. The frequency distribution of T levels in subfertile subjects was 
shifted to the left with respect to the fertile group, indicating that low T levels were a 
general feature of the subfertile group, and that data were not skewed by a few 








Table 1. Descriptive statistics of the various parameters measured in 
the study. 
Column 1 lists the various parameters studied, and column two and three 
indicate the values of the mean, SE of the mean, and the range of the 
fertile and subfertile group respectively. 
 
To check weather the values of the subfertile and fertile groups were the 
same, t-tests (2-tailed) were performed and the corresponding p-values are 
given in column 4. Significant differences were obtained when the levels 













































































































































Figure 1. Frequency distribution of testosterone levels in fertile 
and subfertile subjects. Serum total testosterone in each individual 

















This relative hypogonadism in subfertile men was not age-related since, on average, 
subfertile subjects were younger than fertile controls.  
 
 
There was a tendency, not reaching statistical significance, for the AR CAG length to 
be longer in the subfertile group. No significant differences in SHBG were observed 
between subfertile patients and fertile controls.  
 
No differences in the free and total PSA levels were encountered between the 
subfertile and fertile group. 
 
2.   Bivariate correlations 
All the possible correlations between the different parameters studied, PSA, T, SHBG 
and the number of CAGs, were performed for the infertile and fertile group 
independently. Results are summarised in Tables 2 (for fertile subjects), and 3 (for 
infertile subjects). The most interesting correlations are described below.  
 
2.1 Sex hormone binding-globulin is highly correlated with testosterone 
The most significant correlation in this study was observed between SHBG and T 
(Tables 2 and 3), in both the fertile and subfertile group. SHBG levels were directly 
correlated with T levels (Fig. 2). This was the case when T was expressed as free or 
total. The correlation between total T and SHBG for fertile and subfertile men grouped 
together was of r=0.546, P<0.0019 (data not shown in the tables). This finding was 
surprising as since androgens, unlike estrogens, are considered to have an inhibitory 














Table 2. Results of the bivariate correlations established in the 
fertile group. Values of Pearson’s correlation coefficient (r) are 
indicated at the top of each cell. The second value in the cell 
corresponds to the p-value (p) of each correlation. The numbers in bold 
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Table 3.   Results of the bivariate correlations established in the 
subfertile group. Values of Pearson’s correlation coefficient (r) are 
indicated at the top of each cell. The second value in the cell 
corresponds to the p-value (p) of each correlation. The numbers in bold 
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Figure 2.  Scatter graphs showing the positive correlation between the 
































































































2.2 Levels of testosterone and prostate specific antigen 
T is strongly correlated with PSA levels in subfertile men (Table 3). The relationship 
between T and PSA in subfertile men remained highly significant (P<0.001) when T 
was measured as total or free T, or when total or free PSA was assayed. Since PSA 
values in normal populations are highly skewed, we calculated the log total PSA and 
observed that log total PSA and T remained tightly correlated (r=0.356, p<0.001). 
However in fertile controls, no relationship between T and PSA was observed. (Fig. 3).  
 
2.3 Number of CAG repeats and prostate specific antigen 
CAG repeats were inversely correlated with total PSA (or log total PSA) only in the 
subfertile group (r= -0.229, p= 0.011), (Fig. 4). This correlation was still present after 
adjusting for T (r= -0.216, p= 0.023), (data not shown in the tables) and was thus 
independent of the effect of T on PSA observed. In contrast no correlation was 
observed between CAG repeats and PSA in the fertile group.  
 
2.4 Number of CAG repeats, testosterone, and sex hormone-binding globulin 
The number of CAG repeats was positively correlated to the levels of free T (r=0.210, 
p=0.046), (Fig.5), and SHBG (r=0.216, p=0.040) only in the fertile group. This was 
not the case for the subfertile population studied.  
















Figure 3.  Scatter graphs showing the correlation between the 
levels of total PSA and total T. Fig. 3A shows that there was not a 
correlation between the levels of total T and those PSA in the fertile 
group. This was not the case in the subfertile group, Fig.3B, where 



















































































Figure 4.  Scatter graphs showing the correlation between the 
number of CAG repeats in the AR gene and the levels of total PSA. 
Fig 4A shows that there was not a correlation between the number of 
CAG repeats and the levels of total PSA in the fertile group. In the 
subfertile group, Fig.4 B, there was an inverse correlation between the 


















































































Figure 5.  Scatter graphs showing the correlation between the number 
of CAG repeats in the AR gene and the levels of total T.  Fig 5A shows 
that there was a positive correlation between the number of CAG repeats 
and the levels of total T in the fertile group. On the contrary, in the 




















After lung cancer, prostatic adenocarcinoma is the second leading cause of male cancer 
death in the US (Parker et al., 1997). In Singapore prostate cancer ranks sixth. A 
widely used marker for the diagnosis of prostate cancer is the measurement of the 
serum level of PSA. PSA is a protein secreted by the prostate gland. In general, PSA 
levels increase with advancing clinical stages of tumorogenesis and they are 
proportional to gland and tumour volume (Stamey et al., 1987). PSA determinations 
are commonly used in screening programs for prostate cancer detection and in 
monitoring the following therapy. However, its use as an early-stage tumor marker has 
not been standardized, since a wide disparity in PSA levels occurs within any 
individual clinical stage and not all prostate cancers cause an increase in serum levels 
PSA. On the other hand, elevated PSA levels may appear in non-cancerous conditions 
such as BHP and prostatitis (Schellhammer et al., 1993). Despite its problems, PSA is 
the most reliable marker for tumor growth due to the lack of any other standardized 
tumor marker for prostate cancer. 
 
The mechanism regulating PSA levels remains ambiguous. One theory suggests that 
this mechanism consists of free T entering the prostatic epithelial cell, converting T 
into DHT which binds to the AR and increases PSA production through its binding to 
the androgen responsive elements located upstream from the PSA gene (Andrews et 
al., 1992). Laboratory studies confirmed that the promoter region of the PSA gene 
contains two proximal androgen responsive elements (ARE), located at positions -
170bp and -400bp respectively, upstream of the start of the transcription point. A third 
ARE is located at approximately -4Kb, that functions as an enhancer element. In-vitro 
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studies have demonstrated activation of the expression of the PSA gene by the action 
of the AR. The activation of PSA by androgens is also suggested by the observation 
that when patients, in early stages of prostate growth are given anti-androgen therapies, 
as a standard treatment to block the action of the AR, the PSA levels and prostate 
volume decreases (Ruckle et al., 1993). 
 
Despite the widespread clinical use of PSA as a tumor marker we do not have good 
understanding about its role in the prostate physiology. The relationship between 
androgen action and PSA levels in men without prostate cancer or BPH still remains 
unclear. It was therefore very important to investigate the factors that may regulate the 
expression of the PSA protein in individuals with no evidence of prostate growth, since 
this question has not been adequately addressed in the past. 
 
In this study androgenic parameters relevant to the expression of PSA, such as the 
levels of free and total T, SHBG, the number of the CAG repeats in the AR gene, and 
the levels of PSA, were measured in two groups of subjects. The first included 91 
fertile males and the second 112 subfertile males. 
 
One of the strongest correlations in this study was that serum T levels in subfertile 
patients were significantly lower than that of fertile controls (Table 1, Fig. 1) section 1 
of results (pages 132 and 134 respectively). It has not been generally appreciated that, 
in terms of T production, the subfertile male population is relatively hypogonadic (Fig. 
1), section 1 of results (page 134). Our large study population, totaling more than 200 
men, could be divided into two groups; fertile men with normal T levels and subfertile 
patients whose steady-state T levels were on average 17% to 20% lower. This finding 
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gave us the opportunity to explore the steady state effect of normal versus low-normal 
levels of T on the androgen economy.  
 
In addition to the levels of total T, we measured the levels of free T. The 
measurements of total T by RIA has traditionally been considered a good reliable 
method of androgen status. However, more than 98% of T is protein bound: 
approximately 40% to SHBG and 60% to albumin. Certain physiological stages and 
conditions are associated with changes in the levels of SHBG. This is the reason why 
some investigators have suggested the use of the free T levels as a more suitable 
marker for the androgenic status of the individual. To date the procedures to measure 
free T levels have proved not to be very reliable. The traditional methods for the 
measurement of free T are equilibrium dialysis and ultra-filtration. In the first method 
diluted serum is placed inside a bag of semi-permeable membrane and then placed into 
a protein-free buffer or saline. Small molecules such as free T pass through the 
membrane from the sample into the surrounding buffer. This method is very tedious, 
can not process many samples at the same time, and has many technical errors such as 
the evaporation of water within the flask. The ultra-filtration method is very similar to 
equilibrium dialysis. The difference is that the filtrate, with the dissolved solutes, is 
pulled though the membrane by centrifugal forces. The data we obtained from the 
Count-A-Count for free T levels were very precise. The results were calculated from 
the interpolation of a standard curve calibrated in free T concentrations, and the 
variability among the different measurements was below 15% CV. Free T and total T 
were very strongly correlated (P<0.001) in both fertile and subfertile populations, 
suggesting that use of the more laboratory-friendly total T assay might be sufficient for 
most purposes in the future. 
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The place of SHBG in modulating androgen action is controversial. On one hand, it is 
generally accepted that androgens, unlike estrogens, reduce SHBG production. Thus 
SHBG levels are lower in males than in females, and syndromes of 
hyperandrogenization in females (PCOS, hirsutism and acne) are associated with 
decreased SHBG levels. Administration of T results in a 2-fold lowering of SHBG in 
normal and hypogonadal men (Plymate et al., 1983). On the other hand, other studies 
concluded that levels of T and SHBG in males appear to be positively correlated 
(Carlstrom et al., 1990; Gann et al., 1996). Furthermore, in-vitro experiments with 
hepatic cell lines indicate that androgens increase, rather than decrease, the synthesis 
and secretion of SHBG  (Edmunds et al., 1990) In our study, SHBG levels in the 
serum of both fertile and subfertile men changed in tandem with T. This has important 
implications for androgen action since about 40% of T is physiologically bound to 
SHBG, and is therefore not biologically active. The positive correlation of SHBG with 
T encountered in our population will tend to minimize and moderate the androgenic 
effects of varying total T in men. 
 
Androgen action is further modulated by our finding that AR CAG length correlates 
directly with free T in fertile men. There is increasing evidence from cellular (Tut et 
al., 1997; Chamberlain et al., 1994) and human studies that the intrinsic androgenicity 
of the AR is inversely regulated by the length of its CAG tract. Thus long AR CAG 
tracts, with lower androgenic potential, are associated with male infertility and 
depressed spermatogenesis in Singapore (Tut et al., 1997; Mifsud et al., 2001) and 
other population as extensively discussed in Chapter 1. On the other hand, short CAG 
tracts have higher androgenicity and are associated with androgen-dependent prostate 
cancer (Giovannucci et al., 1997), PCOS (Mifsud et al., 2000), and male pattern 
baldness (Sawaya et al, 1998). If so, the effect of low T in fertile men would be 
 150
balanced by the increased androgenicity of the AR associated with shorter CAG tracts. 
Strikingly, no association between T and AR CAG tract was observed in subfertile 
patients. On the contrary, AR CAG tracts tended to be longer in our subfertile men, 
thereby accentuating the effects of low T, perhaps contributing to defective 
spermatogenesis.  
 
In our study, T strongly correlated with PSA levels only in subfertile men (Table 3), 
section 2 of results (page 137), suggesting that T drives PSA levels only in conditions 
of relative low T. Thus T (free T or total T) was highly correlated (P<0.0001) with 
both free PSA and total PSA in these subfertile men, with low-normal T levels. This 
observation is consistent with previous studies which state that PSA and T are related 
in conditions where T levels are low, that is at puberty (Kim et al., 1998), in castrated 
men (Behre et al., 1994), in women (Escobar-Morreale et al., 1998) and in transsexual 
women where T was administered externally (Goh, 1999). However no correlation 
between T and PSA was observed in our fertile men with normal T levels. 
Interestingly, administration of T to healthy young males did not increase the levels of 
serum PSA (Macindoe et al., 1995; Monath et al., 1995; Copper et al., 1998; Wallace 
et al., 1993). One possible explanation is that in a high androgenic enviroment, the 
androgen response mechanism is saturated and further increases in T cannot induce 
additional AR activity or rise in PSA levels. 
 
The relationship between the number of CAG repeats and the levels of serum PSA, 
was observed only in the infertile group. As in the case of the relationship between the 
levels of T and PSA, the hypoandrogenaemic status of infertile men could be the 
reason why the inverse relationship between the number of CAG repeats and PSA is 
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only observed in infertile men. In these men the AR would not be saturated and 
therefore it is possible to see that the longer is the number of CAG repeats the lower 
are the levels of PSA. 
 
Our data suggest that, firstly, PSA correlates with T only in an environment of 
relatively low androgenicity, such as in subfertile patients. Secondly, in a low 
androgenic environment, an inverse relationship between the number of CAG repeats 
and the levels of PSA was found, indicating that short CAG tracts (associated with 
high AR activity) are related to higher levels of PSA. Fig. 6 summarizes the 
correlations described above. Overall, our study suggests that interpretation of the 
clinical significance of PSA levels is best made in conjunction with T levels and AR 
CAG length. This finding has important implications for screening programs using 
PSA as the biomarker for prostate cancer in different populations, and may assist in the 





















































Figure 6.  Factors in the androgen economy in fertile and subfertile subjects. 
Although testosterone levels in fertile and subfertile subjects overlap to a degree, 
differences in AR CAG tract would tend to accentuate the effects of low T in the 
subfertile group. In this environment of low androgenicity, PSA correlates with both T 
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Correlates with Testosterone in both fertile and subfertile subjects 
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CHAPTER 4: IN VITRO STUDIES OF THE TRANSACTIVATION ABILITY 




The studies described earlier indicated an effect of the CAG length in male infertility, 
PCOS, and levels of PSA, strongly suggesting that the CAG length can influence the 
regulation of androgen driven genes. This chapter will focus on experiments that were 
designed to illustrate the molecular mechanism(s) whereby CAG repeat length 
regulates AR transactivation activity. Reports on the correlation between the number 
of CAG repeats and the activity of the AR to date had been conflicting. Some 
researchers found an inverse relationship between the number of CAG repeats and the 
transactivation of the AR, such as Mhatre et al., (1993), Chamberlain et al. (1994), 
Jenster et al. (1944). Other researchers such as Choong et al. (1996) reported a 
reduction of AR mRNA and AR protein expression with expanded CAG tracts but not 
a decreased transcriptional activity, when the mouse mammary tumor virus (MMTV) 
promoter was used as a reporter system in cotransfection studies in CV-1 cells. 
Similarly, Neuschmid-Kaspar et al. (1996) reported no differences in AR activation 
between expanded CAG tracts containing 40 CAGs (number that is already 
pathological and causes Kennedy’s disease) and values in the normal range.  
 
To date, one of the most commonly used promoters to study androgen action is the 
(MMTV) promoter. It contains the hormone response element (HRE) consisting of 
four repeats of the hexanucleotide 5’-TGTTCT-3’ to which the steroid receptors bind 
(Cato et al., 1988). There are some commercially available reporter systems that 
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include in their sequence the MMTV promoter region, such as the pMAM-neo-LUC 
(Clontech). pMAMneo-LUC contains the firefly luciferase as a reporter gene to 
provide a positive control for the expression of the MMTV-LTR promoter of pMAM-
neo. Luciferase is one of the most sensitive reporter genes available. pMAMneo-LUC 
also expresses ampicilin resistance, which permits positive selection of transformed 
cells. However, the MMTV promoter is a viral promoter and therefore not endogenous 
to the human genome. Functional studies of subtle AR mutations using this promoter 
might not reflect the situation in-vivo. Moreover, the hormone response element (HRE) 
in the MMTV promoter is also the consensus sequence for the glucocorticoid receptor 
(GR) and progesterone receptor (PR). Therefore, in order to overcome the 
aforementioned issues and to study the effect of ARs containing different sizes of poly-
Gln tracts on their transactivation activity, reporter systems containing human 
promoter sequences with AREs are necessary. 
 
Although the expression of many genes is thought to be androgen dependent, the 
number of human genes whose transcription is known to be directly regulated by 
androgens is limited.  Among the best described androgen regulated genes are the 
aldehyde dehydrogenase 1 (ALDH1) which is expressed among other tissues in the 
testis and the PSA which is expressed mainly in the prostate, 
 
1. Aldehyde dehydrogenase gene 1 
Aldehyde dehydrogenase gene 1 (ALDH1) enzymes are considered as general 
detoxifying enzymes, which eliminate toxic aldehydes. In the human, ALDH1 has a 
role in the biosynthesis of retinoic acid, which is a modulator for gene expression and 
cell differentiation. Northern blot analysis showed that liver tissue, pancreas tissue, 
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hepatoma cells, and genital skin fibroblast cells express high levels of ALDH 1 
(Yohida et al., 1993). 
 
The human ALDH1 gene is expressed in the normal genital skin fibroblast cells but 
not in the cells obtained from X-linked AR negative testicular feminization patients 
(Yohida et al., 1993). These findings suggested that the ALDH1 gene is induced by the 
AR complex in genital cells. Moreover a putative ARE exist at positions –688/-674 
(GTGACAgtgTGTTCC), suggesting the possibility of androgen-dependent regulation 
of the ALDH1 expression in genital skin (Yuchio et al., 1995). However, the 
molecular mechanism of the androgen-receptor mediated expression of ALDH1 is 
unknown.  
 
2.  Prostate specific antigen gene 
Prostate specific antigen gene (PSA), a member of the Human Kallikrein gene family 
(hKLK), is a serine protease. The mature form of PSA is a single chain glycoprotein of 
237 aa and has a molecular weight of approximately 30 KD. Three human kallikrein 
had been described, hKLK1for human pancreatic/renal kallikrein, hKLK2 for human 
glandular kallikrein-1, and hKLK3 for PSA which is a well-known prostate-specific 
tumor marker. The three genes are clustered in an area of 60 Kb on human 
chromosome 19q13.2-13.4 (Berg et al., 1999).  
 
The PSA promoter region at position –170bp to –156bp contains the sequence 
AGAACAgcaAGTGCT, named androgen response element I (ARE-I), which 
resembles the consensus sequence GGTACAnnnTGTTCT for the glucocorticoid and 
progesterone receptor. Riegman et al, (1991) demonstrated in cotransfection 
 157
experiments that mutations of this motif abolished the transcription activation by the 
AR. This sequence is thus important for regulation of transcription by their interaction 
with the AR complex. Upstream this region, at position –394bp, there is another 
androgen response element (ARE-II) with the sequence (GGATCAgggAGTCTC) that 
acts in synergy with the ARE-I.  
 
However, the PSA promoter is not specifically activated by androgens alone. Creutjens 
et al., (1997), demonstrated that it can also be activated by glucocorticoids in most of 
the cell lines tested except in the prostatic cells named LNCaP cells. The specificity of 
the PSA promoter in LNCaP cells could be due to the absence of other members of the 
steroid receptor family in this particular cell line, or the presence of certain regulatory 
proteins involved in PSA expression (Creutjens et al., 1997).  
 
In humans, PSA is highly expressed in the luminal epithelial cells of the prostate, an 
androgen dependent organ, and expressed at very low levels in other tissues. For 
instance PSA has also be found in breast cancers, salivary gland neoplasms, cells of 
the male urethra, breast milk, blood and urine. PSA produced in the prostate is secreted 
into the seminal fluid in high concentrations. A major function of PSA is the 
proteolytic cleavage of gel-forming proteins in the seminal fluid, resulting in the 







MATERIALS AND METHODS 
 
Promoter regions of two human genes, PSA and ALDH1, that contain ARE in their 
sequences were cloned in front of the luciferase gene of a reporter system, and their 
responsiveness to androgen action tested in cell culture experiments. The commercially 
available reporter system pMAM-neo–LUC (Clontech) uses the MMTV promoter to 
drive the expression of the luciferase gene. Firstly, the ALDH1, and PSA reporter 
systems, were constructed by subcloning the promoter regions in front of the luciferase 
gene of pMAMneo-LUC after removing the MMTV promoter fragment. 
 
1.   Amplification of the prostate specific antigen promoter regions of 1.6Kb, 
630bp and 100bp  
The regions of 1.6Kb and 630bp upstream of the start point were selected because they 
contained the two ARE necessary for the androgen driven activity of the PSA 
promoter. The longer 1.6 Kb region was selected in order to include some 
neighbouring sequences that might be the target site for proteins acting as coactivators 
of the AR. The PSA 1.6Kb promoter region was isolated from total genomic DNA of a 
healthy individual by PCR. The specific primers designed were the following:  
CATATG Forward: 5’-ACGGTC GATCAAGTCAGCTACTCTGG-3’ 
Reverse: 5’ AGCCGTCAGCTGAAGCTTGGGGCTGGGGAGCC-3’ 
The underlined regions correspond to the restriction sites Nde I and Sal I in the forward 
and reverse primer respectively. The total volume of the reaction was 100µl and it 
contained 200ng of total genomic DNA used as a template, 10x cloned buffer, 0.2µM 
of each primer, 2.5 mM of deoxyrobonucleotide triphosphates and 5U of cloned Pfu 
DNA polymerase enzyme (Stratagene). PCR conditions were as follows, a first cycle 
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at 95°C for 5 minutes followed by 30 cycles of 95°C for 30 sec, 60°C for 30 sec and 
72°C for 5 min. The product of the PCR reaction was purified by the use of Wizard 
PCR preps Rapid Purification System (Promega). The purified PCR product was then 
double digested with the restriction enzymes SalI and Nde I. The reaction contained 10 
units of each enzyme, 10x Sal I buffer and was incubated at 37°C for 4 hours.  
 
The method to isolate the 630bp and 100bp PSA promoter regions was very similar. 
Specific forward primers containing the restriction site for NdeI were designed. 
630bp: 5’-ACGGTC CATATG AGACTCATATTTCTCGGCTA-3’, 
100bp: 5’-ACGGTC CATATGAGGGGGTTGTCCAGCCTCCA-3’ 
The reverse primer remained the same as for the PSA 1.6 Kb fragment. 
 
Partial digestion of the pMAM-neo-LUC Vector. 
The aim was to remove the mammalian viral promoter from the reporter system 
pMAM and to insert instead the human PSA promoter previously isolated. The vector 
contained more than one restriction site for SalI therefore partial digestion on the 
vector was performed in order to isolate the appropriate band. The enzymes used for 
digestion were SalI and NdeI. Firstly, the vector was digested with NdeI and 
subsequently partially digested with Sal I. 
 
2.   Amplification of the aldehyde dehydrogenese 1 gene promoter region 
The ALDH reporter system was similarly constructed. The restriction enzymes chosen 
did not cut the vector or the ALDH1 promoter region selected. The promoter region of 
the ALDH1 gene was obtained from total genomic DNA by PCR amplification using 
the specific primers: 
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Forward: 5’ ACGGTCCATATGGTAACGTTTGCTAGAGCTAC 
Reverse: 5’ ATAGCACGATCGTCTGATTCGGCTCCTGGAAC 
The underlined regions correspond to the restriction sites NdeI and NheI in the forward 
and reverse primers respectively. The PCR reaction included 200ng of genomic DNA 
used as a template, 10x cloned Pfu buffer, 0.2µM of each primer, 2.5 mM of 
deoxynucleotide triphosphate, and 5 U of cloned Pfu DNA polymerase enzyme 
(Stratagene). The PCR conditions were 30 cycles of 95°C for 30 sec, 55°C for 30 sec 
and 72°C for 5 minutes with an initial cycle of 95°C for 5 minutes. Both insert and 
vector were double digested using 10units of the enzymes NdeI and NheI and then 
purified with Wizard PCR Preps Rapid Purification System (Promega). 
 
3.   Ligation reactions 
The PSA and ALDH promoter fragments were ligated to their respective vector by 
using the enzyme T4 ligase (NE Biolabs). The relative amounts of insert and vector 
were previously estimated in an agarose gel. 
 
4.   Transformation 
Epicurian Coli XL1-Blue MRF’ Kan (Stratagene) were used for transformation. Firstly 
20µl of cells were thawed on ice and incubated for 10 minutes with occasional 
swirling. 1 µl of the ligation reaction was added to the cells and then incubated on ice 
for another 30min. Cells were heated at 42°C for 90 sec, and afterwards placed on ice 
for another 2 min. 0.25ml of SOC media previously warmed at 37°C was added and 
the new mixture incubated at 37°C for 1 hour while shaking at the speed of 250rpm. 
75µl of the cells were plated in a LB-ampicillin agar plate while the remaining quantity 
was plated into another plate to avoid overgrowth in a single plate. Plates were 
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incubated overnight at 37°C. The following morning the positive colonies were 
selected, and the presence of the expected insert checked. The procedure was the 
following; colonies were slightly touched with a tip and the tip deposit on 30µl of TE 
media. The mixture was heated at 95°C for 5min to brake the cells. Then 1µl was used 
as template for a subsequent 50µl PCR reaction. The PCR conditions were the same as 
the previously used to amplify the promoter region of the respective genes.  
 
5.   Purification of plasmid DNA 
The positive colonies were selected and incubated overnight with 5ml of LB-ampicillin 
media at 37°C with vigorous shaking for 16 hours. 2ml of the bacteria culture were 
used for small-scale extraction using Qiagen plasmid preparation kit. The remaining 
media was used to prepare glycerol stock. From the glycerol stock cells were plated on 
a LB ampicillin agar plate O/N. One single colony was selected and incubated on 30ml 
of LB-ampicillin media for about 10 hours. Afterwards the 30ml were transferred to 
500 ml of LB-ampicillin media. The culture was allowed to grow overnight at 37°C 
under 250rpm of shaking. The plasmid isolation was performed following the Qiagen 
Plasmid maxi preparation Kit protocol. 
 
6.   Sequencing the PSA-LUC construct 
The complete region of the 1.6Kb region was sequenced to confirm the fidelity of the 
enzymatic manipulations. Internal primers were designed in order to cover the whole 
region. Each of the sequence reaction contained 1.6 µg of the PSA-LUC plasmid, 3.2 
pmol of the primer, 8µl of terminator ready reaction mix (PE) in a total volume of 
20µl. The cycling conditions were 5 cycles at 96ºC for 10 seconds, 50ºC for 5 seconds 
and 60ºC for 4 minutes. In order to purify the sample 2µl of 3M sodium acetate 
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(pH5.2) and 50µl of 95% ethanol were added to the previous reaction, mixed, and then 
place on ice for about 10 minutes. After being centrifuged at a maximum speed for 30 
minutes the ethanol solution was discarded and the pellet washed with 70% ethanol. 
The pellet was dried in a vacuum pump. The samples were then re-suspended in 6µl of 
loading buffer. The loading buffer solution contains formamide and EDTA/Blue 
dextran in a ratio 5:1. The composition of the sequencing gel was the same that the 
GeneScan gel, a 4% acrylamide solution. About 2µl of the sequence sample were 
loaded into the gel. The sequencing run took about 7 hours. The ABI PRISM Dye 
Terminator Cycle Sequencing kit (Perkin Elmer) was used for sequencing. The 
automated sequencing was carried out on an ABI PRISM 377 DNA automated 
sequencer.  
 
7.   Transient transfection experiments 
Transient co-transfection experiments were optimized using various cell lines such as 
CV-1, COS-7, LNCaP, and He-La. The reporter system transfected and the amount of 
plasmid employed varied depending on the purpose of the experiment but the protocol 
was very similar. The method to introduce the DNA into the cells was lipofectamine 
(Gigco BRL), a liposomal solution. Since the size of tissue culture plates varied 
throughout the experiments, the relative amounts of DNA were adjusted for this factor. 
When the plates used for transfection were of 60mm of diameter, called p60, the 
procedure was as follow: 200 µl of the solution A, containing the plasmid DNA and 
200µl of solution B, containing the lipofectamine solution were carefully mixed. The 
mixture was incubated for 45 minutes to allow for the formation of the liposomes. 
Cells to be transfected were washed twice in serum free media. The mixture (400µl) 
was added to the cells and supplemented with 2ml of serum free media. Cells were 
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then incubated for 5 hours at 37°C and 5%CO2. During this period the liposomes 
merged with the cellular membrane allowing the DNA to enter into the cell. It was 
important to transfect the cells when they were actively dividing that is in their 
exponential growth phase. After 5 hours of liposomal exposure the media on the cells 
was replaced by the growth media which was supplemented with 10% charcoal treated 
FBS and the hormone used for induction. Cells were then placed in the incubator for 
another 48 hours. 
 
8.   Harvesting the cells 
After the 48 hours period of incubation the cells were harvested from the culture 
plates. Firstly, the cells were washed twice with PBS solution buffer. For the p60 
plates 400µl of the commercially available Reporter Lysis buffer (Promega) was added 
to the cells and with the help of a syringe plunger the cells were scrapped. The lysate 
was deposited in a tube and placed on ice for the subsequent measurement of luciferase 
activity. 
 
9.   Meassurement of luciferase activity 
Cell lysates were centrifuged at 13000rpm to separate the cellular debris from the 
soluble fraction where the luciferase protein was present. The substrate employed was 
the commercially available Luciferase Assay Substrate Lyophilazed (Promega). 100µl 
of the substrate were aliquoted into the each tube. Then 20 µl of the cell extract where 
the luciferase enzyme is present was added. After a quick mix, the tube was placed in 
the luminometer cuvette where the emission of light was measured. The luminometer 
used was TD 20/20 Turner Designs Luminometer (Promega). Luciferase activity was 
measured in RLU. 
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10.   Construction of the new PSA reporter system 
The previous reporter systems were not very effective because the intrinsic base line 
activity, in the absence of hormonal treatment, was very high. In order to solve this 
problem another reporter plasmid was selected, the pGL3-basic luciferase vector 
(Promega). The promoter region selected was the same, the 1.6 Kb region upstream the 
start of the PSA transcription point. It was isolated from the previously engineered 
pM-PSA-LUC reporter system after double digestion with Hind III and KpnI. The 20µl 
reaction contained 10 units of each enzyme, 4µg of the pM-PSA-LUC, and 10x buffer, 
and was incubated at 37C for 2 hours. The fragment of interest was isolated from a 
TAE buffer agarose gel and subsequently gel purified with gene clean kit II  
(Promega). The reporter system, pGL3 was double digested with the same enzymes, 
and then purified with gene clean kit II  (Promega). The following steps include 
ligation, transformation, selection of the transformant bacteria containing the insert of 
interest, and large-scale preparation of the new construct. The new reporter system was 
called pGL3- PSA-LUC. 
 
11.   Mammalian cell two-hybrid system experiments 
The TAD region of the AR gene containing 14, 20 and 28 CAG repeats in the exon 1 
was fused to the VP16 activation domain (pVP16AD-ARTAD), and the DBD-LDB 
region of the AR gene was fused to the pGAL4 domain (pGAL4 DBD-LBD). The 
reporter system used was the GAL4-TATA-LUC that contains multiple Gal 4 binding 
sites. (Lim et al., 2000). Tranfections experiments were performed in HeLA cells using 
the lipofection technique. The transfection experimental procedure was the same as 
described previously. Three independent transfections were performed. The hormone 




Reporter systems containing human promoters sequences of the PSA and ALDH1 
genes were constructed. Initially the regions of interest were cloned into the 
commercially available pMAMneo-LUC by first removing the mouse mammary virus 
promoter region that contains the hormone responsive element (HRE) and inserting 
the selected PSA and ALDH promoter regions. The reporter systems were tested in 
cell culture experiments. 
 
1.  Construction of the ALDH1 reporter system 
The promoter region of the ALDH gene spanning from –977 to +12 was amplified 
using the following flanking primers: 
Forward primer: 5’ACGGTC CATATG GTAACGTTTGCTAGAGCTAC 3' 
Reverse primer: 5’ CAAGGTCCTCGGCTTAGTCT GCTAGC ACGATA 3' 
The underlined regions correspond to the restriction sites for NdeI in the forward 
primer and the Nhe I in the reverse one. The PCR reaction yielded a unique fragment 
of the expected size (989 bp) as shown in Fig. 1A. The fragment was purified with the 
geneclean kit II and then double digested with the corresponding restriction enzymes. 
In order to remove the MMTV promoter region and incorporate the ALDH region, the 
reporter plasmid pMAM was digested using the same enzymes Nde I and NheI and 
subsequently the products of the digestion resolved in a 0.8% agarose gel. The band 
corresponding to the vector without the MMTV promoter was isolated and gel 
purified with the geneclean II Kit (Fig. 1B). The Insert and vector are shown in Fig. 1 
C. E. Coli supercompetent cells (Epicurian Coli XL1-Blue MRF’Kan) were 










Figure 1.  Construction of the ALDH reporter system. 
A) Amplified region of the ALDH promoter region of 989bp after the PCR 
reaction. 
Each reaction (lanes 1-4) contained different amounts of template (total 
genomic DNA). The marker used was the 100bp ladder (M). 
 
B) Product of the pMAM plasmid digestion with the enzymes NdeI and 
NheI. The first band in lane 1 (arrow) corresponds to the pMAM reporter 
system without the MMTV promoter region (8Kb). The marker used to 
estimate the sizes was Hind III-digested λ-DNA (M). 
 
C) Agarose gel to estimate the relative amounts of the vector (V) and 
insert (I) before proceeding with the ligation reaction. The markers used 
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screened for detection of the presence of the plasmid with the insert. One of the 
selected colonies resulted in positive. The positive colony was placed on 5ml of LB-
ampiciline media and incubated overnight at 37°C. Large-scale preparation of the 
plasmid (Quiagen kit) yielded enough DNA to perform the subsequent transfection 
experiments. 
 
2.  Construction of the PSA reporter systems containing the -1.6kb, -630bp and -
100bp promoter regions 
The region comprising the section (–1600, +12) of the PSA promoter gene was 
amplified from total genomic DNA using specific primers with restriction sites for the 
enzymes Sal I and NdeI respectively. As shown in Fig. 2A, the PCR yielded a single 
product of 1.6Kb, the expected size. The product of the PCR was then purified. The 
PCR product was then double digested with the restriction enzymes NdeI and SalI. 
The pMAM plasmid was firstly digested with Nde I followed by partial digestion with 
SalI. The partial digestion resulted in five fragments of the predicted size 
Subsequently the band of interest (approximately 8kb) was selected and gel-purified 
(Fig.2B). The purified plasmid and the PSA promoter region were subsequently 
ligated. After the ligation reaction, E. Coli competent cells (Epicurian Coli XL1-Blue 
MRF’Kan) were used for transformation. After an incubation period of 16 hours at 
37°C some colonies were selected for screening.  
 
One of them contained the plasmid with the newly cloned PSA promoter region (Fig. 
3). The positive colony was allowed to grow for 16 hours at 37°C in LB-ampicilin 
media and then a small-scale plasmid preparation performed. The newly inserted 







Figure 2. Cloning the 1.6Kb region of the PSA promoter gene into the 
pMAMneo-LUC reporter plasmid. 
A) Isolation of the 1.6kb fragment from genomic DNA by PCR. 10μl of 
the PCR was analyzed on a 1% agarose gel previously stained with 
ethidium bromide. The reaction resulted in a unique product (lane 2). Lane 
1 corresponds to the negative control (same reaction components with no 
template DNA). Hind III-digested λ-DNA was used as a size standard 
marker (M) 
 
B) pMAM plasmid after partial digestion with SalI. Lane 1 corresponds to 
the uncut pMAM vector, lane 2 corresponds to the pMAM vector after 
single digestion with NdeI and lane 3 to the pMAM plasmid after partial 
digestion with SalI. The second band of 8Kb corresponded to the band of 
interest thus is the pMAM plasmid after the removal of the MMTV 
promoter sequence. Hind III-digested λ-DNA was used as a size standard 
marker (M).  
 
C) Schematic representation of pMAMneo-LUC indicating the position of 
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Figure 3.   Screening for positive colonies after transformation.  
Each lane in the 1% agarose gel corresponds to each of the colonies selected 
for screening. Only one of the colonies selected (lane 5) contained the 
plasmid with the newly engineered insert. The last lane (C) corresponds to 
the positive control, where the source of DNA was total genomic DNA. 






























incorporated mutations. Fig. 4 A and B show the sequence of the PSA promoter 
region containing the two ARE. Sequence analysis of this promoter revealed the 
presence of a first androgen response element, (ARE-I) at position –170, and (ARE-II) 
at position –400. 
 
To determine which segments of the PSA promoter are necessary and sufficient for 
androgen action, two other reporter systems comprising the regions -630bp and –
100pb upstream of the start of the translation point were similarly constructed. The 
100bp PSA promoter fragment contains no ARE but has a TATA box. This reporter 


























Figure 4.   Sequence analysis of the promoter region of the PSA 
gene. 
Sequence analysis revealed the presence of two ARE. A) ARE-I 
located at position -170 and B) ARE-II at position -400 of the start of 



























3.  Transient  co-transfection experiments  
Firstly, the capability of the AR protein to bind to the ARE at the promoter regions of 
the ALDH and PSA genes and activate the luciferase gene was evaluated. The next 
step was to determine if the size of the poly-Gln stretch in the AR played a role in the 
transactivation capability of the AR. The lengths of the poly-Gln selected in the AR 
were those coded from expression plasmids containing 14, 20 and 28 CAG repeats 
respectively. They were previously constructed in our laboratory (Tut et al., 1997). 
Cells were co-transfected with the AR expression plasmid and one of newly 
engineered reporter systems either pM-PSA-LUC or pM-ALDH-LUC. 
 
3.1 Transient co-transfection experiments to evaluate the responsiveness of  the pM-
ALDH-LUC reporter system to androgen action 
The newly constructed pM-ALDH-LUC reporter system was tested in cell culture 
experiments in CV-1 and COS–7 cell lines. They were selected for transfection 
experiments because they do not express the AR protein. Cells were co-transfected 
with the AR expression plasmid (pSVhARo) containing 20 CAG repeats and the 
reporter system pM-ALDH- LUC. The AR was induced with 1nM of MB. As we can 
see from Fig. 5A and B, the base line activity of the reporter system in the absence of 
hormonal treatment was very high because of high base levels, and the fold induction 
after the hormonal exposure very low (folds induction of 1.06 and 1.30 in C V-1 and 
COS-7 cells respectively), indicating that this ALDH-LUC was not a useful reporter 



















Figure 5   Androgen regulation of the ALDH promoter in CV-1 and 
COS-7 cells. 
CV-1 and COS-7 cells were transiently cotransfected with the ALDH-
LUC reporter system and the AR expression plasmid. Cells were incubated 
for 48 h in the absence (white bars) and presence (black bars) of MB 
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 3.2. Transient co-transfection experiments using the  pM-PSA-LUC reporter systems 
Co-transfection studies were performed in CV-1 cells using one of the reporter 
systems containing the selected regions of the PSA promoter gene (1.6Kb, 630bp or 
100bp) along with the AR expression plasmid. As shown in Fig. 6, the reporter system 
containing the 1.6 Kb fragment induced in a higher manner the expression of the 
luciferase gene compared to the reporter systems containing the 630bp and 100bp 
fragments. The 1.6 kb fragment was therefore selected for further studies.  
 
3.3 Inducibility of the PSA 1.6Kb fragment of the PSA promoter by the androgens 
DHT and MB 
CV-1 cells were cotransfected with either the pM-PSA-LUC or pMAM reporter 
systems, and the AR expression plasmid (PSVhARo). Cells were induced with the 
natural ligand DHT or the more powerful synthetic androgen MB (Fig. 7). The pM-
PSA-LUC reporter system induced 4 fold the expression of the luciferase gene at 
doses of 10nM of DHT. Similar results were obtained with MB whereby the 
maximum fold induction was 5 fold at doses of 1nM. On the contrary, cotransfection 
with the commercial reporter system pMAM resulted in a higher fold induction 
(approximately 20). This was due to its lower base line activity. 
 
3.4  The activity of the 1.6 Kb PSA promoter was evaluated in other cell lines 
In order to elucidate if the high base line of PSA-LUC reporter system was cell type 
specific, co-transfection experiments were done in different cell lines such as CHO, 
COS-7 and LNCaP. The hormone used for induction was MB at doses of 1nM (Fig. 



















Figure 6   Androgen regulation of the PSA promoter in CV-1 cells. 
CV-1 cells were co-transfected with one of the three PSA-LUC reporter 
systems containing the PSA promoter fragments of different sizes (100bp, 
630bp or 1.6Kb) and the AR expression plasmid (PSVhARo). The Y axis 
indicates the fold induction values after exposure to 1nM MB. The 
maximum fold induction was achieved with the 1.6Kb fragment of the 





















































































Figure 7   Dose response activities of the PSA and MMTV promoter 
in CV-1 cells.  
Cells were cotransfected with either pMAM (solid bars) or the PSA-
LUC,1.6Kb reporter system (blank bars) and the AR expression plasmid 
(PSVhARo). After transfection cells were induced with three different 
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Figure 8 Co-transfection experiments with PSA reporter system in 
different cell type lines. 
Co-trasfection experiments were performed in the COS-7, CHO and 
LNCaP cell lines. The highest fold induction of more than 8 was 
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When the cells co-transfected were COS-7 cells the fold induction was of only 1.13. 
The highest fold induction was observed in LNCaP cells whereby a 8.3 fold increased 
was achieved when cells where exposed to doses of 1nM MB. The reason for the 
higher fold induction when LNCaP cells were co-transfected may be due to the 
presence of cell specific coactivators than interact with the AR and modulate the 
activation of the PSA promoter. 
 
In summary, the pM-PSA-LUC reporter system did not prove to be as useful as 
expected. The reason for the low level of induction after androgen exposure was the 
high base line activity of the promoter in the absence of hormone.  
 
3.5 pGL3-PSA- LUC reporter system 
The subsequent steps were to design another reporter system using a different vector. 
The vector chosen was pGL3 basic-luciferase reporter vector (Promega). The 
promoter region selected remained the same, the 1.6Kb region of PSA promoter gene. 
 
The 1.6Kb promoter region of the PSA gene was obtained from the previously 
engineered reporter system. After double digesting them with Hind III and KpnI, the 
band of interest was isolated from a 1% TAE agarose gel and then gel-purified with 
genescan Kit II. The pGL3-basic vector was double digested with the same enzymes 
and after the ligation reaction, E.Coli supercompetent cells were transformed. The 
positive colonies were screened for the presence of the insert. The newly engineered 




3.6 Cotransfection studies with the reporter system PGL3-PSA-LUC 
The newly engineered reporter system, PGL3-PSA-LUC, was tested in CV-1 cells and 
results compared to those of the commercially available pMAM. The newly 
engineered pGL3-PSA-LUC proved to be quite responsive to the action of androgens, 
more so than pMAM. In the first experiment, before optimising the system, the fold 
induction after hormonal stimulation was of 27. The main difference with the 
previously engineered pM-PSA-LUC was that the base line activity, in the absence of 
hormonal treatment, was very low. 
 
3.7 Optimisation of the relative amounts of AR and PGL3-PSA-LUC . 
Various experiments were designed to optimise the best relative amounts of 
PSVhARo and PGL3-PSA-LUC when cells where co-transfected. During the 
optimisation procedure transfection experiments were carried out in 6 well culture 
plates. Firstly, the amount of PGL3-PSA-LUC was kept constant to 333ng/well and 
the amount of PSVhARo added was varied from 40, 80, 166 to 320 ng/well 
respectively. Results indicated that the highest induction was achieved when the 
amount of PSVhARo used was of approximately 100ng/well. Then, the amount of 
PSVhARo was kept constant, and that of pGL3-PSA-LUC was varied from 75, 150, 
333 to 666ng/well respectively. Results indicated than the amount of PSA-LUC of 
666ng/well gave the highest fold induction (30 fold) after hormonal treatment with 
1nM of MB. 
 
3.8 Differences in the CAG length in the AR may transactivate the PGL3-PSA-LUC 
reporter system differently 
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The aim of the construction of reporter systems with human promoters containing 
ARE was ultimately to determine if there were differences in the way AR with 
different length of poly-Gln would activate such human promoters. To address this 
question, co-transfection experiments with the reporter system pGL3-PSA-LUC and 
one of expression plasmids containing 14, 20 or 28 CAG repeats in their AR gene 
were performed. The hormones used for induction were the synthetic MB and the 
naturally occurring DHT and T. A correlation between the number of CAG repeats in 
the AR and its the transactivation capability was not found regardless of the hormone 
and hormonal dose used for induction. The results obtained from the various co-
transfection experiments were quite inconclusive. Perhaps the methodology employed 
was not sensitive enough to detect the hypothesised subtle differences that may exists, 
in spite of repeated  experiments. 
 
4. TAD and LBD interaction using the mammalian cell two-hybrid system 
To further understand the mechanism by which the length of the poly-Gln tract in the 
AR may modulate the transactivation capability of the AR, interactions between the 
TAD and LBD domain of the AR gene were studied by using the mammalian two-
hybrid system.  
 
The TAD domain of the AR containing different CAG repeats length tracts (14, 20 
and 28) were fused to the yeast VP16 activation domain, and the AR-DBD-LBD 
domain to the yeast GAL4 domain. The fusion proteins were co-expressed in HeLa 
cells, and protein-protein interactions were measured with a reporter vector containing 
multiple GAL4 DNA-binding sites, named GAL4-TATA-LUC. 
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Results from three independent transfections provided evidence that the lower the 
number of CAG repeats in the TAD domain of the AR, the stronger was the 
interaction with the LBD domain after hormonal induction with different doses of MB 
(Fig. 9). Because of the high levels of sensitivity of the mammalian two hybrid system 
it was possible to detect the subtle differences in AR activity and explain the 
molecular mechanism by which the length of the CAG tract would affect the intrinsic 



























Fig. 9  Interaction between the NTD and LBD in the mammalian two-
hybrid system. 
The fusion proteins TAD-VP16 and the LBD-GAL4 were co-expressed and 
protein-protein interactions measured with the GAL-4-TATA-LUC reporter 
system. For each experiment three co-transfections were being compared, 
whereby the lengths of the poly-Gln tract in the TAD were 14, 20 and 28 
Gln respectively. The shorter the poly-Gln tract the strongest was the 
interaction of the TAD-VP16 with the LBD-GAL4. The hormone used for 
induction was MD at doses of 0.01nM (white bars), 0.1nM (gray bars) and 















































































TAD, 14CAGs TAD, 28 CAGs TAD, 20 CAGs
 192
DISCUSSION 
Although the expression of many genes is thought to be androgen dependent, the 
number of human genes whose transcription is documented to be directly regulated by 
androgens is limited. A well-known example of a non-human promoter with ARE is 
that of the mouse mammary tumour virus (MMTV). This promoter is regulated by 
glucocorticoids, progestins, and androgens although less efficiently. Nevertheless, one 
of the concerns when using the MMTV promoter it that it is not endogenous to the 
human genome, and therefore studies using this promoter may not reflect the situation 
in vivo. In order to overcome these issues two reporter systems with human promoters 
containing ARE were constructed, the ALDH1 and PSA  
 
ALDH1 is a cytosolic enzyme ubiquitously distributed in various tissues such as liver, 
stomach, brain and red blood cells. The ALDH1 promoter was chosen because this 
gene is expressed in the normal genital skin fibroblast cells but not in the cells 
obtained from AR negative testicular feminization patients (Yohida et al., 1993), 
suggesting that the ALDH1 gene is up-regulated by androgen action.  Moreover, two 
putative AREs exist in the promoter sequence indicating the importance of the AR 
machinery in the expression of the gene. Co-tranfection experiments of the AR 
expression plasmid and the newly constructed ALDH-LUC reporter system indicated 
that the activation of the ALDH1 promoter region by androgens was very low and 
moreover, the base line activity of the reporter in the absence of androgen action very 
high. The reason for the high base line activity could be that the ALDH 1 protein acts 
as a modulator for cell differentiation and is expressed in many tissues; therefore, 
other proteins besides androgens may activate the expression of the ALDH1 gene. 
This made the ALDH1 promoter an unsuitable reporter for androgen action. 
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 The other promoter selected was the PSA promoter. The PSA protein is a member of 
the human kallikrein family whose expression is regulated by androgens (Riegman et 
al., 1991) and it is highly expressed in the luminal epithelial cells of the prostate and 
at low levels in other tissues. The PSA promoter contains two ARE located at 
positions –170bp and -400bp respectively at which the AR binds as homodimer (Kitty 
et al., 1995). Thus, the regions selected to construct the reporter system were the –
630bp and -1.6 Kb upstream of the start of the translation point. The region of -1.6 Kb 
was chosen because adjacent sequences to the ARE may play an important role if the 
activation function of the PSA promoter. As previously described by Riegman et al. 
(1991), when the PSA -1.6 Kb promoter fragment was coupled to a CAT reporter gene 
it induced more potently the expression of the CAT gene than the -630bp fragment. 
 
Initially, when the PSA promoter region was inserted into the commercially available 
pMAM reporter system by removing the MMTV promoter region and introducing the 
PSA promoter region, the activation by androgens was not very high. This was due to 
the high base line activity of the reporter system in the absence of hormonal induction. 
Perhaps an enhancer element was created whereby the new promoter would drive the 
expression of the luciferase gene, even in the absence of androgens.  
 
Thus, it was decided to construct a new reporter system. When the plasmid pGL3 was 
used as a reporter system, despite inserting the same PSA promoter sequence, the 
results were more satisfactory. The base line luciferase activity, in the absence of 
androgens, was very low. Correspondingly, the fold induction in the presence of 
androgens was high being about 20- to 30-fold higher than vehicle. This makes the 
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pGL3-PSA-LUV reporter system a viable one for testing androgen response. This 
reporter system was used subsequently in several publications from our laboratory 
(Loy et al.,  2003, Lim et al., 2000), demonstrating its utility as a measure of androgen 
action. The next step was to analyse if the ARs containing different CAG length 
would activate differently the expression of this PSA-LUC reporter system. The AR-
CAG lengths selected for the transfection experiments were 14, 20 and 28 
respectively. These values are included into what is considered a healthy range (above 
40 CAGs the person develops a neurological disease called spinal bulbar muscular 
atrophy or Kennedy’s disease). HeLa and CV-1 cells were selected for co-transfection 
experiments because they express the AR protein at very low levels.  
 
Finding differences in the way the ARs containing different lengths would differently 
activate the PSA promoter prove to be a difficult task because of many factors, which 
more than likely led to the inconsistency of the results achieved. One of the difficult 
aspects of this experimental procedure was that 3 different co-transfections were being 
compared. The liposomal structure enclosing the DNA is not a stable chemical 
structure and brusque manipulation could result in a reduction in the number of 
liposomes. Extreme care was taken to overcome this problem. Another important 
aspect to consider is the tertiary structure of the plasmid DNA used for transfection. It 
appears that the higher the amount of supercoiled DNA structure in the plasmid, the 
higher is the transfection efficiency. In time the supercoiled structure is converted into 
a circular DNA. Taking this fact into consideration, the large-scale preparation of the 
three AR plasmids used for transfection was performed at the same time. Another 
issue was that the amount of DNA used for the three transfections that had to be 
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exactly the same. The amount of DNA to be transfected was calculated by measuring 
the absorbance of the plasmid DNA at 260nm.  
 
All the issues mentioned above were taken into consideration. Despite that, the 
disparity of results obtained from the different co-transfection experiments made the 
task of drawing conclusion from the results a problematical one. A possible 
explanation as why the results from the different transfection experiments were 
inconsistent is that the PSA is a human promoter and therefore other transcription 
factors besides the AR can activate its expression. Secondly, the AR acts in 
conjunction with other proteins named coactivators. Various coactivators interact in a 
direct or indirect way with the poly-Gln region and modulate the activity of the AR 
such as the Ras-related nuclear protein ARA 24 (Hsiao et al., 1999). AR-
CAG/ARA24 interaction becomes stronger as the number of glutamines decreases, 
increasing the coactivation capability. So a possibility as why the differences in 
transactivation were not encountered in cotransfections experiments using HeLa and 
CV-1 cells could be due to the absence of the coactivators essential for the poly-Gln 
interaction. In a recent study by Beiling et al. (2000) the researchers reported that AR 
constructs containing 15, 24 and 31 CAGs respectively, all in the normal range, 
activated differently the human probasin promoter when the cells used for 
cotransfection were COS-1 and LNCaP. On the contrary, when the co-transfected 
cells were PC3 and MCF-7, no differences were observed. The cell specific nature of 
this correlation suggests that the presence of coactivators, besides the AR protein is 
involved in the transactivation process. Thirdly, the differences in AR transactivation 
conferred by the CAG tract length could be promoter specific. In a recent report by 
Anuradha et al. (2002) the investigators confirmed that not statistically significant or 
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consistent differences were noted when AR plasmids with two different CAG repeats 
length (9 or 29) were co-transfected in PC-3 cells with a reporter system containing 
the PSA promoter. On the contrary, Irvine et al. (2000) performed co-trasfection 
studies in PC-3 cells using AR expression plasmids containing 9, 21, 29, 42 and 50 
CAG repeats respectively and the MMTV promoter as reporter system. The authors 
reported the existence of a statistically significant poly-Gln size effect on AR 
transactivation activity. Therefore it is probable that the differences in the 
transactivation capability of the AR containing different CAG length are promoter 
specific. 
 
In order to pursue our aim to understand the molecular mechanism by which the CAG 
length plays a role in the intrinsic activity of the AR, the interaction between the TAD 
with different CAG lengths, and the LBD of the AR were tested in the mammalian 
two-hybrid system. The physical and functional interactions between the LBD and the 
TAD in the AR have been reported, and it has been postulated that this interaction is 
essential for the dimerization of the AR (Langley et al., 1995). As a result of this close 
interaction many mutations in the LBD affect this contact, resulting in a decrease of 
the activity of the AR (Lim et al., 2000). Some investigators have postulated that this 
interaction is the result of a direct AR LBD-TAD contact (He et al., 1999), and the 
importance of coactivators in facilitating this interaction has been extensively reported 
in the literature (He et al., 2002). Mutations in the AR TAD have been shown to affect 
the recognition motifs sequences for coactivator binding, thereby severely disrupting 
the action of the AR (Alen et al., 1999). In addition, it has been demonstrated that a 
change in CAG length can affect the interaction of the AR with certain coactivators, 
such as ARA24 (Hsiao et al., 1999) and GRIP1 (Irvine et al., 2000), becoming 
 197
stronger as the number of CAGs decreases. With the above in mind, we investigated 
the role of the poly-Gln tract in the TAD-LBD interaction using the mammalian two-
hybrid system. The high sensitivity of this method makes it suitable for the detection 
of small interactions between the proteins studied. Our results from three different 
experiments indicated that the shorter the poly-Gln tract in the TAD, the stronger was 
the binding to the LBD. This interaction was androgen-dependent, and preliminary 
experiments indicated that it might be hormone dose dependent. The TAD contains a 
ligand-independent, constitutive activation function generally referred to as AF-1 that 
is repressed by the unliganded LBD in the wild type AR (Jenster et al., 1991). The AR 
LBD also contains an activation function (AF-2) but unlike AF-1, AF-2 is ligand 
dependent. Importantly, targeted transactivation of AR responsive genes requires de 
coordinated activities of both AF-1 and AF-2, although their relative contributions to 
this process can vary depending on the promoter and cellular context (Snoek et al., 
1998). 
 
The results from the experiments reported in this thesis suggest a new molecular 
mechanism to explain the implications of the CAG tract length in the AR activity.  
The interaction between the LBD and TAD could be modulated by the length of the 
poly-Gln tract in the TAD, being stronger as the number of CAG decreases, due to 








Androgens are critical for sexual differentiation and maintenance of secondary sexual 
characteristics in man. All androgens act in conjunction with the AR protein which is 
encoded by a single copy gene in the X-chromosome. Since the cloning and structure-
elucidation of the AR gene (Lubahn  et al., 1988), numerous AR gene mutations have 
been described that result in complete androgen insensitivity and sexual reversal in 
otherwise healthy 46 XY individuals. To date more than 300 such mutations are 
documented in a mutational database (www.mcgill.ca/androgendb). Recently, it is 
increasingly apparent that AR mutations can result in a spectrum of androgen 
insensitivity phenotypes, ranging from the complete to the minimal forms of androgen 
insensitivity.  The latter is the least well characterized of all the androgen insensitivity 
phenotypes. In this thesis, we asked what phenotypes may result from minimal 
changes in AR function. In this regard, we were intrigued by reports that patients with 
pathologically expanded AR CAG repeats in SBMA have gynecomastia, low 
virilization, oligospermia or azoospermia and testicular atrophy (La Spada et al., 
1991). Furthermore preliminary studies have suggested that the length of the CAG 
repeats might be related to changes in AR transactivation and function (Chamberlain et 
al., 1994; Tut et al., 1997). Therefore, the purpose of this work was to determine the 
role of the CAG length in the AR gene activity and its effects in AR-regulated 
phenotypes in men and women. The work presented in this thesis aimed to examine 
the mildest form of changes in androgen action in those whose phenotypes are 
generally regarded as normal.  
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 The first question was to identify a proper phenotype for study. We decided to study 
firstly male subjects with defective spermatogenesis and infertility, secondly the 
regulation of serum PSA in men, and thirdly PCOS in women. When this study was 
initiated only one publication had reported an association between the CAG repeat 
length and male infertility in a population of predominantly Chinese ethnic 
background (Tut et al., 1997). Our studies involved (Chapter 1; CAG repeat 
polymorphism in the androgen receptor gene and male infertility) two populations of 
different ethnic backgrounds; one from Singapore consisting mainly of ethnic Chinese 
subjects, and the other from the US composed of Caucasian subjects. The technology 
employed to measure the number of CAGs (GeneScan) was precise with  resolution to 
the base pair level. To our gratification, our results showed that azoospermic patients 
have statistically significant longer CAG repeat tracts compared to fertile controls, and 
this difference was observed in both Singapore and US populations. This indicated to 
us that the length of the CAG tract might have crucial role in the spermatogenic 
process. 
 
Since the first studies from our group (Tut et al., 1997), more than 20 follow-up 
publications have reported the relationship between the length of AR CAG tract and 
male infertility. Consistent with the inverse relationship between CAG repeat length 
and AR function, this study and those of other groups have shown that longer CAG 
repeats are found in the AR of patients with defective spermatogenesis. In a 
Singaporean population of mixed Asian origin, patients with a CAG tract of more than 
28 repeats in their AR had more than a 4-fold increased risk of reduced 
spermatogenesis (Tut et al., 1997). This trend was also observed in Australian 
(Dowsing et al., 1999), Japanese (Yoshida et al., 1999)  American (Mifsud et al., 
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 2001; Patrizio et al., 2001) and French (Wallerand et al., 2001) populations wherein 
subfertile men with idiopathic azoospermia or oligozoospermia had significantly 
longer CAG repeat tracts than controls. Remarkably, longer AR CAG repeats are also 
associated with moderate to severe undermasculinization in male infants (Lim et al., 
2000). Together, the data support the hypothesis that longer CAG tracts have reduced 
intrinsic AR activity, leading to depressed spermatogenesis and male infertility. 
However, these findings could not be corroborated in studies involving Swedish 
(Giwercman et al., 1998) or German populations (Dadze et al., 2000; von Eckardstein 
et al., 2001), Dutch (Van Golde et al., 2002) or Danish (Rajpert-De Meyts et al., 2002) 
studies wherein no statistically significant relationship was found between the size of 
CAG repeats and idiopathic defective spermatogenesis. The causes of the disparity 
from different studies remain unclear and it has been suggested to be related to 
ethnicity differences (Rajpert-De Meyts et al., 2002). In my opinion, one key 
contributory factor may be the selection criteria for patients. The patients presented in 
this thesis were karyotyped and genetic tests for male infertility, such as Y-
chromosome microdeletions and AR point mutations, were performed. The patients 
who tested positive for the above mention  genetic causes of male infertility were not 
included in our study. In addition to the genetic analysis, all patients underwent a 
physical examination and those with obstructive genital syndromes were excluded 
from the study. Using these selection criteria, our data indicate that there is an 
association between azoospermia and CAG length. Azoospermic patients have 
statistically longer CAG tracts compared to the fertile controls, and this difference was 
independent of the ethnic background since it was present in both populations. In 
addition, for the US population each unit increase in CAG length was associated with a 
20% increase in the odds of being azoospermic. Interestingly long CAG repeat length 
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 can influence the effectiveness of hormonal male contraception by rendering those 
with incomplete GnRH suppression azoospermic (Eckardsterin et al, 2002). In an 
Israeli infertile population, the mean length of the AR-CAG was also significantly 
longer than in fertile men (Madgar et al., 2002). Our data indicate that having more 
than 26 CAG repeats, the probabilities of being azoospermic increase. This number 
may be of value as a reference point in other populations since it was significant for 
both Singapore (Tut et al., 1997) and US patients (Mifsud et al., 2000). Our studies 
provide the basis for an additional test in the assessment of male infertility. This is of 
special importance for those patients involved in assisted reproductive programs, 
specifically for those with an unclear cause of infertility classified as “idiopathic”. 
Recent advances in assisted reproductive technologies have made it possible for 
couples to conceive, even in the absence of spermatozoa in the ejaculate through 
testicular biopsy and epididymal sperm aspiration (Chan et al., 2000). Screening and 
genetic counselling would be recommended for these patients. Another useful clinical 
observation was that most azoospermic patients with > 26 CAGs had spermatozoa 
present in their seminiferous tubules. It is plausible that boosting intratesticular levels 
of androgens might improve spermatogenesis in these patients. This therapeutic 
modality would be explored in future studies. 
 
The second aim of the project was to test the hypothesis that the length of the CAG 
stretch in the AR gene could play a role in the development of PCOS, a disease with a 
significant genetic component. A number of genes have been implicated in the 
development of PCOS, mainly those relating to the androgen synthetic pathway (Carey 
et al., 1994; Gharani et al., 1997). The present study included 91 PCOS patients and 
112 healthy controls of a population of predominantly Chinese ethnic background. 
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 Women have two copies of the AR gene and these two alleles were examined for each 
subject. The data showed that when the shorter of the two alleles were compared, 
women with PCOS had a lower number of CAG repeats compare to the controls, 
although this difference was not statistically significant. When the PCOS patients were 
divided into two groups, those with low and high levels of testosterone, PCOS patients 
with low testosterone levels had significant shorter CAG tracts, as well as higher 
frequency of the short allele compared to those patients with high levels of 
testosterone. Thus we have identified a subset of PCOS patients whose testosterone 
levels might not be increased, but have short CAG tracts at least in one of the alleles. 
The higher activity conferred by the short AR allele might enhance the intrinsic 
androgenicity of the AR leading to PCOS in this subset of patients. Women have two 
X chromosomes, in most cases have two different AR alleles, one of them being 
inactivated through methylation (Lyon et al., 1989). This indicates the possibility that 
in the subset of PCOS patients with low testosterone levels, the AR allele with the 
longer number of CAG repeats might be preferentially inactivated. More studies are 
needed to confirm the skewed pattern of X-chromosomal inactivation in PCOS 
women. Thus, from the results of our study  we can introduce the novel concept that 
hyperandrogenism in the subset of PCOS patients with normal androgen levels could 
be conferred by short AR CAG tracts. This finding can explain why 37% of 
Singaporean subjects have clinical and ultrasound evidence for PCOS without raised 
serum androgens. Since the publication of our report (Mifsud et al., 2000), several 
studies have indicated the validity of our findings. Women with relatively few CAG 
repeats in the AR gene, resulting in higher transcriptional activity of the receptor, 
displayed higher levels of serum androgens, but lower levels of LH than women with 
longer CAG repeat sequences in a Swedish population (Westberg et al., 2001).  Short 
 203
 CAG lengths also increases the risk of precocious pubarche (pubic hair <8 yrs) and 
ovarian hyperandrogenism in a Spanish population (Ibanez et al., 2003). Among these 
menarchal girls with precocious pubarche, shorter CAG biallelic mean were associated 
with higher 17-hydroxy-progesterone levels post leuprolide administration, higher 
testosterone levels, acne, hirsutism scores, and more menstrual irregularities. 
Collectively, all these studies highlight the role of androgen sensitivity in the patho-
physiology of PCOS. Our studies will help resolve the problem of definition that 
bedevils the studies in PCOS. By defining specific subsets of PCOS, entry criteria can 
be further refined, hopefully leading to definitive studies of this very common and 
distressing condition. Clearer appreciation of how different defects in the androgen 
signalling pathways cause PCOS, will lead to novel therapeutic solutions. The 
challenge for the future is to ascertain whether anti-androgen therapy may still be 
useful in these subjects with clinical evidence for PCOS but whose androgens are 
within normal limits.  
 
Having gained the knowledge that the CAG repeat length plays a role in the activity of 
the AR, the third objective of the study was to determine the androgen-related factors, 
including the levels of T and SHBG, as well as the CAG repeat number in the AR 
gene, that may be involved in the regulation of the concentrations of the tumor marker 
PSA. Our study population was composed of two different groups of individuals, a 
subfertile and a fertile male population. The first observation was that the levels of T 
were significantly lower for the subfertile group when compared to the fertile one. 
Different correlations between the different androgenic parameters were investigated 
and the main conclusions were that in the fertile group, there was a positive correlation 
between the levels of T and the CAG repeat number and this correlation was not found 
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 in the subfertile group. In subfertile subjects, T strongly correlated with PSA 
concentrations, and independent of T, total PSA negatively correlated with the AR 
CAG length. Overall our data suggest that, firstly, PSA correlates with T only in an 
environment of relatively low androgenicity, such as in subfertile men. Secondly, in 
such a low androgenic environment, short CAG tracts (associated with high AR 
activity) correlate positively with PSA concentrations. These results suggest that 
interpretation of PSA is best made in conjunction with T concentrations and the AR 
CAG length. These findings are relevant for the screening of prostate cancer, which to 
a large extent is dependent on serum PSA. One of the current problems is to 
distinguish between a "suspicious cancer-related PSA increase" or "cancer-related PSA 
increase". Cut-off points of PSA levels are controversial especially at the lower end of 
the spectrum (Ito et al., 2003). There is a debate whether increase from cero to 4.0 
ng/mL is significant and whether diagnostic/therapeutic modalities like more intensive 
monitoring and biopsies should be undertaken in these cases. Our data suggest that for 
those individuals with low testosterone levels, a lower cut-off point of PSA may be 
appropriate as these may be due to an increased AR androgencity, and not prostate 
cancer. More clinical studies are required to prove the validity of this approach and 
whether current rates of over-detection (Draisma et al.,  2003) of prostate cancer may 
be improved. 
 
The last part of the project aimed to study in vitro the effect of the CAG repeat length 
on the AR activity. Various in-vitro co-transfection experiments were performed. 
Two human promoters (PSA and ALDH1) that were known to be androgen regulated 
were constructed. The purpose of these studies was to determine if AR genes of 
different CAG length would activate the luciferase reporter system with different 
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 intensities and consequently, to find a correlation between the number of repeats and 
the intrinsic activity of the AR. No consistent correlation was observed while using 
the PSA promoter. Perhaps these differences in AR activities were very subtle and 
difficult to detect under the experimental conditions employed or are promoter 
specific. To overcome this problem, a more sensitive method was designed, this time 
using the mammalian two-hybrid system technology. The AR LBD-TAD interactions 
were studied using TAD of different CAG repeat lengths. The results indicated that 
the shorter the CAG tract the stronger is the interaction between the two domains. A 
recent study (Callewaert et al., 2003)  also reported that a deletion of the repeat 
positively affected the interactions of the ligand-binding domain with the amino-
terminal domain. The authors concluded that this was dependent on the recruitment of 
the p160 coactivator SRC-1e to the amino-terminal domain of the AR as reflected by 
an enhanced coactivation of the AR by SRC-1e. More studies are needed to validate 
this mode of action, and to further comprehend the underlying molecular 
mechanism(s).  
 
Glutamine-rich regions of proteins occur widely in both prokaryotes and eukaryotes. 
They are frequently found as polyglutamine tracts, encoded by CAG repeats, often of 
considerable length. Despite this wide distribution, the functions of CAG repeats in 
healthy subjects are often unclear. The work presented in this thesis aimed to further 
clarify the role of the AR-CAG repeat length in diseases/conditions where the CAG 
repeat length still falls into the healthy range. We concluded that the CAG tracts were 
longer in those subfertiles/infertile patients with azoospermia in two ethnically 
different populations such as Caucasian and Chinese, and shorter in one of the alleles 
in a subset of female PCOS patients whose testosterone levels were not raised. 
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 Furthermore, PSA levels were negatively correlated with AR CAG length in those 
individuals with low testosterone levels. These three clinical studies associated with 
the in-vitro studies suggest an effect of the CAG length on the AR TAD-LBD 
interactions and validate the model that shorter CAG tracts confer higher intrinsic 
activity to the AR and leading to diseases characterized by high androgenic levels such 
as PCOS.  In contrast, longer CAG tracts will reduce AR activity predisposing the 
individuals to diseases were the androgen action is impaired such as defective 
spermatogenesis.  
 
Since the publication of our studies in 2000, there has been increasing evidence from 
numerous studies in a variety of patient populations and diverse disciplines, that AR 
CAG tracts have a subtle but critical role in diseases and processes regulated by 
androgens. There has been growing interests in the topic by many authors and a 
number of publications have followed our studies. A summary of these publications is 
presented in Table 1. Several reports have appeared indicating that CAG tracts regulate 
the AR function in ageing men and women. Harkonen et al. reported that men with 
long CAG repeats show significantly more depressed mood, anxiety, wish to be dead 
and decreased beard growth (Harkonen et al., 2003). According to the studies by 
Zitzmann et al., high number of repeats are related to the increased age-dependent 
bone loss in men (Zitzmann et al., 2001) and increased risk of osteoporosis in women 
(Chen et al., 2003). The prostate volume and growth in testosterone-substituted 
hypogonadal men was also found dependent on the CAG repeat polymorphism of the 
androgen receptor gene (Zitzmann et al., 2003). On the other hand, short alleles appear 
to be associated with early onset of Alzheimer’s disease in men (Lehmann et al., 
2003). Short alleles are also independently correlated with cardiovascular risk by 
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increasing low body fat mass and plasma insulin while at the same time, decreasing the 
level of high density lipoprotein concentrations in older men (Zitzmann et al., 2003) 
and obesity indices in older women (Gustafson et al., 2003).  
Epidemiological studies are emerging that suggest associations between CAG repeats 
and hormone dependent malignancies. Sasaki et al. reported that endometrial cancer 
patients have significantly longer AR (Sasaki et al., 2003). Short CAG repeats were 
associated with an increased prostate cancer risk in Hispanic men (Balic et al., 2003). 
Long AR alleles have been also associated with increased risk of early onset of breast 
cancer (Suter et al., 2003), increased breast cancer risk among women with a first-
degree of family history of breast cancer (Haiman et al., 2002) and ovarian cancer 
(Santarosa et al., 2002). Although not uniformly unanimous, these studies 
cumulatively provide strong evidence that the AR CAG length within the normal 
polymorphic range can indeed regulate AR function in cases of health or disease.




DISEASE OUTCOME ETHNICITY REFERENCE 
Hormone Related Cancers 
Ovarian Cancer Women with >22 greater risk than women < 22 CAGs (OR=2.17, 95% CI 1.10-3.20) Caucasian Santarosa et al., 2002 
Prostate volume Prostate growth under substitute testosterone levels were dependent on (CAG)n with lower effect on longer CAGs Cauasian Zitzmann et al., 2003 
Prostate cancer Men with < 18 CAGs have 3-fold increased risk of prostate cancer than men with <18 CAGs 
Caucasian 
(Hispanic) Balic et al., 2003 
Endometrial cancer Endometrial cancer patients had longer alleles than controls  Japanese Sasaki et al., 2003) 
Breast cancer 
Women with one or two alleles with > 22 CAGs and first 
degree family history of breast cancer have greater risk of 
breast cancer (OR=1.70, 95%CI 1.20-2.40) 
Caucasian Haiman et al., 2002 










Age dependent bone 
density in healthy 
males 
Men with CAGs of 22-31 have increased age dependent 
bone loss compared to men with CAGs of 14-21 
 




Women with > 20 CAGs greater risk than women <20 
(OR 4.2, 95% CI 1.0-17.2)  
 
Chinesse Chen et al., 2003 
Central obesity in 
women 
Women with < 25 CAGs had higher waist and hip 
circumferences Caucasian Gustafson et al., 2003 
Andropausal 
symptoms in ageing 
men 
CAG repeat number correlates with depression, 
depressed mood, anxiety, decreased beard growth. Caucasian Harkonen et al., 2003 





Biallelec mean of <20 CAGs was associated with ovarian 
hyperandrogenism Caucasian Ibanez et al., 2003 
Alzheimer’s disease 
(AD) in men 
< 20 CAGs were associated with AD 
OR=2.5, 95% CI:1.2-5.0 in men  Caucasian Lehmann et al., 2003 
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 The occurrence of the more than 32 AR alleles (CAG length from 8 to 39) in the 
normal healthy population implies corresponding differences in androgen sensitivity 
among healthy subjects. What are the advantages to the species of such variation in 
AR sensitivity? Evolutionary studies of a number of genes involved in the human 
triplet expansion diseases have indicated that the repeats in these genes have arisen by 
gradual expansion of the tandem repeat, apparently resulting from replication slippage. 
Studies in Escherichia coli (Rosenberg et al., 1994) have shown that nutritional factors 
or other type of stress might increase the rate of mutation by down-regulating the 
mismatch DNA repair system. Thus environmental challenges would increase the rate 
of variability in the genome, enabling species to adapt to new challenges. Repeats are 
generally absent in rodent homologue genes and comparative studies indicate an 
increase in repeat length during primate evolution, with humans generally having the 
longest repeats (Rubinsztein et al., 1994). Repeat number variation of these 
polymorphic regions would also provide a ready and inexhaustible supply of new 
quantitative genetic variation for rapid evolutionary adaptation of species to novel 
ecological challenges, or rapid divergence of an isolated population. This rate of 
mutational variation can enable a population faced with continuing environmental 
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